<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Cardiovasc Drugs Ther</journal-id><journal-id journal-id-type="iso-abbrev">Cardiovasc Drugs Ther</journal-id><journal-title-group><journal-title>Cardiovascular Drugs and Therapy</journal-title></journal-title-group><issn pub-type="ppub">0920-3206</issn><issn pub-type="epub">1573-7241</issn><publisher><publisher-name>Springer US</publisher-name><publisher-loc>New York</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">39017904</article-id><article-id pub-id-type="pmc">PMC11680629</article-id>
<article-id pub-id-type="publisher-id">7608</article-id><article-id pub-id-type="doi">10.1007/s10557-024-07608-7</article-id><article-categories><subj-group subj-group-type="heading"><subject>Invited: BSCR Marshall Submissions</subject></subj-group></article-categories><title-group><article-title>Immunotherapy in the Context of Aortic Valve Diseases</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-7436-3873</contrib-id><name><surname>Bartoli-Leonard</surname><given-names>Francesca</given-names></name><address><email>f.bartoli-leonard@bristol.ac.uk</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Pennel</surname><given-names>Tim</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Caputo</surname><given-names>Massimo</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/0524sp257</institution-id><institution-id institution-id-type="GRID">grid.5337.2</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 7603</institution-id><institution>Bristol Medical School, Faculty of Health Sciences, </institution><institution>University of Bristol, </institution></institution-wrap>Bristol, UK </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03jzzxg14</institution-id><institution>Bristol Heart Institute, University Hospital Bristol and Weston NHS Foundation Trust, </institution></institution-wrap>Bristol, UK </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03p74gp79</institution-id><institution-id institution-id-type="GRID">grid.7836.a</institution-id><institution-id institution-id-type="ISNI">0000 0004 1937 1151</institution-id><institution>Chris Barnard Division of Cardiothoracic Surgery, </institution><institution>University of Cape Town, </institution></institution-wrap>Cape Town, South Africa </aff></contrib-group><pub-date pub-type="epub"><day>17</day><month>7</month><year>2024</year></pub-date><pub-date pub-type="pmc-release"><day>17</day><month>7</month><year>2024</year></pub-date><pub-date pub-type="ppub"><year>2024</year></pub-date><volume>38</volume><issue>6</issue><fpage>1173</fpage><lpage>1185</lpage><history><date date-type="accepted"><day>8</day><month>7</month><year>2024</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2024</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><title>Abstract&#x000a0;&#x000a0;&#x000a0;</title><sec><title>Purpose</title><p id="Par1">Aortic valve disease (AVD) affects millions of people around the world, with no pharmacological intervention available. Widely considered a multi-faceted disease comprising both regurgitative pathogenesis, in which retrograde blood flows back through to the left ventricle, and aortic valve stenosis, which is characterized by the thickening, fibrosis, and subsequent mineralization of the aortic valve leaflets, limiting the anterograde flow through the valve, surgical intervention is still the main treatment, which incurs considerable risk to the patient.</p></sec><sec><title>Results</title><p id="Par2">Though originally thought of as a passive degeneration of the valve or a congenital malformation that has occurred before birth, the paradigm of AVD is shifting, and research into the inflammatory drivers of valve disease as a potential mechanism to modulate the pathobiology of this life-limiting pathology is taking center stage. Following limited success in mainstay therapeutics such as statins and mineralisation inhibitors, immunomodulatory strategies are being developed. Immune cell therapy has begun to be adopted in the cancer field, in which T cells (chimeric antigen receptor (CAR) T cells) are isolated from the patient, programmed to attack the cancer, and then re-administered to the patient. Within cardiac research, a novel T cell&#x02013;based therapeutic approach has been developed to target lipid nanoparticles responsible for increasing cardiac fibrosis in a failing heart. With clonally expanded T-cell populations recently identified within the diseased valve, their unique epitope presentation may serve to identify novel targets for the treatment of valve disease.</p></sec><sec><title>Conclusion</title><p id="Par3">Taken together, targeted T-cell therapy may hold promise as a therapeutic platform to target a multitude of diseases with an autoimmune aspect, and this review aims to frame this in the context of cardiovascular disease, delineating what is currently known in the field, both clinically and translationally.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Aortic valve disease</kwd><kwd>Immune response</kwd><kwd>Calcification</kwd><kwd>T cells</kwd><kwd>Cardiovascular disease</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000274</institution-id><institution>British Heart Foundation</institution></institution-wrap></funding-source><award-id>CH/17/1/32804</award-id><principal-award-recipient><name><surname>Caputo</surname><given-names>Massimo</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer Science+Business Media, LLC, part of Springer Nature 2024</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par4">Aortic stenosis (AS) is a progressive obstructive disease of the aortic valve that increases the resistance across the left ventricular outflow tract. In its severe form, increased afterload results in left ventricular dysfunction, symptoms of left ventricular failure, and ultimately death [<xref ref-type="bibr" rid="CR1">1</xref>]. The mechanism of this hemodynamic dysfunction within the valve [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR3">3</xref>] occurs through osteogenic differentiation of valvular interstitial cells; calcification develops, culminating in calcific aortic valve disease (CAVD) [<xref ref-type="bibr" rid="CR4">4</xref>&#x02013;<xref ref-type="bibr" rid="CR8">8</xref>]. Once mild valve obstruction is established, disease progression is inevitable, with surgical intervention as the only course of treatment once a patient is symptomatic [<xref ref-type="bibr" rid="CR8">8</xref>&#x02013;<xref ref-type="bibr" rid="CR10">10</xref>]. Although previously thought to be a passive, degenerative pathology that occurs as a result of aging, aortic fatigue, or systemic deterioration of the matrix within the valve, it has more recently been demonstrated to be a result of a paradigm shift, suggested to be an active and cellular driven disease; however, treatment modalities have not yet caught up with this dogma [<xref ref-type="bibr" rid="CR11">11</xref>&#x02013;<xref ref-type="bibr" rid="CR14">14</xref>]. With AVD representing a substantial and ever-increasing disease burden on the aging population, CAVD and subsequent AS are expected to increase from 2.5 million cases to 4.5 million by 2030 [<xref ref-type="bibr" rid="CR15">15</xref>], and thus, there is now significant urgency for developing non-invasive treatment strategies for this ever-growing pathogenic population.</p><p id="Par5">The diagnosis of AS is challenging when asymptomatic, and as such, most patients first present in its severe form with end-stage disease, where intervention is increasingly challenging and at times palliative. Due to the insidious nature of the symptoms of AS, such as decreased exercise tolerance, dyspnea, chest pain, and dizziness, patients often do not recognize the gradual limitations as a symptom, resulting in patients often not self-reporting. Thus, recent advances in echocardiography-based diagnostic techniques for valvular pathology are critical in diagnosing pathogenesis early [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>], though stratifying which patients receive this beneficial diagnostic test has no current consensus [<xref ref-type="bibr" rid="CR15">15</xref>]. It is known, however, that aging significantly correlates with moderate to severe symptoms of AS, producing yet another barrier in treatment strategies, with aged patients at higher risk for mortality during and directly after surgical intervention [<xref ref-type="bibr" rid="CR18">18</xref>].</p><p id="Par6">The current mainstay for treatment of symptomatic AS is aortic valve replacement (AVR) either by open surgery (SAVR) with a mechanical or bioprosthetic valve, transcatheter aortic valve replacement (TAVR), or more rarely balloon valvuloplasty [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR19">19</xref>&#x02013;<xref ref-type="bibr" rid="CR23">23</xref>]. Surgical replacement is still considered the gold standard, though valvuloplasty does however offer a shorter relief for palliative patients and contraindications to SAVR or TAVR [<xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR25">25</xref>]. Conversely, balloon valvuloplasty still has a role in pediatric patients, allowing for more growth in the child before a definitive surgical valve replacement [<xref ref-type="bibr" rid="CR25">25</xref>]. While the ideal valve prosthesis would be completely biocompatible without the need for anticoagulants or a limited lifespan [<xref ref-type="bibr" rid="CR26">26</xref>], the current options are sub-optimal implants available, all with their own limitations and advantages. Limitations include but are not limited to coagulation complications with mechanical valves, a limited lifespan, degradation, and the need for reintervention with bioprosthetic valves [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR28">28</xref>]. Although bioprosthetic valves do not require anticoagulation and exhibit outstanding hemodynamics even in small roots/annulus, they lack the durability of mechanical valves.</p><p id="Par7">While AVR remains the gold standard treatment therapy for symptomatic disease, deficiencies in the current devices available lead us to explore the biology of AS as a potential therapeutic solution to prevent progression to symptomatic severe disease. Thus, this review will outline the immune-driven degenerative process, highlighting where key immune cells come into play, before outlining potential immunomodulatory therapeutics, which should be considered for long-term treatment in aortic valve disease.</p></sec><sec id="Sec2"><title>Immune Cells Within the Aortic Valve</title><sec id="Sec3"><title>Resident Immune Cells</title><p id="Par8">Classically, aortic valves consist predominantly of two resident stromal cell populations: aortic valve interstitial cells (VICs) and aortic valve endothelial cells (VECs), the latter of which act as the interface of the valve and circulating blood [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR30">30</xref>]. VICs are fibroblast-like cells derived from the cardiac neural crest, represent the dominant phenotype within the valve, and are responsible for the pathogenic calcification occurring during disease progression [<xref ref-type="bibr" rid="CR31">31</xref>]. Layered within the extracellular matrix, VICs lay down further matrixes during development and homeostasis, which may provide an anchor to infiltrating immune cells.</p><p id="Par9">Though the valve remains relatively acellular, the presence of leukocytes within the healthy aortic valve has been described. Hematopoietic marker CD45&#x02009;+&#x02009;can be seen on 10&#x02013;15% of cells within the valve [<xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR33">33</xref>], with this fraction increasing as the patient ages [<xref ref-type="bibr" rid="CR34">34</xref>]. The majority of CD45&#x02009;+&#x02009;cells have been identified as surveilling antigen-presenting cells (APCs) which present antigens to the adaptive immune cells, known as either dendritic cells or macrophages, eliciting a targeted response. However, recent studies have suggested the presence of tissue-resident B and T cells within the valve [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR35">35</xref>], although due to their suggested low population number and difficulty of obtaining healthy valve tissue, this remains largely unconfirmed. APCs, more frequently identified as macrophages than dendritic cells within the valve [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR33">33</xref>], are responsible for the majority of low-level inflammation occurring within the healthy valve.</p><p id="Par10">Sub-analysis of the CD45&#x02009;+&#x02009;cells confirmed the presence of a major histocompatibility complex (MHC) class II&#x02009;+&#x02009;CD11c&#x02009;+&#x02009;CD86&#x02009;+&#x02009;dendritic cell&#x02013;like population within the healthy valve and in atherosclerosis [<xref ref-type="bibr" rid="CR36">36</xref>&#x02013;<xref ref-type="bibr" rid="CR39">39</xref>]. CD11c&#x02009;+&#x02009;and CD86&#x02009;+&#x02009;work in conjunction to co-stimulate T cells with MHC II antigen presentation, propagating T-cell activation [<xref ref-type="bibr" rid="CR40">40</xref>, <xref ref-type="bibr" rid="CR41">41</xref>].</p><p id="Par11">Secondly, CD68&#x02009;+&#x02009;and CD206&#x02009;+&#x02009;macrophages, previously described as M2, which are characterized as being responsible for wound healing and tissue repair have been identified within healthy valves and notably reduced in calcified valves [<xref ref-type="bibr" rid="CR40">40</xref>]. The vast heterogeneity of tissue-resident macrophages suggests their multi-faceted role within the valve and may have originated during embryonic development, rather than by monocyte recruitment in an uninjured setting [<xref ref-type="bibr" rid="CR42">42</xref>]. Suspected to be resident within the valves during development to clear apoptotic cells in the embryonic valves during the mid-late gestational period, cellular RNA sequencing studies have identified upregulation of immune activity in this gestational period [<xref ref-type="bibr" rid="CR43">43</xref>, <xref ref-type="bibr" rid="CR44">44</xref>], and macrophages may remain in situ following birth. Conversely, murine models with the genetic depletion of endocardial-derived macrophage resulted in increased apoptotic bodies within the valve, suggestive of insufficient clearance, leading to thickened vales and remodelling [<xref ref-type="bibr" rid="CR45">45</xref>].</p><p id="Par12">Within the non-pathological valve, immune cells may act as surveillance cells, able to phagocytose pathogens and traffic to the lymphatic system, consistently being replaced and replenished [<xref ref-type="bibr" rid="CR36">36</xref>], and may contribute to the local paracrine cytokine signaling within the valve, maintaining homeostasis.</p></sec><sec id="Sec4"><title>Infiltrating Immune Cells</title><p id="Par13">Similar to atherosclerosis and coronary artery disease, AVD has been suggested to be driven by inflammatory mechanisms, which promote the induction of pro-fibrotic and osteogenic pathways within the valves (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). Both innate and adaptive immune cells are present in diseased valves, with infiltration by T lymphocytes suggested to be a critical driver of pathogenesis [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR35">35</xref>].<fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p>Role of immune cells in aortic valve disease. Complex immune cell networks play a crucial role in aortic valve disease. VECs under disturbed flow express adhesion molecules, allowing immune cells to infiltrate the valve. Adaptive immune cells, T lymphocytes and B cells, infiltrate the valve through the damaged endothelium. T-cell differentiation leads to the expression of both pro- and anti-inflammatory cytokines depending on the T-cell subtype. B cells respond to oxLDL through interaction with APC and produce pro-inflammatory cytokines and auto-antibodies, promoting further inflammation cascades. APCs, dendritic cells and macrophages, differentiate within the tissue from circulating monocytes. Both lipid and apoptotic body antigens are present within the valve, promoting an adaptive immune cell response and proliferation. Neutrophils enter the valve and produce inflammatory cytokines, reactive oxygen species, and cytotoxic granules, promoting cellular apoptosis and inflammation. APC, antigen-presenting cells; BMP2, bone morphogenic protein-2; DC, dendritic cell; IFN&#x003b3;, interferon-gamma; MCP-1, monocyte chemoattractant protein-1; oxLDL, oxidized low-density lipoprotein; ROS, reactive oxygen species; RUNX2, runt-related transcription factor-2; TGF&#x003b2;, tumor growth factor-beta; TLR, Toll-like receptor; TNAP, tissue non-specific alkaline phosphatase; TNF&#x003b1;, tumor necrosis factor-alpha; VECs, valvular endothelial cells; VIC, valvular interstitial cell</p></caption><graphic xlink:href="10557_2024_7608_Fig1_HTML" id="MO1"/></fig></p><p id="Par14">Through changes in the hemodynamic forces across the valve, VECs undergo phenotypic switching, leading to endothelial dysfunction leading to expression of adhesion molecules [<xref ref-type="bibr" rid="CR46">46</xref>]. Propagated by the attraction of immune cells to the damaged and now exposed fibrotic matrix behind the VECs, immune cells produce pro-inflammatory cytokines and promote expression of endothelial nitric oxide synthase (eNOS) within the valve [<xref ref-type="bibr" rid="CR47">47</xref>, <xref ref-type="bibr" rid="CR48">48</xref>], demonstrated to be increased in pathogenic valves. Through the increase in eNOS and subsequent oxidative stress, the valve moves in a positive feedback loop into further damage and inflammation, until surgical treatment is sought [<xref ref-type="bibr" rid="CR49">49</xref>&#x02013;<xref ref-type="bibr" rid="CR51">51</xref>].</p><p id="Par15">Peripheral-derived monocytes often characterized as short-lived circulating cells can differentiate into both DCs and macrophages following activation through polarizing markers within the valve [<xref ref-type="bibr" rid="CR40">40</xref>]. Classical monocytes, CD14<sup>hi</sup> and CD16<sup>null</sup>, comprise 90% of circulating monocytes and are strongly implicated in the propagation of pro-inflammatory signals releasing both TNF&#x003b1; and nitric oxide perpetuating an inflammatory environment [<xref ref-type="bibr" rid="CR52">52</xref>&#x02013;<xref ref-type="bibr" rid="CR54">54</xref>]. Conversely, CD14<sup>lo</sup> and CD16<sup>hi</sup> non-classical monocytes constitutively produce IL-1RA and promote a reparative phenotype when differentiating into macrophages and surveilling the endothelium. In severe aortic valve stenosis and valve calcification CD14<sup>hi</sup>, CD16&#x02009;+&#x02009;intermediate monocytes have been shown to be present, expanding from a negligible population to up to 8% of the circulating monocytes [<xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR53">53</xref>, <xref ref-type="bibr" rid="CR55">55</xref>&#x02013;<xref ref-type="bibr" rid="CR57">57</xref>]. Exhibiting large amounts of reactive oxygen species and inflammatory markers, interferon-gamma (IFN&#x003b3;) intermediate monocytes represent the greatest proponent of chronic inflammation within the valve of all monocytes.</p><p id="Par16">Once monocytes have infiltrated the tissue, they differentiate into macrophages or dendritic cells. Macrophages have been consistently associated with the progression and severity of atherosclerosis [<xref ref-type="bibr" rid="CR58">58</xref>&#x02013;<xref ref-type="bibr" rid="CR61">61</xref>] and identified in stenotic and calcified aortic valves [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR62">62</xref>]. Following endothelial dysfunction within the valve, adhesion markers are upregulated allowing for increased monocyte infiltration and remodeling of the extracellular matrix, propagating further inflammation. Pro-inflammatory macrophage expression-induced nitric oxide synthase (iNOS) TNF&#x003b1;, IL-6, IL-12, and MCP-1 serve to attract further pro-inflammatory cells to the region and propagate the inflammatory cascade [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR63">63</xref>]. Notably conditioned media taken from pro-inflammatory macrophages can polarize VICs to a fibro-calcific phenotype, giving further evidence to their pathogenic role in disease progression [<xref ref-type="bibr" rid="CR62">62</xref>, <xref ref-type="bibr" rid="CR64">64</xref>, <xref ref-type="bibr" rid="CR65">65</xref>]. Oxidized LDL (oxLDL) present in a high lipid environment conducive to AVD promotes monocyte maturation, adhesion to the ECM, and the differentiation of macrophages to foam cells through scavenger receptor lipid uptake [<xref ref-type="bibr" rid="CR66">66</xref>&#x02013;<xref ref-type="bibr" rid="CR69">69</xref>]. Foam cells release pro-inflammatory markers IL-1&#x003b2; and TNF&#x003b1;, while inhibiting IFN&#x003b3;-induced inflammation. The terminal differentiation of macrophages into foam cells limits the cell&#x02019;s ability to phenotypically shift to an anti-inflammatory phenotype [<xref ref-type="bibr" rid="CR59">59</xref>, <xref ref-type="bibr" rid="CR66">66</xref>, <xref ref-type="bibr" rid="CR70">70</xref>&#x02013;<xref ref-type="bibr" rid="CR72">72</xref>], as they continue to promote osteoclastogenic activity through RANKL activation and inhibit osteoblast formation.</p><p id="Par17">B cells are distinct from other immune cells, with their ability to respond to both self and foreign antigens through the immunoglobulin B-cell receptors. Through atherosclerotic studies, B cells have been demonstrated to promote a pro-atherogenic response through secretion of granulocyte&#x02013;macrophage colony-stimulating factor (GM-CSF) which promotes the polarization of pro-inflammatory monocytes/macrophages to the localized area [<xref ref-type="bibr" rid="CR57">57</xref>, <xref ref-type="bibr" rid="CR63">63</xref>, <xref ref-type="bibr" rid="CR73">73</xref>]. The pro-inflammatory environment of the valve enhances the pathogenic switching of B cells from producing IgG to IgE, the latter of which has been associated with echocardiographic markers of aortic stenosis severity [<xref ref-type="bibr" rid="CR74">74</xref>]. Through the promotion of macrophage localization, B cells have been suggested to be implicated in the progressive thickening of the valves, contributing to pathogenic degradation [<xref ref-type="bibr" rid="CR75">75</xref>&#x02013;<xref ref-type="bibr" rid="CR78">78</xref>].</p><p id="Par18">T lymphocytes have been shown to promote pathological remodeling during coronary disease and atherosclerosis in chorus with macrophages [<xref ref-type="bibr" rid="CR60">60</xref>, <xref ref-type="bibr" rid="CR79">79</xref>, <xref ref-type="bibr" rid="CR80">80</xref>]; however, their role in AVD pathogenesis is still misunderstood. Utilizing in vivo imaging, cell lineage tracing, and murine models, T cells have been identified as critical drivers of pathogenesis in atherosclerosis [<xref ref-type="bibr" rid="CR39">39</xref>, <xref ref-type="bibr" rid="CR81">81</xref>&#x02013;<xref ref-type="bibr" rid="CR83">83</xref>], further suggesting a possible cross-over with calcific valve degeneration [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR51">51</xref>, <xref ref-type="bibr" rid="CR84">84</xref>&#x02013;<xref ref-type="bibr" rid="CR86">86</xref>]. First described through histology as co-localizing with IL-2, T lymphocytes were believed to be skewed toward a CD4&#x02009;+&#x02009;rather than CD8&#x02009;+&#x02009;subset, with cytotoxic T-cell infiltrates aggregating around regions of calcification and dysfunction [<xref ref-type="bibr" rid="CR87">87</xref>]. In end-stage aortic stenosis, T cells have been co-localized around neoangiogenic regions, indicative of an immunomodulatory process and the culmination of chronic remodeling within the valve [<xref ref-type="bibr" rid="CR88">88</xref>]. CD4&#x02009;+&#x02009;T cells have the capacity to differentiate into both T helper or T regulatory cells, dampening down the response through physical interactions and releasing cytokines to other immune cells [<xref ref-type="bibr" rid="CR89">89</xref>]. Releasing TNF&#x003b1; and CD4&#x02009;+&#x02009;T helper cells has been shown to enhance mineralization matrix nodule synthesis through the promotion of osteogenic VIC differentiation and the sequestering of pro-fibrotic enhancers in the valve [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR51">51</xref>, <xref ref-type="bibr" rid="CR85">85</xref>]. Pro-inflammatory Th17 CD4&#x02009;+&#x02009;T cells promote calcification and pathogenesis through TGF&#x003b2; release and apoptosis of neighboring cells through IL-6 and IL-21, promoting fibrosis and mineralization through apoptotic-driven mechanisms [<xref ref-type="bibr" rid="CR90">90</xref>, <xref ref-type="bibr" rid="CR91">91</xref>]. Moreover, IL-21 promotes osteoblastic differentiation in VICs through the upregulation of alkaline phosphatase and RUNX2, further promoting calcification within the tissue [<xref ref-type="bibr" rid="CR92">92</xref>]. Notably, the hallmark of Th17 and IL-17 has been shown to correlate with the severity of hypertension and atherosclerosis and seen in CAVD patient plasma correlating with disease progression [<xref ref-type="bibr" rid="CR93">93</xref>]. Conversely, regulatory T cells (Treg) promote immunologic tolerance within tissue, suppressing pro-inflammatory responses and reducing IgE production. Treg populations have been found within severe aortic stenosis, with little understanding of whether this is a resolving response or a response to the propagation of further inflammation [<xref ref-type="bibr" rid="CR51">51</xref>, <xref ref-type="bibr" rid="CR89">89</xref>, <xref ref-type="bibr" rid="CR94">94</xref>]. CD8&#x02009;+&#x02009;T cells also known as cytotoxic T cells play a critical role against intracellular pathogens through the secretion of pro-inflammatory cytokines, the utilization of the FasL to bind and promote apoptosis within the target cell, and finally the release of serine-protease granzymes and perforin to breakdown and target the cell for apoptosis [<xref ref-type="bibr" rid="CR56">56</xref>, <xref ref-type="bibr" rid="CR87">87</xref>, <xref ref-type="bibr" rid="CR95">95</xref>, <xref ref-type="bibr" rid="CR96">96</xref>]. Within aortic stenosis, CD8&#x02009;+&#x02009;cells have been suggested to contribute to disease progression, through the impairment of osteoclast function, reducing the cell&#x02019;s ability to reabsorb calcium from the valvular matrix [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR96">96</xref>, <xref ref-type="bibr" rid="CR97">97</xref>]. More recently, clonal expansion within CD8&#x02009;+&#x02009;T cells has been shown to occur within the tissue, rather than the peripheral, correlating with the trafficking of monocytes into the lesion. With the limited T-cell repertoire present in the valve and increased CD8&#x02009;+&#x02009;population within late-stage disease, targeting these cells against specific pathogenic epitopes may be a viable option for immunotherapy to target aortic valve disease.</p></sec></sec><sec id="Sec5"><title>Non-surgical Treatment of Aortic Valve Disease</title><p id="Par19">Understanding the immunological process in valve disease may provide a fresh perspective on the treatment and future dissent into pathogenesis. Currently, no drug strategies in the treatment of AVD have proven effective in the clinic, leaving valve replacement the only option [<xref ref-type="bibr" rid="CR98">98</xref>]. The use of lipid-lowering therapies has shown reasonable success in large-scale atherosclerotic studies [<xref ref-type="bibr" rid="CR99">99</xref>&#x02013;<xref ref-type="bibr" rid="CR102">102</xref>], with a reduction of overall disease burden and increased life expectancy. With AVD correlating with dyslipidemia and early studies identifying substantial lipid accumulation in aortic leaflets [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR103">103</xref>&#x02013;<xref ref-type="bibr" rid="CR108">108</xref>], lipid-lowering therapies were believed to be a viable option in the reduction of calcific burden in AVD. While several preclinical studies have suggested that 3-hydroxy-3-methylgutaryl-coenzyme A (HMG-CoA), also known as <italic>statins</italic>, may reduce the calcific burden in AVD, clinical trials have not demonstrated a therapeutic benefit for this patient cohort. Notably, the <italic>Scottish Aortic Stenosis and Lipid Lowering Trial, Impact on Regression</italic> (SALTIRE) study [<xref ref-type="bibr" rid="CR109">109</xref>] utilizing atorvastatin to reduce calcific aortic stenosis showed no benefit in improving outcomes or halting disease progression. Additionally, the <italic>Aortic Stenosis Progression Observation: Measuring Effects of Rosuvastatin</italic> (ASTRONOMER) trial [<xref ref-type="bibr" rid="CR110">110</xref>] assessing the effect of rosuvastatin in asymptomatic patients with mild to moderate AS demonstrated no reduction in the progression of AS, giving further evidence to the limited efficacy in lipid-lowering therapies in aortic valve disease.</p><p id="Par20">Immunomodulatory drugs have also shown limited efficacy in the treatment of calcific vascular disease, though limited studies have been conducted on the valve. Parallels between AVD and atherosclerosis, while mechanistically distinct, can be drawn. In regard to uncontrolled immune responses and chronic inflammation, atherosclerosis is initiated via activation of the endothelium layer, followed by a cascade of lipid deposition, fibrosis, and calcification, resulting in a narrowing of the vessel and a positive feedback loop of inflammation [<xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR39">39</xref>, <xref ref-type="bibr" rid="CR59">59</xref>]. Conversely, lipid deposition and inflammation are the nuclei cause of AVD, resulting in a thickening, fibrosis, and calcification within the valve leaflets [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR14">14</xref>]. While the pathogenesis differs, clinical trials have attempted to utilize similar therapies for both pathologies, to limited effects. Since the turn of the century, a multitude of clinical trials have attempted to utilize anti-inflammatory therapies for the reduction of atherosclerosis, none of which have shown marked success: oxLDL antibody, BI-204 to inhibit the uptake of oxLDL into macrophages [<xref ref-type="bibr" rid="CR111">111</xref>], and losmapimod, p38-MAPK inhibitor to inhibit the differentiation of macrophages into foam cells have had limited success, in part due to either the insufficient inflammation present to sequester or the mechanistic redundancy in the trans-differentiation of macrophages to foam cells [<xref ref-type="bibr" rid="CR112">112</xref>]. Alternatively, targeting secreted phospholipases A2 (sPLA2) which were shown to promote inflammation within atherosclerosis and increase in expression with calcified aortic valves [<xref ref-type="bibr" rid="CR113">113</xref>] was attempted through the use of varespladib, atreleuton, and veliflapon, to limit the promotion of leukocyte recruitment within the vasculature [<xref ref-type="bibr" rid="CR114">114</xref>&#x02013;<xref ref-type="bibr" rid="CR116">116</xref>]. All of these showed limited efficacy, suggesting that attempting to limit infiltration and propagation of cells might require a more targeted approach than predominately lipid-driven pathogenesis. Conversely, however, the Canakinumab Anti-inflammatory Thrombosis Outcome Study (CANTOS) demonstrated that anti-inflammatory drug targeting of interleukin 1-beta led to significantly lower rates of recurrent cardiovascular events [<xref ref-type="bibr" rid="CR117">117</xref>], highlighting the critical role the immune response plays in pathogenesis.</p></sec><sec id="Sec6"><title>Immunotherapy as an Emerging Avenue for the Treatment of Aortic Valve Disease</title><p id="Par21">As highlighted above, the pharmacological treatment of chronic inflammatory-driven pathologies such as AVD is critically lacking. While in vitro studies have shown the efficacy of a multitude of drugs [<xref ref-type="bibr" rid="CR118">118</xref>&#x02013;<xref ref-type="bibr" rid="CR120">120</xref>], few have been able to replicate the success in vivo, suggesting the need for new approaches. While the potential for immune modulation to impact the heart has been appreciated for decades, targeting immune modulation in atherosclerosis has been heavily discussed [<xref ref-type="bibr" rid="CR121">121</xref>, <xref ref-type="bibr" rid="CR122">122</xref>], but still not implemented fully within atherosclerosis or AVD. Recent work in the cardiac fibrosis field has highlighted the opportunity to engage cellular targeted approaches, through advancements in lipid nanoparticles carrying messenger RNA (mRNA) which can specifically prime and engineer T cells, or any other type of cell, to target specific markers [<xref ref-type="bibr" rid="CR123">123</xref>&#x02013;<xref ref-type="bibr" rid="CR125">125</xref>]. While immune responses against foreign epitopes are similar to those raised against pathogens and act quickly to remove the infection, the ability of the endogenous T cells is limited, due to suppression by central or peripheral tolerance mechanisms, namely, through thymic elimination of high-affinity T-cell receptors to self-antigens, leaving a predominantly low-affinity self-responsive population [<xref ref-type="bibr" rid="CR126">126</xref>]. Notably, T-cell receptors against self-epitopes have a 1.5 log lower affinity for cognate MHC:peptide complex, relative to the virus-specific TCR counterparts, suggesting an inherent inadequacy to remove self-epitopes [<xref ref-type="bibr" rid="CR127">127</xref>, <xref ref-type="bibr" rid="CR128">128</xref>]. The recent development of engineering T cells allows the genetically targeted reprogramming of T cells with chimeric antigen receptors (CARs). CARs are synthetic receptors, which alter the ability of the T cell, now known as a CAR-T cell, to recognize pre-defined surface antigens with a higher degree of specificity in a non-MHC restricted manner, allowing the CAR-T cell to target any specific cell surface receptor in the cell membrane [<xref ref-type="bibr" rid="CR129">129</xref>, <xref ref-type="bibr" rid="CR130">130</xref>]. With the known presence of T cells within both the healthy valve and the elevated infiltration during valve degeneration, CAR-T therapy would be capable of specifically targeting pathogenically activated VICs or pro-inflammatory cells with a unique membrane protein signature.</p><p id="Par22">Identification of the appropriate marker to target, however, is a challenging question [<xref ref-type="bibr" rid="CR131">131</xref>]. Unlike in cancer, where a specific mutation can be identified and targeted as the unique marker of cancer, linage-specific markers, such as bone morphogenic proteins, osteocalcin, and alkaline phosphatase, which are often associated with AVD cannot be used [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR13">13</xref>], as targeting their normal counterparts expressing them will cause unacceptable side effects [<xref ref-type="bibr" rid="CR132">132</xref>]. Thus, the best identification method of CAR-T targets may come from understanding the specific mutations within the individual patient through sequencing [<xref ref-type="bibr" rid="CR123">123</xref>], for a personalized medicine approach to treatment.</p><p id="Par23">Through the use of CAR-T has been standardized as a second line of defense in cancer treatments, CAR can in fact be applied to a range of immune cell&#x02013;driven pathologies, giving them the signal to target specific antigens and initiate an antigen-specific immune response. Conventional CAR-T therapy involves the isolation of cells from healthy donors, genetically modifying the T cells ex vivo to target the surface protein found on a tumor cell, expanding the cell population, and then re-injecting the expanded cell population into the patient to target the tumor [<xref ref-type="bibr" rid="CR129">129</xref>, <xref ref-type="bibr" rid="CR130">130</xref>]. The selection, expansion and reintroduction process can introduce unwanted allergic responses to the injected cells and with a reduction in the host immune system leaves the patient vulnerable to opportunistic infections. Seminal work in the blood cancer field has demonstrated the efficacy of these mechanisms, though using retroviral transduction to produce long-term CAR expression in the cells, lasting for months if not years within the patient [<xref ref-type="bibr" rid="CR131">131</xref>]. Within the field of cancer, this long-lasting impact is precisely what is required to continue to sequester cancer cells as they grow, taking a persistent role in the body for long-term therapeutic efficacy. However, with the discrepancy in temporal profile in AVD compared to cancer, the requirement for persistent CAR-T activation is less. Thus, the long-term persistence of pathogenic cells within the valve may present a safety risk. Transient-engineered T cells, such as those generated in vivo, without the need to remove and reinject blood cells, offer a preferential alternative. A recent groundbreaking study developed a novel method to generate transient CAR-T cardiac targeting cells in vivo, bypassing the requirement for manufacturing and long-term safety of these cells [<xref ref-type="bibr" rid="CR123">123</xref>, <xref ref-type="bibr" rid="CR133">133</xref>]. Through their approach, modified mRNA targeting a specific pathogenic marker is packaged into lipid nanoparticles (LNPs) encased in an antibody-laden membrane.</p><p id="Par24">These antibodies target uptake by a specific cell type, in this case, CD5, a T-cell surface protein which selectively activates T-cell endocytosis and is not required for T-cell effector function. Through endocytosis-driven release of the mRNA once taken up by the cells, the mRNA is translated to generate the CAR-T cells in vivo (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>). The transient stability of mRNA is well documented; mRNA is restricted to the cytoplasm of the cell, unable to undergo genetic integration and diluted during cell division, and the CAR expression within these T cells cannot be permanent. Within the murine model, a consistent CAR&#x02009;+&#x02009;T cell population was identified 48&#x000a0;h post-LNP injection, across each major T-cell subset, with a decline in a cell population within 10&#x000a0;days.<fig id="Fig2"><label>Fig.&#x000a0;2</label><caption><p>Proposed mechanism of CAR-T for aortic valve disease. Targeting resident T cells present in the valve against pathogenic aortic valve cells through the use of LNPs and known T-cell receptor targeting. Identification of a potential target may be identified through sequencing screening of a calcified tissue or liquid biopsy. LNP decorated with antibodies targeting T-cell surface receptors is endocytosed and encapsulated in an endosome within the T cell. Following endosome escape, mRNA is released into the cytoplasm and translated into a CAR, which is presented on the T-cell surface, specifically targeting cell surface protein on a target cell. LNP, lipid nano-particle; CAR, chimeric antigen receptor, VIC, valvular interstitial cell</p></caption><graphic xlink:href="10557_2024_7608_Fig2_HTML" id="MO2"/></fig></p><p id="Par25">A similar methodology has also been implemented in the removal of senescent cells [<xref ref-type="bibr" rid="CR134">134</xref>]. Similarly to the pathogenic cells within AVD, senescent cells do not divide or create an immunosuppressive environment; in comparison to cancer, this may present fewer barriers to the development of therapeutically efficacious CAR-T therapy. By targeting only senolytic cells rather than highly replicative cells, the risk of potential cascading effects of removing functional cells is limited, thus minimizing side effects. With the success of mRNA-LNP vaccines for COVID-19, the efficacy and safety of this mechanism of delivery have been extensively documented and thus present a viable path for the development of scalable immunotherapies. The use of these cells in a model of heart failure gives the first proof of concept that modified mRNA encapsulated in LNPs targeting T cells could be delivered to address a chronic cardiac pathology through the production of functionally engineered T cells in vivo. In comparison to cancer, where the presence of a single cell left behind can be devastating, AVD due to its slow pathogenic development would require a much lower dose, with the removal of 30&#x02013;50% potentially able to restore adequate valve function. Critically, utilization of this therapeutic strategy would require comparing proteomic or gene expression profiles of a multitude of pathogenic and healthy valves to identify a target unique to AVD [<xref ref-type="bibr" rid="CR132">132</xref>, <xref ref-type="bibr" rid="CR135">135</xref>]. The ideal antigens for engagement in CAR-T would be highly expressed on target cells, but not in vital tissues with a CAR signature unique so as to not mistarget. The heterogeneity and complexity of AVD may require a combination of antigens to target to deliver acceptable efficacy, with the potential for personalized medicine to play a leading role in the development of such precise therapy. Incredible progress has been achieved in the preclinical use of engineered T cells, and the ability to extend the use of these cells beyond oncology to one of the leading cardiac pathologies globally offers an exciting opportunity.</p></sec><sec id="Sec7"><title>Conclusions</title><p id="Par26">Though advances have been made in the surgical interventional strategies for the treatment of aortic valve disease, pharmacological interventions are still lacking, highlighting the need for novel approaches to address the ever-growing clinical burden. Clinical trials utilizing statins and lipid-lowering therapies have demonstrated limited efficacy and highlighted the requirement for differing treatment strategies between valve and vascular pathologies, with the preservation of the dynamic valve hemodynamic environment critical for restoring the function of the valve. With the inclusion of multi-omics datasets and single-cell technologies to aid the understanding of the cellular and inflammatory landscape within the valve, targeted therapies such as immune-targeting lipid-delivered targets might offer such resolve in the future.</p></sec></body><back><fn-group><fn><p><bold>Publisher's Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><notes notes-type="author-contribution"><title>Author Contribution</title><p>FBL wrote the first draft of the manuscript, proof-reading, and editing supported by TP and MC. All authors read and approved the final manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This work was supported by Bristol and Weston Hospitals Charity and the Elizabeth Blackwell Institute, University of Bristol; the Wellcome Trust Institutional Strategic Support Fund (ISSF3, 204813/Z/16/Z) to FBL. Capability Funding BHF Translational Award Grant (TA/F/21/210028) and British Heart Foundation Professor of Congenital Cardiac Surgery chair (CH/17/1/32804) and support from the Bristol NIHR Biomedical Research Centre to MC.</p></notes><notes notes-type="data-availability"><title>Data Availability</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Code Availability</title><p>Not applicable.</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Ethics Approval</title><p id="Par27">Not applicable.</p></notes><notes id="FPar2"><title>Consent to Participate</title><p id="Par28">Not applicable.</p></notes><notes id="FPar3"><title>Consent for Publication</title><p id="Par29">Not applicable.</p></notes><notes id="FPar4" notes-type="COI-statement"><title>Competing Interests</title><p id="Par30">The authors declare no competing interests.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name><surname>Otto</surname><given-names>CM</given-names></name><name><surname>Prendergast</surname><given-names>B</given-names></name></person-group><article-title>Aortic-valve stenosis&#x02013;from patients at risk to severe valve obstruction</article-title><source>N Engl J Med</source><year>2014</year><volume>371</volume><fpage>744</fpage><lpage>756</lpage><pub-id pub-id-type="doi">10.1056/NEJMra1313875</pub-id><pub-id pub-id-type="pmid">25140960</pub-id>
</element-citation><mixed-citation id="mc-CR1" publication-type="journal">Otto CM, Prendergast B. Aortic-valve stenosis&#x02013;from patients at risk to severe valve obstruction. N Engl J Med. 2014;371:744&#x02013;56. 10.1056/NEJMra1313875.<pub-id pub-id-type="pmid">25140960</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>Lindman</surname><given-names>BR</given-names></name><name><surname>Sukul</surname><given-names>D</given-names></name><name><surname>Dweck</surname><given-names>MR</given-names></name><name><surname>Madhavan</surname><given-names>MV</given-names></name><name><surname>Arsenault</surname><given-names>BJ</given-names></name><name><surname>Coylewright</surname><given-names>M</given-names></name><name><surname>Merryman</surname><given-names>WD</given-names></name><name><surname>Newby</surname><given-names>DE</given-names></name><name><surname>Lewis</surname><given-names>J</given-names></name><name><surname>Harrell</surname><given-names>FE</given-names><suffix>Jr</suffix></name><etal/></person-group><article-title>Evaluating medical therapy for calcific aortic stenosis: JACC state-of-the-art review</article-title><source>J Am Coll Cardiol</source><year>2021</year><volume>78</volume><fpage>2354</fpage><lpage>2376</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2021.09.1367</pub-id><pub-id pub-id-type="pmid">34857095</pub-id>
</element-citation><mixed-citation id="mc-CR2" publication-type="journal">Lindman BR, Sukul D, Dweck MR, Madhavan MV, Arsenault BJ, Coylewright M, Merryman WD, Newby DE, Lewis J, Harrell FE Jr, et al. Evaluating medical therapy for calcific aortic stenosis: JACC state-of-the-art review. J Am Coll Cardiol. 2021;78:2354&#x02013;76. 10.1016/j.jacc.2021.09.1367.<pub-id pub-id-type="pmid">34857095</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Dweck</surname><given-names>MR</given-names></name><name><surname>Loganath</surname><given-names>K</given-names></name><name><surname>Bing</surname><given-names>R</given-names></name><name><surname>Treibel</surname><given-names>TA</given-names></name><name><surname>McCann</surname><given-names>GP</given-names></name><name><surname>Newby</surname><given-names>DE</given-names></name><name><surname>Leipsic</surname><given-names>J</given-names></name><name><surname>Fraccaro</surname><given-names>C</given-names></name><name><surname>Paolisso</surname><given-names>P</given-names></name><name><surname>Cosyns</surname><given-names>B</given-names></name><etal/></person-group><article-title>Multi-modality imaging in aortic stenosis an EACVI clinical consensus document</article-title><source>Eur Heart J Cardiovasc Imaging</source><year>2023</year><pub-id pub-id-type="doi">10.1093/ehjci/jead153</pub-id><pub-id pub-id-type="pmid">37861420</pub-id>
</element-citation><mixed-citation id="mc-CR3" publication-type="journal">Dweck MR, Loganath K, Bing R, Treibel TA, McCann GP, Newby DE, Leipsic J, Fraccaro C, Paolisso P, Cosyns B, et al. Multi-modality imaging in aortic stenosis an EACVI clinical consensus document. Eur Heart J Cardiovasc Imaging. 2023. 10.1093/ehjci/jead153.<pub-id pub-id-type="pmid">37861420</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Boudoulas</surname><given-names>H</given-names></name><name><surname>Vavuranakis</surname><given-names>M</given-names></name><name><surname>Wooley</surname><given-names>CF</given-names></name></person-group><article-title>Valvular heart disease: the influence of changing etiology on nosology</article-title><source>J Heart Valve Dis</source><year>1994</year><volume>3</volume><fpage>516</fpage><lpage>526</lpage><pub-id pub-id-type="pmid">8000586</pub-id>
</element-citation><mixed-citation id="mc-CR4" publication-type="journal">Boudoulas H, Vavuranakis M, Wooley CF. Valvular heart disease: the influence of changing etiology on nosology. J Heart Valve Dis. 1994;3:516&#x02013;26.<pub-id pub-id-type="pmid">8000586</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>Wilson</surname><given-names>PWF</given-names></name><name><surname>Kauppila</surname><given-names>LI</given-names></name><name><surname>O&#x02019;Donnell</surname><given-names>CJ</given-names></name><name><surname>Kiel</surname><given-names>DP</given-names></name><name><surname>Hannan</surname><given-names>M</given-names></name><name><surname>Polak</surname><given-names>JM</given-names></name><name><surname>Cupples</surname><given-names>LA</given-names></name></person-group><article-title>Abdominal aortic calcific deposits are an important predictor of vascular morbidity and mortality</article-title><source>Circulation</source><year>2001</year><volume>103</volume><fpage>1529</fpage><lpage>1534</lpage><pub-id pub-id-type="doi">10.1161/01.CIR.103.11.1529</pub-id><pub-id pub-id-type="pmid">11257080</pub-id>
</element-citation><mixed-citation id="mc-CR5" publication-type="journal">Wilson PWF, Kauppila LI, O&#x02019;Donnell CJ, Kiel DP, Hannan M, Polak JM, Cupples LA. Abdominal aortic calcific deposits are an important predictor of vascular morbidity and mortality. Circulation. 2001;103:1529&#x02013;34. 10.1161/01.CIR.103.11.1529.<pub-id pub-id-type="pmid">11257080</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>Freeman</surname><given-names>RV</given-names></name><name><surname>Otto</surname><given-names>CM</given-names></name></person-group><article-title>Spectrum of calcific aortic valve disease</article-title><source>Circulation</source><year>2005</year><volume>111</volume><fpage>3316</fpage><lpage>3326</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.104.486738</pub-id><pub-id pub-id-type="pmid">15967862</pub-id>
</element-citation><mixed-citation id="mc-CR6" publication-type="journal">Freeman RV, Otto CM. Spectrum of calcific aortic valve disease. Circulation. 2005;111:3316&#x02013;26. 10.1161/CIRCULATIONAHA.104.486738.<pub-id pub-id-type="pmid">15967862</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>R</given-names></name><name><surname>Strom</surname><given-names>JA</given-names></name><name><surname>Ondrovic</surname><given-names>L</given-names></name><name><surname>Joseph</surname><given-names>B</given-names></name><name><surname>VanAuker</surname><given-names>MD</given-names></name></person-group><article-title>Age-related changes in the aortic valve affect leaflet stress distributions: implications for aortic valve degeneration</article-title><source>J Heart Valve Dis</source><year>2008</year><volume>17</volume><fpage>290</fpage><lpage>298 </lpage><pub-id pub-id-type="pmid">18592926</pub-id>
</element-citation><mixed-citation id="mc-CR7" publication-type="journal">Singh R, Strom JA, Ondrovic L, Joseph B, VanAuker MD. Age-related changes in the aortic valve affect leaflet stress distributions: implications for aortic valve degeneration. J Heart Valve Dis. 2008;17:290&#x02013;8 (discussion 299).<pub-id pub-id-type="pmid">18592926</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>Yadgir</surname><given-names>S</given-names></name><name><surname>Johnson</surname><given-names>CO</given-names></name><name><surname>Aboyans</surname><given-names>V</given-names></name><name><surname>Adebayo</surname><given-names>OM</given-names></name><name><surname>Adedoyin</surname><given-names>RA</given-names></name><name><surname>Afarideh</surname><given-names>M</given-names></name><name><surname>Alahdab</surname><given-names>F</given-names></name><name><surname>Alashi</surname><given-names>A</given-names></name><name><surname>Alipour</surname><given-names>V</given-names></name><name><surname>Arabloo</surname><given-names>J</given-names></name><etal/></person-group><article-title>Global, regional, and national burden of calcific aortic valve and degenerative mitral valve diseases, 1990&#x02013;2017</article-title><source>Circulation</source><year>2020</year><volume>141</volume><fpage>1670</fpage><lpage>1680</lpage><pub-id pub-id-type="doi">10.1161/circulationaha.119.043391</pub-id><pub-id pub-id-type="pmid">32223336</pub-id>
</element-citation><mixed-citation id="mc-CR8" publication-type="journal">Yadgir S, Johnson CO, Aboyans V, Adebayo OM, Adedoyin RA, Afarideh M, Alahdab F, Alashi A, Alipour V, Arabloo J, et al. Global, regional, and national burden of calcific aortic valve and degenerative mitral valve diseases, 1990&#x02013;2017. Circulation. 2020;141:1670&#x02013;80. 10.1161/circulationaha.119.043391.<pub-id pub-id-type="pmid">32223336</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>Lindman</surname><given-names>BR</given-names></name><name><surname>Clavel</surname><given-names>MA</given-names></name><name><surname>Mathieu</surname><given-names>P</given-names></name><name><surname>Iung</surname><given-names>B</given-names></name><name><surname>Lancellotti</surname><given-names>P</given-names></name><name><surname>Otto</surname><given-names>CM</given-names></name><name><surname>Pibarot</surname><given-names>P</given-names></name></person-group><article-title>Calcific aortic stenosis</article-title><source>Nat Rev Dis Primers</source><year>2016</year><volume>2</volume><fpage>16006</fpage><pub-id pub-id-type="doi">10.1038/nrdp.2016.6</pub-id><pub-id pub-id-type="pmid">27188578</pub-id>
</element-citation><mixed-citation id="mc-CR9" publication-type="journal">Lindman BR, Clavel MA, Mathieu P, Iung B, Lancellotti P, Otto CM, Pibarot P. Calcific aortic stenosis. Nat Rev Dis Primers. 2016;2:16006. 10.1038/nrdp.2016.6.<pub-id pub-id-type="pmid">27188578</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name><surname>Otto</surname><given-names>CM</given-names></name></person-group><article-title>Heartbeat: time to treat the whole patient, not just the valve, when calcific aortic stenosis is present</article-title><source>Heart</source><year>2020</year><volume>106</volume><fpage>1621</fpage><lpage>1623</lpage><pub-id pub-id-type="doi">10.1136/heartjnl-2020-318316</pub-id><pub-id pub-id-type="pmid">33046623</pub-id>
</element-citation><mixed-citation id="mc-CR10" publication-type="journal">Otto CM. Heartbeat: time to treat the whole patient, not just the valve, when calcific aortic stenosis is present. Heart. 2020;106:1621&#x02013;3. 10.1136/heartjnl-2020-318316.<pub-id pub-id-type="pmid">33046623</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>Freeman</surname><given-names>RV</given-names></name><name><surname>Otto</surname><given-names>CM</given-names></name></person-group><article-title>Spectrum of calcific aortic valve disease: pathogenesis, disease progression, and treatment strategies</article-title><source>Circulation</source><year>2005</year><volume>111</volume><fpage>3316</fpage><lpage>3326</lpage><pub-id pub-id-type="doi">10.1161/circulationaha.104.486738</pub-id><pub-id pub-id-type="pmid">15967862</pub-id>
</element-citation><mixed-citation id="mc-CR11" publication-type="journal">Freeman RV, Otto CM. Spectrum of calcific aortic valve disease: pathogenesis, disease progression, and treatment strategies. Circulation. 2005;111:3316&#x02013;26. 10.1161/circulationaha.104.486738.<pub-id pub-id-type="pmid">15967862</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Bartoli-Leonard</surname><given-names>F</given-names></name><name><surname>Zimmer</surname><given-names>J</given-names></name><name><surname>Aikawa</surname><given-names>E</given-names></name></person-group><article-title>Innate and adaptive immunity: the understudied driving force of heart valve disease</article-title><source>Cardiovasc Res</source><year>2021</year><volume>117</volume><fpage>2506</fpage><lpage>2524</lpage><pub-id pub-id-type="doi">10.1093/cvr/cvab273</pub-id><pub-id pub-id-type="pmid">34432007</pub-id>
</element-citation><mixed-citation id="mc-CR12" publication-type="journal">Bartoli-Leonard F, Zimmer J, Aikawa E. Innate and adaptive immunity: the understudied driving force of heart valve disease. Cardiovasc Res. 2021;117:2506&#x02013;24. 10.1093/cvr/cvab273.<pub-id pub-id-type="pmid">34432007</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name><surname>Erkhem-Ochir</surname><given-names>B</given-names></name><name><surname>Tatsuishi</surname><given-names>W</given-names></name><name><surname>Yokobori</surname><given-names>T</given-names></name><name><surname>Ohno</surname><given-names>T</given-names></name><name><surname>Hatori</surname><given-names>K</given-names></name><name><surname>Handa</surname><given-names>T</given-names></name><name><surname>Oyama</surname><given-names>T</given-names></name><name><surname>Shirabe</surname><given-names>K</given-names></name><name><surname>Saeki</surname><given-names>H</given-names></name><name><surname>Abe</surname><given-names>T</given-names></name></person-group><article-title>Inflammatory and immune checkpoint markers are associated with the severity of aortic stenosis</article-title><source>JTCVS Open</source><year>2021</year><volume>5</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1016/j.xjon.2020.11.007</pub-id><pub-id pub-id-type="pmid">36003161</pub-id>
</element-citation><mixed-citation id="mc-CR13" publication-type="journal">Erkhem-Ochir B, Tatsuishi W, Yokobori T, Ohno T, Hatori K, Handa T, Oyama T, Shirabe K, Saeki H, Abe T. Inflammatory and immune checkpoint markers are associated with the severity of aortic stenosis. JTCVS Open. 2021;5:1&#x02013;12. 10.1016/j.xjon.2020.11.007.<pub-id pub-id-type="pmid">36003161</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name><surname>Yu Chen</surname><given-names>H</given-names></name><name><surname>Dina</surname><given-names>C</given-names></name><name><surname>Small</surname><given-names>AM</given-names></name><name><surname>Shaffer</surname><given-names>CM</given-names></name><name><surname>Levinson</surname><given-names>RT</given-names></name><name><surname>Helgad&#x000f3;ttir</surname><given-names>A</given-names></name><name><surname>Capoulade</surname><given-names>R</given-names></name><name><surname>Munter</surname><given-names>HM</given-names></name><name><surname>Martinsson</surname><given-names>A</given-names></name><name><surname>Cairns</surname><given-names>BJ</given-names></name><etal/></person-group><article-title>Dyslipidemia, inflammation, calcification, and adiposity in aortic stenosis: a genome-wide study</article-title><source>Eur Heart J</source><year>2023</year><volume>44</volume><fpage>1927</fpage><lpage>1939</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehad142</pub-id><pub-id pub-id-type="pmid">37038246</pub-id>
</element-citation><mixed-citation id="mc-CR14" publication-type="journal">Yu Chen H, Dina C, Small AM, Shaffer CM, Levinson RT, Helgad&#x000f3;ttir A, Capoulade R, Munter HM, Martinsson A, Cairns BJ, et al. Dyslipidemia, inflammation, calcification, and adiposity in aortic stenosis: a genome-wide study. Eur Heart J. 2023;44:1927&#x02013;39. 10.1093/eurheartj/ehad142.<pub-id pub-id-type="pmid">37038246</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name><surname>Yutzey</surname><given-names>KE</given-names></name><name><surname>Demer</surname><given-names>LL</given-names></name><name><surname>Body</surname><given-names>SC</given-names></name><name><surname>Huggins</surname><given-names>GS</given-names></name><name><surname>Towler</surname><given-names>DA</given-names></name><name><surname>Giachelli</surname><given-names>CM</given-names></name><name><surname>Hofmann-Bowman</surname><given-names>MA</given-names></name><name><surname>Mortlock</surname><given-names>DP</given-names></name><name><surname>Rogers</surname><given-names>MB</given-names></name><name><surname>Sadeghi</surname><given-names>MM</given-names></name><etal/></person-group><article-title>Calcific aortic valve disease: a consensus summary from the alliance of investigators on calcific aortic valve disease</article-title><source>Arterioscler Thromb Vasc Biol</source><year>2014</year><volume>34</volume><fpage>2387</fpage><lpage>2393</lpage><pub-id pub-id-type="doi">10.1161/atvbaha.114.302523</pub-id><pub-id pub-id-type="pmid">25189570</pub-id>
</element-citation><mixed-citation id="mc-CR15" publication-type="journal">Yutzey KE, Demer LL, Body SC, Huggins GS, Towler DA, Giachelli CM, Hofmann-Bowman MA, Mortlock DP, Rogers MB, Sadeghi MM, et al. Calcific aortic valve disease: a consensus summary from the alliance of investigators on calcific aortic valve disease. Arterioscler Thromb Vasc Biol. 2014;34:2387&#x02013;93. 10.1161/atvbaha.114.302523.<pub-id pub-id-type="pmid">25189570</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name><surname>Maganti</surname><given-names>K</given-names></name><name><surname>Rigolin</surname><given-names>VH</given-names></name><name><surname>Sarano</surname><given-names>ME</given-names></name><name><surname>Bonow</surname><given-names>RO</given-names></name></person-group><article-title>Valvular heart disease: diagnosis and management</article-title><source>Mayo Clin Proc</source><year>2010</year><volume>85</volume><fpage>483</fpage><lpage>500</lpage><pub-id pub-id-type="doi">10.4065/mcp.2009.0706</pub-id><pub-id pub-id-type="pmid">20435842</pub-id>
</element-citation><mixed-citation id="mc-CR16" publication-type="journal">Maganti K, Rigolin VH, Sarano ME, Bonow RO. Valvular heart disease: diagnosis and management. Mayo Clin Proc. 2010;85:483&#x02013;500. 10.4065/mcp.2009.0706.<pub-id pub-id-type="pmid">20435842</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>S</given-names></name><name><surname>Chung</surname><given-names>WB</given-names></name><name><surname>Lee</surname><given-names>KY</given-names></name><name><surname>Jung</surname><given-names>MH</given-names></name><name><surname>Jung</surname><given-names>HO</given-names></name><name><surname>Chang</surname><given-names>K</given-names></name><name><surname>Youn</surname><given-names>HJ</given-names></name></person-group><article-title>Trans-aortic flow turbulence and aortic valve inflammation: a pilot study using blood speckle imaging and (18)F-sodium fluoride positron emission tomography/computed tomography in patients with moderate aortic stenosis</article-title><source>J Cardiovasc Imaging</source><year>2023</year><volume>31</volume><fpage>145</fpage><lpage>149</lpage><pub-id pub-id-type="doi">10.4250/jcvi.2022.0118</pub-id><pub-id pub-id-type="pmid">37488920</pub-id>
</element-citation><mixed-citation id="mc-CR17" publication-type="journal">Park S, Chung WB, Lee KY, Jung MH, Jung HO, Chang K, Youn HJ. Trans-aortic flow turbulence and aortic valve inflammation: a pilot study using blood speckle imaging and (18)F-sodium fluoride positron emission tomography/computed tomography in patients with moderate aortic stenosis. J Cardiovasc Imaging. 2023;31:145&#x02013;9. 10.4250/jcvi.2022.0118.<pub-id pub-id-type="pmid">37488920</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name><surname>Shimoni</surname><given-names>O</given-names></name><name><surname>Rapp</surname><given-names>O</given-names></name><name><surname>Klempner</surname><given-names>R</given-names></name><name><surname>Segev</surname><given-names>A</given-names></name><name><surname>Pounds</surname><given-names>C</given-names></name><name><surname>Massalha</surname><given-names>E</given-names></name></person-group><article-title>Age disparity among severe aortic stenosis patients: AVR treatment rates and clinical outcomes among octogenarians</article-title><source>Eur Heart J</source><year>2023</year><volume>44</volume><fpage>ehad655</fpage><lpage>2664</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehad655.2664</pub-id></element-citation><mixed-citation id="mc-CR18" publication-type="journal">Shimoni O, Rapp O, Klempner R, Segev A, Pounds C, Massalha E. Age disparity among severe aortic stenosis patients: AVR treatment rates and clinical outcomes among octogenarians. Eur Heart J. 2023;44:ehad655-2664. 10.1093/eurheartj/ehad655.2664.</mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name><surname>Boskovski</surname><given-names>MT</given-names></name><name><surname>Gleason</surname><given-names>TG</given-names></name></person-group><article-title>Current therapeutic options in aortic stenosis</article-title><source>Circ Res</source><year>2021</year><volume>128</volume><fpage>1398</fpage><lpage>1417</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.121.318040</pub-id><pub-id pub-id-type="pmid">33914604</pub-id>
</element-citation><mixed-citation id="mc-CR19" publication-type="journal">Boskovski MT, Gleason TG. Current therapeutic options in aortic stenosis. Circ Res. 2021;128:1398&#x02013;417. 10.1161/CIRCRESAHA.121.318040.<pub-id pub-id-type="pmid">33914604</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>SJ</given-names></name><name><surname>Ok</surname><given-names>YJ</given-names></name><name><surname>Kim</surname><given-names>HJ</given-names></name><name><surname>Kim</surname><given-names>Y-J</given-names></name><name><surname>Kim</surname><given-names>S</given-names></name><name><surname>Ahn</surname><given-names>J-M</given-names></name><name><surname>Kim</surname><given-names>D-H</given-names></name><name><surname>Choi</surname><given-names>J-S</given-names></name><name><surname>Kim</surname><given-names>JB</given-names></name></person-group><article-title>Evaluating reference ages for selecting prosthesis types for heart valve replacement in Korea</article-title><source>JAMA Netw Open</source><year>2023</year><volume>6</volume><fpage>e2314671</fpage><lpage>e2314671</lpage><pub-id pub-id-type="doi">10.1001/jamanetworkopen.2023.14671</pub-id><pub-id pub-id-type="pmid">37213100</pub-id>
</element-citation><mixed-citation id="mc-CR20" publication-type="journal">Park SJ, Ok YJ, Kim HJ, Kim Y-J, Kim S, Ahn J-M, Kim D-H, Choi J-S, Kim JB. Evaluating reference ages for selecting prosthesis types for heart valve replacement in Korea. JAMA Netw Open. 2023;6:e2314671&#x02013;e2314671. 10.1001/jamanetworkopen.2023.14671.<pub-id pub-id-type="pmid">37213100</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name><surname>Lieberman</surname><given-names>EB</given-names></name><name><surname>Bashore</surname><given-names>TM</given-names></name><name><surname>Hermiller</surname><given-names>JB</given-names></name><name><surname>Wilson</surname><given-names>JS</given-names></name><name><surname>Pieper</surname><given-names>KS</given-names></name><name><surname>Keeler</surname><given-names>GP</given-names></name><name><surname>Pierce</surname><given-names>CH</given-names></name><name><surname>Kisslo</surname><given-names>KB</given-names></name><name><surname>Harrison</surname><given-names>JK</given-names></name><name><surname>Davidson</surname><given-names>CJ</given-names></name></person-group><article-title>Balloon aortic valvuloplasty in adults: failure of procedure to improve long-term survival</article-title><source>J Am Coll Cardiol</source><year>1995</year><volume>26</volume><fpage>1522</fpage><lpage>1528</lpage><pub-id pub-id-type="doi">10.1016/0735-1097(95)00363-0</pub-id><pub-id pub-id-type="pmid">7594080</pub-id>
</element-citation><mixed-citation id="mc-CR21" publication-type="journal">Lieberman EB, Bashore TM, Hermiller JB, Wilson JS, Pieper KS, Keeler GP, Pierce CH, Kisslo KB, Harrison JK, Davidson CJ. Balloon aortic valvuloplasty in adults: failure of procedure to improve long-term survival. J Am Coll Cardiol. 1995;26:1522&#x02013;8. 10.1016/0735-1097(95)00363-0.<pub-id pub-id-type="pmid">7594080</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name><surname>Jammoul</surname><given-names>N</given-names></name><name><surname>Dupasquier</surname><given-names>V</given-names></name><name><surname>Akodad</surname><given-names>M</given-names></name><name><surname>Meunier</surname><given-names>PA</given-names></name><name><surname>Moulis</surname><given-names>L</given-names></name><name><surname>Soltani</surname><given-names>S</given-names></name><name><surname>Macia</surname><given-names>JC</given-names></name><name><surname>Robert</surname><given-names>P</given-names></name><name><surname>Schmutz</surname><given-names>L</given-names></name><name><surname>Steinecker</surname><given-names>M</given-names></name><etal/></person-group><article-title>Long-term follow-up of balloon-expandable valves according to the implantation strategy: insight from the DIRECTAVI trial</article-title><source>Am Heart J</source><year>2024</year><volume>270</volume><fpage>13</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1016/j.ahj.2024.01.005</pub-id><pub-id pub-id-type="pmid">38253304</pub-id>
</element-citation><mixed-citation id="mc-CR22" publication-type="journal">Jammoul N, Dupasquier V, Akodad M, Meunier PA, Moulis L, Soltani S, Macia JC, Robert P, Schmutz L, Steinecker M, et al. Long-term follow-up of balloon-expandable valves according to the implantation strategy: insight from the DIRECTAVI trial. Am Heart J. 2024;270:13&#x02013;22. 10.1016/j.ahj.2024.01.005.<pub-id pub-id-type="pmid">38253304</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name><surname>Iwasaki</surname><given-names>M</given-names></name><name><surname>Konishi</surname><given-names>A</given-names></name><name><surname>Takahara</surname><given-names>M</given-names></name><name><surname>Kohsaka</surname><given-names>S</given-names></name><name><surname>Okuda</surname><given-names>M</given-names></name><name><surname>Hayashi</surname><given-names>T</given-names></name><name><surname>Takamisawa</surname><given-names>I</given-names></name><name><surname>Ishii</surname><given-names>H</given-names></name><name><surname>Amano</surname><given-names>T</given-names></name><name><surname>Shinke</surname><given-names>T</given-names></name><etal/></person-group><article-title>Volume-outcome relationship in balloon aortic valvuloplasty: results of a consecutive, patient-level data analysis from a Japanese nationwide multicentre registry (J-SHD)</article-title><source>BMJ Open</source><year>2023</year><volume>13</volume><fpage>e073597</fpage><pub-id pub-id-type="doi">10.1136/bmjopen-2023-073597</pub-id><pub-id pub-id-type="pmid">37848296</pub-id>
</element-citation><mixed-citation id="mc-CR23" publication-type="journal">Iwasaki M, Konishi A, Takahara M, Kohsaka S, Okuda M, Hayashi T, Takamisawa I, Ishii H, Amano T, Shinke T, et al. Volume-outcome relationship in balloon aortic valvuloplasty: results of a consecutive, patient-level data analysis from a Japanese nationwide multicentre registry (J-SHD). BMJ Open. 2023;13:e073597. 10.1136/bmjopen-2023-073597.<pub-id pub-id-type="pmid">37848296</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name><surname>Saleemi</surname><given-names>SA</given-names></name><name><surname>Noaman</surname><given-names>S</given-names></name><name><surname>Brookes</surname><given-names>J</given-names></name><name><surname>Dick</surname><given-names>RJL</given-names></name></person-group><article-title>Clinical outcomes associated with balloon aortic valvuloplasty in the contemporary era</article-title><source>Heart Lung Circ</source><year>2024</year><volume>33</volume><fpage>33</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.1016/j.hlc.2023.10.019</pub-id><pub-id pub-id-type="pmid">38142218</pub-id>
</element-citation><mixed-citation id="mc-CR24" publication-type="journal">Saleemi SA, Noaman S, Brookes J, Dick RJL. Clinical outcomes associated with balloon aortic valvuloplasty in the contemporary era. Heart Lung Circ. 2024;33:33&#x02013;7. 10.1016/j.hlc.2023.10.019.<pub-id pub-id-type="pmid">38142218</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name><surname>O'Halloran</surname><given-names>CP</given-names></name><name><surname>Ramlogan</surname><given-names>S</given-names></name><name><surname>Husain</surname><given-names>N</given-names></name><name><surname>Fox</surname><given-names>J</given-names></name><name><surname>Nugent</surname><given-names>AW</given-names></name><name><surname>Tannous</surname><given-names>P</given-names></name></person-group><article-title>Echocardiogram-guided balloon valvuloplasty of the aortic valve in neonates and infants reduces contrast exposure with maintained efficacy and less aortic regurgitation</article-title><source>Pediatr Cardiol</source><year>2023</year><pub-id pub-id-type="doi">10.1007/s00246-023-03188-9</pub-id><pub-id pub-id-type="pmid">37391604</pub-id>
</element-citation><mixed-citation id="mc-CR25" publication-type="journal">O&#x02019;Halloran CP, Ramlogan S, Husain N, Fox J, Nugent AW, Tannous P. Echocardiogram-guided balloon valvuloplasty of the aortic valve in neonates and infants reduces contrast exposure with maintained efficacy and less aortic regurgitation. Pediatr Cardiol. 2023. 10.1007/s00246-023-03188-9.<pub-id pub-id-type="pmid">37391604</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name><surname>Harris</surname><given-names>AG</given-names></name><name><surname>Iacobazzi</surname><given-names>D</given-names></name><name><surname>Caputo</surname><given-names>M</given-names></name><name><surname>Bartoli-Leonard</surname><given-names>F</given-names></name></person-group><article-title>Graft rejection in paediatric congenital heart disease</article-title><source>Transl Pediatr</source><year>2023</year><volume>12</volume><fpage>1572</fpage><lpage>1591 </lpage><pub-id pub-id-type="doi">10.21037/tp-23-80</pub-id><pub-id pub-id-type="pmid">37692547</pub-id>
</element-citation><mixed-citation id="mc-CR26" publication-type="journal">Harris AG, Iacobazzi D, Caputo M, Bartoli-Leonard F. Graft rejection in paediatric congenital heart disease. Transl Pediatr. 2023;12:1572&#x02013;91. 10.21037/tp-23-80.<pub-id pub-id-type="pmid">37692547</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name><surname>Human</surname><given-names>P</given-names></name><name><surname>Bezuidenhout</surname><given-names>D</given-names></name><name><surname>Aikawa</surname><given-names>E</given-names></name><name><surname>Zilla</surname><given-names>P</given-names></name></person-group><article-title>Residual bioprosthetic valve immunogenicity: forgotten, not lost</article-title><source>Front Cardiovasc Med</source><year>2022</year><volume>8</volume><fpage>760635</fpage><pub-id pub-id-type="doi">10.3389/fcvm.2021.760635</pub-id><pub-id pub-id-type="pmid">35059444</pub-id>
</element-citation><mixed-citation id="mc-CR27" publication-type="journal">Human P, Bezuidenhout D, Aikawa E, Zilla P. Residual bioprosthetic valve immunogenicity: forgotten, not lost. Front Cardiovasc Med. 2022;8:760635.<pub-id pub-id-type="pmid">35059444</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name><surname>Kostyunin</surname><given-names>AE</given-names></name><name><surname>Yuzhalin</surname><given-names>AE</given-names></name><name><surname>Rezvova</surname><given-names>MA</given-names></name><name><surname>Ovcharenko</surname><given-names>EA</given-names></name><name><surname>Glushkova</surname><given-names>TV</given-names></name><name><surname>Kutikhin</surname><given-names>AG</given-names></name></person-group><article-title>Degeneration of bioprosthetic heart valves: update 2020</article-title><source>J Am Heart Assoc</source><year>2020</year><volume>9</volume><fpage>e018506</fpage><pub-id pub-id-type="doi">10.1161/JAHA.120.018506</pub-id><pub-id pub-id-type="pmid">32954917</pub-id>
</element-citation><mixed-citation id="mc-CR28" publication-type="journal">Kostyunin AE, Yuzhalin AE, Rezvova MA, Ovcharenko EA, Glushkova TV, Kutikhin AG. Degeneration of bioprosthetic heart valves: update 2020. J Am Heart Assoc. 2020;9:e018506. 10.1161/JAHA.120.018506.<pub-id pub-id-type="pmid">32954917</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name><surname>Kraler</surname><given-names>S</given-names></name><name><surname>Blaser</surname><given-names>MC</given-names></name><name><surname>Aikawa</surname><given-names>E</given-names></name><name><surname>Camici</surname><given-names>GG</given-names></name><name><surname>L&#x000fc;scher</surname><given-names>TF</given-names></name></person-group><article-title>Calcific aortic valve disease: from molecular and cellular mechanisms to medical therapy</article-title><source>Eur Heart J</source><year>2022</year><volume>43</volume><fpage>683</fpage><lpage>697</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehab757</pub-id><pub-id pub-id-type="pmid">34849696</pub-id>
</element-citation><mixed-citation id="mc-CR29" publication-type="journal">Kraler S, Blaser MC, Aikawa E, Camici GG, L&#x000fc;scher TF. Calcific aortic valve disease: from molecular and cellular mechanisms to medical therapy. Eur Heart J. 2022;43:683&#x02013;97. 10.1093/eurheartj/ehab757.<pub-id pub-id-type="pmid">34849696</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name><surname>Goody</surname><given-names>PR</given-names></name><name><surname>Hosen</surname><given-names>MR</given-names></name><name><surname>Christmann</surname><given-names>D</given-names></name><name><surname>Niepmann</surname><given-names>ST</given-names></name><name><surname>Zietzer</surname><given-names>A</given-names></name><name><surname>Adam</surname><given-names>M</given-names></name><name><surname>B&#x000f6;nner</surname><given-names>F</given-names></name><name><surname>Zimmer</surname><given-names>S</given-names></name><name><surname>Nickenig</surname><given-names>G</given-names></name><name><surname>Jansen</surname><given-names>F</given-names></name></person-group><article-title>Aortic valve stenosis: from basic mechanisms to novel therapeutic targets</article-title><source>Arterioscler Thromb Vasc Biol</source><year>2020</year><volume>40</volume><fpage>885</fpage><lpage>900</lpage><pub-id pub-id-type="doi">10.1161/atvbaha.119.313067</pub-id><pub-id pub-id-type="pmid">32160774</pub-id>
</element-citation><mixed-citation id="mc-CR30" publication-type="journal">Goody PR, Hosen MR, Christmann D, Niepmann ST, Zietzer A, Adam M, B&#x000f6;nner F, Zimmer S, Nickenig G, Jansen F. Aortic valve stenosis: from basic mechanisms to novel therapeutic targets. Arterioscler Thromb Vasc Biol. 2020;40:885&#x02013;900. 10.1161/atvbaha.119.313067.<pub-id pub-id-type="pmid">32160774</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>W</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Shen</surname><given-names>H</given-names></name><name><surname>Zeng</surname><given-names>Z</given-names></name><name><surname>Yin</surname><given-names>K</given-names></name><name><surname>Priest</surname><given-names>JR</given-names></name><name><surname>Zhou</surname><given-names>Z</given-names></name></person-group><article-title>Single-cell transcriptomic landscape of cardiac neural crest cell derivatives during development</article-title><source>EMBO Rep</source><year>2021</year><volume>22</volume><fpage>e52389 </fpage><pub-id pub-id-type="doi">10.15252/embr.202152389</pub-id><pub-id pub-id-type="pmid">34569705</pub-id>
</element-citation><mixed-citation id="mc-CR31" publication-type="journal">Chen W, Liu X, Li W, Shen H, Zeng Z, Yin K, Priest JR, Zhou Z. Single-cell transcriptomic landscape of cardiac neural crest cell derivatives during development. EMBO Rep. 2021;22:e52389. 10.15252/embr.202152389.<pub-id pub-id-type="pmid">34569705</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name><surname>Hulin</surname><given-names>A</given-names></name><name><surname>Anstine</surname><given-names>LJ</given-names></name><name><surname>Kim</surname><given-names>AJ</given-names></name><name><surname>Potter</surname><given-names>SJ</given-names></name><name><surname>DeFalco</surname><given-names>T</given-names></name><name><surname>Lincoln</surname><given-names>J</given-names></name><name><surname>Yutzey</surname><given-names>KE</given-names></name></person-group><article-title>Macrophage transitions in heart valve development and myxomatous valve disease</article-title><source>Arterioscler Thromb Vasc Biol</source><year>2018</year><volume>38</volume><fpage>636</fpage><lpage>644</lpage><pub-id pub-id-type="doi">10.1161/atvbaha.117.310667</pub-id><pub-id pub-id-type="pmid">29348122</pub-id>
</element-citation><mixed-citation id="mc-CR32" publication-type="journal">Hulin A, Anstine LJ, Kim AJ, Potter SJ, DeFalco T, Lincoln J, Yutzey KE. Macrophage transitions in heart valve development and myxomatous valve disease. Arterioscler Thromb Vasc Biol. 2018;38:636&#x02013;44. 10.1161/atvbaha.117.310667.<pub-id pub-id-type="pmid">29348122</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><mixed-citation publication-type="other">Bartoli-Leonard F, Chelvanambi S, Pham T, Turner ME, Blaser MC, Caputo M, Aikawa M, Pang A, Muehlschlegel J, Aikawa E. Single-cell T cell receptor sequencing of paired tissue and blood samples reveals clonal expansion of CD8+ effector T cells in patients with calcific aortic valve disease. <italic>bioRxiv</italic>. 2023:2023.2007.2008.548203. 10.1101/2023.07.08.548203</mixed-citation></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name><surname>Hulin</surname><given-names>A</given-names></name><name><surname>Hortells</surname><given-names>L</given-names></name><name><surname>Gomez-Stallons</surname><given-names>MV</given-names></name><name><surname>O'Donnell</surname><given-names>A</given-names></name><name><surname>Chetal</surname><given-names>K</given-names></name><name><surname>Adam</surname><given-names>M</given-names></name><name><surname>Lancellotti</surname><given-names>P</given-names></name><name><surname>Oury</surname><given-names>C</given-names></name><name><surname>Potter</surname><given-names>SS</given-names></name><name><surname>Salomonis</surname><given-names>N</given-names></name><etal/></person-group><article-title>Maturation of heart valve cell populations during postnatal remodeling</article-title><source>Development</source><year>2019</year><volume>146</volume><fpage>dev.173047</fpage><pub-id pub-id-type="doi">10.1242/dev.173047</pub-id></element-citation><mixed-citation id="mc-CR34" publication-type="journal">Hulin A, Hortells L, Gomez-Stallons MV, O&#x02019;Donnell A, Chetal K, Adam M, Lancellotti P, Oury C, Potter SS, Salomonis N, et al. Maturation of heart valve cell populations during postnatal remodeling. Development. 2019;146:dev.173047. 10.1242/dev.173047.</mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name><surname>Raddatz</surname><given-names>MA</given-names></name><name><surname>Madhur</surname><given-names>MS</given-names></name><name><surname>Merryman</surname><given-names>WD</given-names></name></person-group><article-title>Adaptive immune cells in calcific aortic valve disease</article-title><source>Am J Physiol Heart Circ Physiol</source><year>2019</year><volume>317</volume><fpage>H141</fpage><lpage>h155</lpage><pub-id pub-id-type="doi">10.1152/ajpheart.00100.2019</pub-id><pub-id pub-id-type="pmid">31050556</pub-id>
</element-citation><mixed-citation id="mc-CR35" publication-type="journal">Raddatz MA, Madhur MS, Merryman WD. Adaptive immune cells in calcific aortic valve disease. Am J Physiol Heart Circ Physiol. 2019;317:H141-h155. 10.1152/ajpheart.00100.2019.<pub-id pub-id-type="pmid">31050556</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name><surname>Hajdu</surname><given-names>Z</given-names></name><name><surname>Romeo</surname><given-names>SJ</given-names></name><name><surname>Fleming</surname><given-names>PA</given-names></name><name><surname>Markwald</surname><given-names>RR</given-names></name><name><surname>Visconti</surname><given-names>RP</given-names></name><name><surname>Drake</surname><given-names>CJ</given-names></name></person-group><article-title>Recruitment of bone marrow-derived valve interstitial cells is a normal homeostatic process</article-title><source>J Mol Cell Cardiol</source><year>2011</year><volume>51</volume><fpage>955</fpage><lpage>965</lpage><pub-id pub-id-type="doi">10.1016/j.yjmcc.2011.08.006</pub-id><pub-id pub-id-type="pmid">21871458</pub-id>
</element-citation><mixed-citation id="mc-CR36" publication-type="journal">Hajdu Z, Romeo SJ, Fleming PA, Markwald RR, Visconti RP, Drake CJ. Recruitment of bone marrow-derived valve interstitial cells is a normal homeostatic process. J Mol Cell Cardiol. 2011;51:955&#x02013;65. 10.1016/j.yjmcc.2011.08.006.<pub-id pub-id-type="pmid">21871458</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>SH</given-names></name><name><surname>Choi</surname><given-names>JH</given-names></name></person-group><article-title>Involvement of immune cell network in aortic valve stenosis: communication between valvular interstitial cells and immune cells</article-title><source>Immune Netw</source><year>2016</year><volume>16</volume><fpage>26</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.4110/in.2016.16.1.26</pub-id><pub-id pub-id-type="pmid">26937229</pub-id>
</element-citation><mixed-citation id="mc-CR37" publication-type="journal">Lee SH, Choi JH. Involvement of immune cell network in aortic valve stenosis: communication between valvular interstitial cells and immune cells. Immune Netw. 2016;16:26&#x02013;32. 10.4110/in.2016.16.1.26.<pub-id pub-id-type="pmid">26937229</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name><surname>Zernecke</surname><given-names>A</given-names></name></person-group><article-title>Dendritic cells in atherosclerosis: evidence in mice and humans</article-title><source>Arterioscler Thromb Vasc Biol</source><year>2015</year><volume>35</volume><fpage>763</fpage><lpage>770</lpage><pub-id pub-id-type="doi">10.1161/atvbaha.114.303566</pub-id><pub-id pub-id-type="pmid">25675999</pub-id>
</element-citation><mixed-citation id="mc-CR38" publication-type="journal">Zernecke A. Dendritic cells in atherosclerosis: evidence in mice and humans. Arterioscler Thromb Vasc Biol. 2015;35:763&#x02013;70. 10.1161/atvbaha.114.303566.<pub-id pub-id-type="pmid">25675999</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name><surname>Ait-Oufella</surname><given-names>H</given-names></name><name><surname>Sage</surname><given-names>AP</given-names></name><name><surname>Mallat</surname><given-names>Z</given-names></name><name><surname>Tedgui</surname><given-names>A</given-names></name></person-group><article-title>Adaptive (T and B Cells) Immunity and control by dendritic cells in atherosclerosis</article-title><source>Circ Res</source><year>2014</year><volume>114</volume><fpage>1640</fpage><lpage>1660</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.114.302761</pub-id><pub-id pub-id-type="pmid">24812352</pub-id>
</element-citation><mixed-citation id="mc-CR39" publication-type="journal">Ait-Oufella H, Sage AP, Mallat Z, Tedgui A. Adaptive (T and B Cells) Immunity and control by dendritic cells in atherosclerosis. Circ Res. 2014;114:1640&#x02013;60. 10.1161/CIRCRESAHA.114.302761.<pub-id pub-id-type="pmid">24812352</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>G</given-names></name><name><surname>Qiao</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Li</surname><given-names>F</given-names></name><name><surname>Shi</surname><given-names>J</given-names></name><name><surname>Dong</surname><given-names>N</given-names></name></person-group><article-title>The shift of macrophages toward M1 phenotype promotes aortic valvular calcification</article-title><source>J Thorac Cardiovasc Surg</source><year>2017</year><volume>153</volume><fpage>1318</fpage><lpage>1327.e1311</lpage><pub-id pub-id-type="doi">10.1016/j.jtcvs.2017.01.052</pub-id><pub-id pub-id-type="pmid">28283241</pub-id>
</element-citation><mixed-citation id="mc-CR40" publication-type="journal">Li G, Qiao W, Zhang W, Li F, Shi J, Dong N. The shift of macrophages toward M1 phenotype promotes aortic valvular calcification. J Thorac Cardiovasc Surg. 2017;153:1318-1327.e1311. 10.1016/j.jtcvs.2017.01.052.<pub-id pub-id-type="pmid">28283241</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>J-H</given-names></name><name><surname>Do</surname><given-names>Y</given-names></name><name><surname>Cheong</surname><given-names>C</given-names></name><name><surname>Koh</surname><given-names>H</given-names></name><name><surname>Boscardin</surname><given-names>SB</given-names></name><name><surname>Oh</surname><given-names>Y-S</given-names></name><name><surname>Bozzacco</surname><given-names>L</given-names></name><name><surname>Trumpfheller</surname><given-names>C</given-names></name><name><surname>Park</surname><given-names>CG</given-names></name><name><surname>Steinman</surname><given-names>RM</given-names></name></person-group><article-title>Identification of antigen-presenting dendritic cells in mouse aorta and cardiac valves</article-title><source>J Exp Med</source><year>2009</year><volume>206</volume><fpage>497</fpage><lpage>505</lpage><pub-id pub-id-type="doi">10.1084/jem.20082129</pub-id><pub-id pub-id-type="pmid">19221394</pub-id>
</element-citation><mixed-citation id="mc-CR41" publication-type="journal">Choi J-H, Do Y, Cheong C, Koh H, Boscardin SB, Oh Y-S, Bozzacco L, Trumpfheller C, Park CG, Steinman RM. Identification of antigen-presenting dendritic cells in mouse aorta and cardiac valves. J Exp Med. 2009;206:497&#x02013;505. 10.1084/jem.20082129.<pub-id pub-id-type="pmid">19221394</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name><surname>Davies</surname><given-names>LC</given-names></name><name><surname>Jenkins</surname><given-names>SJ</given-names></name><name><surname>Allen</surname><given-names>JE</given-names></name><name><surname>Taylor</surname><given-names>PR</given-names></name></person-group><article-title>Tissue-resident macrophages</article-title><source>Nat Immunol</source><year>2013</year><volume>14</volume><fpage>986</fpage><lpage>995</lpage><pub-id pub-id-type="doi">10.1038/ni.2705</pub-id><pub-id pub-id-type="pmid">24048120</pub-id>
</element-citation><mixed-citation id="mc-CR42" publication-type="journal">Davies LC, Jenkins SJ, Allen JE, Taylor PR. Tissue-resident macrophages. Nat Immunol. 2013;14:986&#x02013;95. 10.1038/ni.2705.<pub-id pub-id-type="pmid">24048120</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>B</given-names></name><name><surname>Farrar</surname><given-names>E</given-names></name><name><surname>Lui</surname><given-names>W</given-names></name><name><surname>Lu</surname><given-names>P</given-names></name><name><surname>Zhang</surname><given-names>D</given-names></name><name><surname>Alfieri</surname><given-names>CM</given-names></name><name><surname>Mao</surname><given-names>K</given-names></name><name><surname>Chu</surname><given-names>M</given-names></name><name><surname>Yang</surname><given-names>D</given-names></name><etal/></person-group><article-title>Notch-Tnf signalling is required for development and homeostasis of arterial valves</article-title><source>Eur Heart J</source><year>2015</year><volume>38</volume><fpage>675</fpage><lpage>686</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehv520</pub-id></element-citation><mixed-citation id="mc-CR43" publication-type="journal">Wang Y, Wu B, Farrar E, Lui W, Lu P, Zhang D, Alfieri CM, Mao K, Chu M, Yang D, et al. Notch-Tnf signalling is required for development and homeostasis of arterial valves. Eur Heart J. 2015;38:675&#x02013;86. 10.1093/eurheartj/ehv520.</mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name><surname>Gottlieb Sen</surname><given-names>D</given-names></name><name><surname>Halu</surname><given-names>A</given-names></name><name><surname>Razzaque</surname><given-names>A</given-names></name><name><surname>Gorham</surname><given-names>JM</given-names></name><name><surname>Hartnett</surname><given-names>J</given-names></name><name><surname>Seidman</surname><given-names>JG</given-names></name><name><surname>Aikawa</surname><given-names>E</given-names></name><name><surname>Seidman</surname><given-names>CE</given-names></name></person-group><article-title>The transcriptional signature of growth in human fetal aortic valve development</article-title><source>Ann Thorac Surg</source><year>2018</year><volume>106</volume><fpage>1834</fpage><lpage>1840</lpage><pub-id pub-id-type="doi">10.1016/j.athoracsur.2018.06.034</pub-id><pub-id pub-id-type="pmid">30071238</pub-id>
</element-citation><mixed-citation id="mc-CR44" publication-type="journal">Gottlieb Sen D, Halu A, Razzaque A, Gorham JM, Hartnett J, Seidman JG, Aikawa E, Seidman CE. The transcriptional signature of growth in human fetal aortic valve development. Ann Thorac Surg. 2018;106:1834&#x02013;40. 10.1016/j.athoracsur.2018.06.034.<pub-id pub-id-type="pmid">30071238</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name><surname>Aikawa</surname><given-names>E</given-names></name><name><surname>Whittaker</surname><given-names>P</given-names></name><name><surname>Farber</surname><given-names>M</given-names></name><name><surname>Mendelson</surname><given-names>K</given-names></name><name><surname>Padera</surname><given-names>RF</given-names></name><name><surname>Aikawa</surname><given-names>M</given-names></name><name><surname>Schoen</surname><given-names>FJ</given-names></name></person-group><article-title>Human semilunar cardiac valve remodeling by activated cells from fetus to adult: implications for postnatal adaptation, pathology, and tissue engineering</article-title><source>Circulation</source><year>2006</year><volume>113</volume><fpage>1344</fpage><lpage>1352</lpage><pub-id pub-id-type="doi">10.1161/circulationaha.105.591768</pub-id><pub-id pub-id-type="pmid">16534030</pub-id>
</element-citation><mixed-citation id="mc-CR45" publication-type="journal">Aikawa E, Whittaker P, Farber M, Mendelson K, Padera RF, Aikawa M, Schoen FJ. Human semilunar cardiac valve remodeling by activated cells from fetus to adult: implications for postnatal adaptation, pathology, and tissue engineering. Circulation. 2006;113:1344&#x02013;52. 10.1161/circulationaha.105.591768.<pub-id pub-id-type="pmid">16534030</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>X</given-names></name><name><surname>Zhao</surname><given-names>D</given-names></name><name><surname>Yuan</surname><given-names>P</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Yun</surname><given-names>Y</given-names></name><name><surname>Cui</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>T</given-names></name><name><surname>Ma</surname><given-names>J</given-names></name><name><surname>Sun</surname><given-names>L</given-names></name><name><surname>Ma</surname><given-names>H</given-names></name><etal/></person-group><article-title>Endothelial-to-mesenchymal transition in calcific aortic valve disease</article-title><source>Acta Cardiol Sin</source><year>2020</year><volume>36</volume><fpage>183</fpage><lpage>194</lpage><pub-id pub-id-type="doi">10.6515/acs.202005_36(3).20200213a</pub-id><pub-id pub-id-type="pmid">32425433</pub-id>
</element-citation><mixed-citation id="mc-CR46" publication-type="journal">Ma X, Zhao D, Yuan P, Li J, Yun Y, Cui Y, Zhang T, Ma J, Sun L, Ma H, et al. Endothelial-to-mesenchymal transition in calcific aortic valve disease. Acta Cardiol Sin. 2020;36:183&#x02013;94. 10.6515/acs.202005_36(3).20200213a.<pub-id pub-id-type="pmid">32425433</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47.</label><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name><surname>Driscoll</surname><given-names>K</given-names></name><name><surname>Cruz</surname><given-names>AD</given-names></name><name><surname>Butcher</surname><given-names>JT</given-names></name></person-group><article-title>Inflammatory and biomechanical drivers of endothelial-interstitial interactions in calcific aortic valve disease</article-title><source>Circ Res</source><year>2021</year><volume>128</volume><fpage>1344</fpage><lpage>1370</lpage><pub-id pub-id-type="doi">10.1161/circresaha.121.318011</pub-id><pub-id pub-id-type="pmid">33914601</pub-id>
</element-citation><mixed-citation id="mc-CR47" publication-type="journal">Driscoll K, Cruz AD, Butcher JT. Inflammatory and biomechanical drivers of endothelial-interstitial interactions in calcific aortic valve disease. Circ Res. 2021;128:1344&#x02013;70. 10.1161/circresaha.121.318011.<pub-id pub-id-type="pmid">33914601</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR48"><label>48.</label><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>R</given-names></name><name><surname>Chen</surname><given-names>W</given-names></name><name><surname>Ma</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name></person-group><article-title>M1/M2 macrophages and associated mechanisms in congenital bicuspid aortic valve stenosis</article-title><source>Exp Ther Med</source><year>2014</year><volume>7</volume><fpage>935</fpage><lpage>940</lpage><pub-id pub-id-type="doi">10.3892/etm.2014.1529</pub-id><pub-id pub-id-type="pmid">24669254</pub-id>
</element-citation><mixed-citation id="mc-CR48" publication-type="journal">Wang R, Chen W, Ma Z, Li L, Chen X. M1/M2 macrophages and associated mechanisms in congenital bicuspid aortic valve stenosis. Exp Ther Med. 2014;7:935&#x02013;40. 10.3892/etm.2014.1529.<pub-id pub-id-type="pmid">24669254</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR49"><label>49.</label><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name><surname>Lupieri</surname><given-names>A</given-names></name><name><surname>Nagata</surname><given-names>Y</given-names></name><name><surname>Passos</surname><given-names>LSA</given-names></name><name><surname>Beker-Greene</surname><given-names>D</given-names></name><name><surname>Kirkwood</surname><given-names>KA</given-names></name><name><surname>Wylie-Sears</surname><given-names>J</given-names></name><name><surname>Alvandi</surname><given-names>Z</given-names></name><name><surname>Higashi</surname><given-names>H</given-names></name><name><surname>Hung</surname><given-names>JW</given-names></name><name><surname>Singh</surname><given-names>SA</given-names></name><etal/></person-group><article-title>Integration of functional imaging, cytometry, and unbiased proteomics reveals new features of endothelial-to-mesenchymal transition in ischemic mitral valve regurgitation in human patients</article-title><source>Front Cardiovasc Med</source><year>2021</year><volume>8</volume><fpage>688396</fpage><pub-id pub-id-type="doi">10.3389/fcvm.2021.688396</pub-id><pub-id pub-id-type="pmid">34458332</pub-id>
</element-citation><mixed-citation id="mc-CR49" publication-type="journal">Lupieri A, Nagata Y, Passos LSA, Beker-Greene D, Kirkwood KA, Wylie-Sears J, Alvandi Z, Higashi H, Hung JW, Singh SA, et al. Integration of functional imaging, cytometry, and unbiased proteomics reveals new features of endothelial-to-mesenchymal transition in ischemic mitral valve regurgitation in human patients. Front Cardiovasc Med. 2021;8:688396. 10.3389/fcvm.2021.688396.<pub-id pub-id-type="pmid">34458332</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR50"><label>50.</label><citation-alternatives><element-citation id="ec-CR50" publication-type="journal"><person-group person-group-type="author"><name><surname>Shu</surname><given-names>L</given-names></name><name><surname>Yuan</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>F</given-names></name><name><surname>Cai</surname><given-names>Z</given-names></name></person-group><article-title>Oxidative stress and valvular endothelial cells in aortic valve calcification</article-title><source>Biomed Pharmacother</source><year>2023</year><volume>163</volume><fpage>114775</fpage><pub-id pub-id-type="doi">10.1016/j.biopha.2023.114775</pub-id><pub-id pub-id-type="pmid">37116353</pub-id>
</element-citation><mixed-citation id="mc-CR50" publication-type="journal">Shu L, Yuan Z, Li F, Cai Z. Oxidative stress and valvular endothelial cells in aortic valve calcification. Biomed Pharmacother. 2023;163:114775. 10.1016/j.biopha.2023.114775.<pub-id pub-id-type="pmid">37116353</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR51"><label>51.</label><citation-alternatives><element-citation id="ec-CR51" publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Bai</surname><given-names>Z</given-names></name><name><surname>Quan</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>C</given-names></name></person-group><article-title>Identification of oxidative stress-related genes associated with immune cells in aortic valve stenosis based on bioinformatics analysis</article-title><source>Cell Mol Biol (Noisy-le-grand)</source><year>2023</year><volume>69</volume><fpage>204</fpage><lpage>209 </lpage><pub-id pub-id-type="doi">10.14715/cmb/2023.69.15.35</pub-id><pub-id pub-id-type="pmid">38279441</pub-id>
</element-citation><mixed-citation id="mc-CR51" publication-type="journal">Li S, Bai Z, Quan J, Chen C. Identification of oxidative stress-related genes associated with immune cells in aortic valve stenosis based on bioinformatics analysis. Cell Mol Biol (Noisy-le-grand). 2023;69:204&#x02013;9. 10.14715/cmb/2023.69.15.35.<pub-id pub-id-type="pmid">38279441</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR52"><label>52.</label><citation-alternatives><element-citation id="ec-CR52" publication-type="journal"><person-group person-group-type="author"><name><surname>Thomas</surname><given-names>G</given-names></name><name><surname>Tacke</surname><given-names>R</given-names></name><name><surname>Hedrick</surname><given-names>CC</given-names></name><name><surname>Hanna</surname><given-names>RN</given-names></name></person-group><article-title>Nonclassical patrolling monocyte function in the vasculature</article-title><source>Arterioscler Thromb Vasc Biol</source><year>2015</year><volume>35</volume><fpage>1306</fpage><lpage>1316</lpage><pub-id pub-id-type="doi">10.1161/ATVBAHA.114.304650</pub-id><pub-id pub-id-type="pmid">25838429</pub-id>
</element-citation><mixed-citation id="mc-CR52" publication-type="journal">Thomas G, Tacke R, Hedrick CC, Hanna RN. Nonclassical patrolling monocyte function in the vasculature. Arterioscler Thromb Vasc Biol. 2015;35:1306&#x02013;16. 10.1161/ATVBAHA.114.304650.<pub-id pub-id-type="pmid">25838429</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR53"><label>53.</label><citation-alternatives><element-citation id="ec-CR53" publication-type="journal"><person-group person-group-type="author"><name><surname>Hewing</surname><given-names>B</given-names></name><name><surname>Au</surname><given-names>SC-D</given-names></name><name><surname>Ludwig</surname><given-names>A</given-names></name><name><surname>Ellerbroek</surname><given-names>R</given-names></name><name><surname>van Dijck</surname><given-names>P</given-names></name><name><surname>Hartmann</surname><given-names>L</given-names></name><name><surname>Grubitzsch</surname><given-names>H</given-names></name><name><surname>Giannini</surname><given-names>C</given-names></name><name><surname>Laule</surname><given-names>M</given-names></name><name><surname>Stangl</surname><given-names>V</given-names></name><etal/></person-group><article-title>Severe aortic valve stenosis in adults is associated with increased levels of circulating intermediate monocytes</article-title><source>J Cardiovasc Transl Res</source><year>2017</year><volume>10</volume><fpage>27</fpage><lpage>34 </lpage><pub-id pub-id-type="doi">10.1007/s12265-016-9726-9</pub-id><pub-id pub-id-type="pmid">28097522</pub-id>
</element-citation><mixed-citation id="mc-CR53" publication-type="journal">Hewing B, Au SC-D, Ludwig A, Ellerbroek R, van Dijck P, Hartmann L, Grubitzsch H, Giannini C, Laule M, Stangl V, et al. Severe aortic valve stenosis in adults is associated with increased levels of circulating intermediate monocytes. J Cardiovasc Transl Res. 2017;10:27&#x02013;34. 10.1007/s12265-016-9726-9.<pub-id pub-id-type="pmid">28097522</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR54"><label>54.</label><citation-alternatives><element-citation id="ec-CR54" publication-type="journal"><person-group person-group-type="author"><name><surname>Schwartzenberg</surname><given-names>S</given-names></name><name><surname>Meledin</surname><given-names>V</given-names></name><name><surname>Zilberman</surname><given-names>L</given-names></name><name><surname>Goland</surname><given-names>S</given-names></name><name><surname>George</surname><given-names>J</given-names></name><name><surname>Shimoni</surname><given-names>S</given-names></name></person-group><article-title>Low circulating monocyte count is associated with severe aortic valve stenosis</article-title><source>Isr Med Assoc J</source><year>2013</year><volume>15</volume><fpage>500</fpage><lpage>504</lpage><pub-id pub-id-type="pmid">24340842</pub-id>
</element-citation><mixed-citation id="mc-CR54" publication-type="journal">Schwartzenberg S, Meledin V, Zilberman L, Goland S, George J, Shimoni S. Low circulating monocyte count is associated with severe aortic valve stenosis. Isr Med Assoc J. 2013;15:500&#x02013;4.<pub-id pub-id-type="pmid">24340842</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR55"><label>55.</label><citation-alternatives><element-citation id="ec-CR55" publication-type="journal"><person-group person-group-type="author"><name><surname>Abplanalp</surname><given-names>WT</given-names></name><name><surname>Mas-Peiro</surname><given-names>S</given-names></name><name><surname>Cremer</surname><given-names>S</given-names></name><name><surname>John</surname><given-names>D</given-names></name><name><surname>Dimmeler</surname><given-names>S</given-names></name><name><surname>Zeiher</surname><given-names>AM</given-names></name></person-group><article-title>Association of clonal hematopoiesis of indeterminate potential with inflammatory gene expression in patients with severe degenerative aortic valve stenosis or chronic postischemic heart failure</article-title><source>JAMA Cardiol</source><year>2020</year><volume>5</volume><fpage>1</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1001/jamacardio.2020.2468</pub-id></element-citation><mixed-citation id="mc-CR55" publication-type="journal">Abplanalp WT, Mas-Peiro S, Cremer S, John D, Dimmeler S, Zeiher AM. Association of clonal hematopoiesis of indeterminate potential with inflammatory gene expression in patients with severe degenerative aortic valve stenosis or chronic postischemic heart failure. JAMA Cardiol. 2020;5:1&#x02013;6. 10.1001/jamacardio.2020.2468.</mixed-citation></citation-alternatives></ref><ref id="CR56"><label>56.</label><citation-alternatives><element-citation id="ec-CR56" publication-type="journal"><person-group person-group-type="author"><name><surname>Mazur</surname><given-names>P</given-names></name><name><surname>Mielimonka</surname><given-names>A</given-names></name><name><surname>Natorska</surname><given-names>J</given-names></name><name><surname>Wypasek</surname><given-names>E</given-names></name><name><surname>Gaw&#x00119;da</surname><given-names>B</given-names></name><name><surname>Sobczyk</surname><given-names>D</given-names></name><name><surname>Kapusta</surname><given-names>P</given-names></name><name><surname>Malinowski</surname><given-names>KP</given-names></name><name><surname>Kapelak</surname><given-names>B</given-names></name></person-group><article-title>Lymphocyte and monocyte subpopulations in severe aortic stenosis at the time of surgical intervention</article-title><source>Cardiovasc Pathol</source><year>2018</year><volume>35</volume><fpage>1</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1016/j.carpath.2018.03.004</pub-id><pub-id pub-id-type="pmid">29727769</pub-id>
</element-citation><mixed-citation id="mc-CR56" publication-type="journal">Mazur P, Mielimonka A, Natorska J, Wypasek E, Gaw&#x00119;da B, Sobczyk D, Kapusta P, Malinowski KP, Kapelak B. Lymphocyte and monocyte subpopulations in severe aortic stenosis at the time of surgical intervention. Cardiovasc Pathol. 2018;35:1&#x02013;7. 10.1016/j.carpath.2018.03.004.<pub-id pub-id-type="pmid">29727769</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR57"><label>57.</label><citation-alternatives><element-citation id="ec-CR57" publication-type="journal"><person-group person-group-type="author"><name><surname>Sraeyes</surname><given-names>S</given-names></name><name><surname>Pham</surname><given-names>DH</given-names></name><name><surname>Gee</surname><given-names>TW</given-names></name><name><surname>Hua</surname><given-names>J</given-names></name><name><surname>Butcher</surname><given-names>JT</given-names></name></person-group><article-title>Monocytes and macrophages in heart valves: uninvited guests or critical performers?</article-title><source>Curr Opin Biomed Eng</source><year>2018</year><volume>5</volume><fpage>82</fpage><lpage>89</lpage><pub-id pub-id-type="doi">10.1016/j.cobme.2018.02.003</pub-id><pub-id pub-id-type="pmid">30276357</pub-id>
</element-citation><mixed-citation id="mc-CR57" publication-type="journal">Sraeyes S, Pham DH, Gee TW, Hua J, Butcher JT. Monocytes and macrophages in heart valves: uninvited guests or critical performers? Curr Opin Biomed Eng. 2018;5:82&#x02013;9. 10.1016/j.cobme.2018.02.003.<pub-id pub-id-type="pmid">30276357</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR58"><label>58.</label><citation-alternatives><element-citation id="ec-CR58" publication-type="journal"><person-group person-group-type="author"><name><surname>Barrett</surname><given-names>TJ</given-names></name></person-group><article-title>Macrophages in atherosclerosis regression</article-title><source>Arterioscler Thromb Vasc Biol</source><year>2020</year><volume>40</volume><fpage>20</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1161/ATVBAHA.119.312802</pub-id><pub-id pub-id-type="pmid">31722535</pub-id>
</element-citation><mixed-citation id="mc-CR58" publication-type="journal">Barrett TJ. Macrophages in atherosclerosis regression. Arterioscler Thromb Vasc Biol. 2020;40:20&#x02013;33. 10.1161/ATVBAHA.119.312802.<pub-id pub-id-type="pmid">31722535</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR59"><label>59.</label><citation-alternatives><element-citation id="ec-CR59" publication-type="journal"><person-group person-group-type="author"><name><surname>Fadini</surname><given-names>GP</given-names></name><name><surname>Simoni</surname><given-names>F</given-names></name><name><surname>Cappellari</surname><given-names>R</given-names></name><name><surname>Vitturi</surname><given-names>N</given-names></name><name><surname>Galasso</surname><given-names>S</given-names></name><name><surname>Vigili de Kreutzenberg</surname><given-names>S</given-names></name><name><surname>Previato</surname><given-names>L</given-names></name><name><surname>Avogaro</surname><given-names>A</given-names></name></person-group><article-title>Pro-inflammatory monocyte-macrophage polarization imbalance in human hypercholesterolemia and atherosclerosis</article-title><source>Atherosclerosis</source><year>2014</year><volume>237</volume><fpage>805</fpage><lpage>808</lpage><pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2014.10.106</pub-id><pub-id pub-id-type="pmid">25463124</pub-id>
</element-citation><mixed-citation id="mc-CR59" publication-type="journal">Fadini GP, Simoni F, Cappellari R, Vitturi N, Galasso S, Vigili de Kreutzenberg S, Previato L, Avogaro A. Pro-inflammatory monocyte-macrophage polarization imbalance in human hypercholesterolemia and atherosclerosis. Atherosclerosis. 2014;237:805&#x02013;8. 10.1016/j.atherosclerosis.2014.10.106.<pub-id pub-id-type="pmid">25463124</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR60"><label>60.</label><citation-alternatives><element-citation id="ec-CR60" publication-type="journal"><person-group person-group-type="author"><name><surname>Fernandez</surname><given-names>DM</given-names></name><name><surname>Rahman</surname><given-names>AH</given-names></name><name><surname>Fernandez</surname><given-names>NF</given-names></name><name><surname>Chudnovskiy</surname><given-names>A</given-names></name><name><surname>Amir</surname><given-names>EAD</given-names></name><name><surname>Amadori</surname><given-names>L</given-names></name><name><surname>Khan</surname><given-names>NS</given-names></name><name><surname>Wong</surname><given-names>CK</given-names></name><name><surname>Shamailova</surname><given-names>R</given-names></name><name><surname>Hill</surname><given-names>CA</given-names></name><etal/></person-group><article-title>Single-cell immune landscape of human atherosclerotic plaques</article-title><source>Nat Med</source><year>2019</year><volume>25</volume><fpage>1576</fpage><lpage>1588</lpage><pub-id pub-id-type="doi">10.1038/s41591-019-0590-4</pub-id><pub-id pub-id-type="pmid">31591603</pub-id>
</element-citation><mixed-citation id="mc-CR60" publication-type="journal">Fernandez DM, Rahman AH, Fernandez NF, Chudnovskiy A, Amir EAD, Amadori L, Khan NS, Wong CK, Shamailova R, Hill CA, et al. Single-cell immune landscape of human atherosclerotic plaques. Nat Med. 2019;25:1576&#x02013;88. 10.1038/s41591-019-0590-4.<pub-id pub-id-type="pmid">31591603</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR61"><label>61.</label><citation-alternatives><element-citation id="ec-CR61" publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>JL</given-names></name><name><surname>Newby</surname><given-names>AC</given-names></name></person-group><article-title>Macrophage heterogeneity in atherosclerotic plaques</article-title><source>Curr Opin Lipidol</source><year>2009</year><volume>20</volume><fpage>370</fpage><lpage>378</lpage><pub-id pub-id-type="doi">10.1097/MOL.0b013e3283309848</pub-id><pub-id pub-id-type="pmid">19741337</pub-id>
</element-citation><mixed-citation id="mc-CR61" publication-type="journal">Johnson JL, Newby AC. Macrophage heterogeneity in atherosclerotic plaques. Curr Opin Lipidol. 2009;20:370&#x02013;8. 10.1097/MOL.0b013e3283309848.<pub-id pub-id-type="pmid">19741337</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR62"><label>62.</label><citation-alternatives><element-citation id="ec-CR62" publication-type="journal"><person-group person-group-type="author"><name><surname>Grim</surname><given-names>JC</given-names></name><name><surname>Aguado</surname><given-names>BA</given-names></name><name><surname>Vogt</surname><given-names>BJ</given-names></name><name><surname>Batan</surname><given-names>D</given-names></name><name><surname>Andrichik</surname><given-names>CL</given-names></name><name><surname>Schroeder</surname><given-names>ME</given-names></name><name><surname>Gonzalez-Rodriguez</surname><given-names>A</given-names></name><name><surname>Yavitt</surname><given-names>FM</given-names></name><name><surname>Weiss</surname><given-names>RM</given-names></name><name><surname>Anseth</surname><given-names>KS</given-names></name></person-group><article-title>Secreted factors from proinflammatory macrophages promote an osteoblast-like phenotype in valvular interstitial cells</article-title><source>Arterioscler Thromb Vasc Biol</source><year>2020</year><volume>40</volume><fpage>e296</fpage><lpage>e308</lpage><pub-id pub-id-type="doi">10.1161/atvbaha.120.315261</pub-id><pub-id pub-id-type="pmid">32938214</pub-id>
</element-citation><mixed-citation id="mc-CR62" publication-type="journal">Grim JC, Aguado BA, Vogt BJ, Batan D, Andrichik CL, Schroeder ME, Gonzalez-Rodriguez A, Yavitt FM, Weiss RM, Anseth KS. Secreted factors from proinflammatory macrophages promote an osteoblast-like phenotype in valvular interstitial cells. Arterioscler Thromb Vasc Biol. 2020;40:e296&#x02013;308. 10.1161/atvbaha.120.315261.<pub-id pub-id-type="pmid">32938214</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR63"><label>63.</label><citation-alternatives><element-citation id="ec-CR63" publication-type="journal"><person-group person-group-type="author"><name><surname>H&#x000f6;gerle</surname><given-names>BA</given-names></name><name><surname>Schneider</surname><given-names>M</given-names></name><name><surname>Sudrow</surname><given-names>K</given-names></name><name><surname>Souidi</surname><given-names>N</given-names></name><name><surname>Stolk</surname><given-names>M</given-names></name><name><surname>Werner</surname><given-names>I</given-names></name><name><surname>Biermann</surname><given-names>A</given-names></name><name><surname>Brockbank</surname><given-names>KGM</given-names></name><name><surname>Stock</surname><given-names>UA</given-names></name><name><surname>Seifert</surname><given-names>M</given-names></name></person-group><article-title>Effects on human heart valve immunogenicity in vitro by high concentration cryoprotectant treatment</article-title><source>J Tissue Eng Regen Med</source><year>2018</year><volume>12</volume><fpage>e1046</fpage><lpage>e1055</lpage><pub-id pub-id-type="doi">10.1002/term.2426</pub-id><pub-id pub-id-type="pmid">28130912</pub-id>
</element-citation><mixed-citation id="mc-CR63" publication-type="journal">H&#x000f6;gerle BA, Schneider M, Sudrow K, Souidi N, Stolk M, Werner I, Biermann A, Brockbank KGM, Stock UA, Seifert M. Effects on human heart valve immunogenicity in vitro by high concentration cryoprotectant treatment. J Tissue Eng Regen Med. 2018;12:e1046&#x02013;55. 10.1002/term.2426.<pub-id pub-id-type="pmid">28130912</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR64"><label>64.</label><citation-alternatives><element-citation id="ec-CR64" publication-type="journal"><person-group person-group-type="author"><name><surname>Hjortnaes</surname><given-names>J</given-names></name><name><surname>Butcher</surname><given-names>J</given-names></name><name><surname>Figueiredo</surname><given-names>J-L</given-names></name><name><surname>Riccio</surname><given-names>M</given-names></name><name><surname>Kohler</surname><given-names>RH</given-names></name><name><surname>Kozloff</surname><given-names>KM</given-names></name><name><surname>Weissleder</surname><given-names>R</given-names></name><name><surname>Aikawa</surname><given-names>E</given-names></name></person-group><article-title>Arterial and aortic valve calcification inversely correlates with osteoporotic bone remodelling: a role for inflammation</article-title><source>Eur Heart J</source><year>2010</year><volume>31</volume><fpage>1975</fpage><lpage>1984</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehq237</pub-id><pub-id pub-id-type="pmid">20601388</pub-id>
</element-citation><mixed-citation id="mc-CR64" publication-type="journal">Hjortnaes J, Butcher J, Figueiredo J-L, Riccio M, Kohler RH, Kozloff KM, Weissleder R, Aikawa E. Arterial and aortic valve calcification inversely correlates with osteoporotic bone remodelling: a role for inflammation. Eur Heart J. 2010;31:1975&#x02013;84. 10.1093/eurheartj/ehq237.<pub-id pub-id-type="pmid">20601388</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR65"><label>65.</label><citation-alternatives><element-citation id="ec-CR65" publication-type="journal"><person-group person-group-type="author"><name><surname>Karadimou</surname><given-names>G</given-names></name><name><surname>Plunde</surname><given-names>O</given-names></name><name><surname>Pawelzik</surname><given-names>SC</given-names></name><name><surname>Carracedo</surname><given-names>M</given-names></name><name><surname>Eriksson</surname><given-names>P</given-names></name><name><surname>Franco-Cereceda</surname><given-names>A</given-names></name><name><surname>Paulsson-Berne</surname><given-names>G</given-names></name><name><surname>B&#x000e4;ck</surname><given-names>M</given-names></name></person-group><article-title>TLR7 expression is associated with M2 macrophage subset in calcific aortic valve stenosis</article-title><source>Cells</source><year>2020</year><volume>9</volume><fpage>1710</fpage><pub-id pub-id-type="doi">10.3390/cells9071710</pub-id><pub-id pub-id-type="pmid">32708790</pub-id>
</element-citation><mixed-citation id="mc-CR65" publication-type="journal">Karadimou G, Plunde O, Pawelzik SC, Carracedo M, Eriksson P, Franco-Cereceda A, Paulsson-Berne G, B&#x000e4;ck M. TLR7 expression is associated with M2 macrophage subset in calcific aortic valve stenosis. Cells. 2020;9:1710. 10.3390/cells9071710.<pub-id pub-id-type="pmid">32708790</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR66"><label>66.</label><citation-alternatives><element-citation id="ec-CR66" publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>W</given-names></name><name><surname>Yin</surname><given-names>Y</given-names></name><name><surname>Zhou</surname><given-names>Z</given-names></name><name><surname>He</surname><given-names>M</given-names></name><name><surname>Dai</surname><given-names>Y</given-names></name></person-group><article-title>OxLDL-induced IL-1 beta secretion promoting foam cells formation was mainly via CD36 mediated ROS production leading to NLRP3 inflammasome activation</article-title><source>Inflamm Res</source><year>2014</year><volume>63</volume><fpage>33</fpage><lpage>43</lpage><pub-id pub-id-type="doi">10.1007/s00011-013-0667-3</pub-id><pub-id pub-id-type="pmid">24121974</pub-id>
</element-citation><mixed-citation id="mc-CR66" publication-type="journal">Liu W, Yin Y, Zhou Z, He M, Dai Y. OxLDL-induced IL-1 beta secretion promoting foam cells formation was mainly via CD36 mediated ROS production leading to NLRP3 inflammasome activation. Inflamm Res. 2014;63:33&#x02013;43. 10.1007/s00011-013-0667-3.<pub-id pub-id-type="pmid">24121974</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR67"><label>67.</label><citation-alternatives><element-citation id="ec-CR67" publication-type="journal"><person-group person-group-type="author"><name><surname>Nagy</surname><given-names>L</given-names></name><name><surname>Tontonoz</surname><given-names>P</given-names></name><name><surname>Alvarez</surname><given-names>JG</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Evans</surname><given-names>RM</given-names></name></person-group><article-title>Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma</article-title><source>Cell</source><year>1998</year><volume>93</volume><fpage>229</fpage><lpage>240</lpage><pub-id pub-id-type="doi">10.1016/s0092-8674(00)81574-3</pub-id><pub-id pub-id-type="pmid">9568715</pub-id>
</element-citation><mixed-citation id="mc-CR67" publication-type="journal">Nagy L, Tontonoz P, Alvarez JG, Chen H, Evans RM. Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma. Cell. 1998;93:229&#x02013;40. 10.1016/s0092-8674(00)81574-3.<pub-id pub-id-type="pmid">9568715</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR68"><label>68.</label><citation-alternatives><element-citation id="ec-CR68" publication-type="journal"><person-group person-group-type="author"><name><surname>Nakagawa</surname><given-names>T</given-names></name><name><surname>Nozaki</surname><given-names>S</given-names></name><name><surname>Nishida</surname><given-names>M</given-names></name><name><surname>Yakub</surname><given-names>JM</given-names></name><name><surname>Tomiyama</surname><given-names>Y</given-names></name><name><surname>Nakata</surname><given-names>A</given-names></name><name><surname>Matsumoto</surname><given-names>K</given-names></name><name><surname>Funahashi</surname><given-names>T</given-names></name><name><surname>Kameda-Takemura</surname><given-names>K</given-names></name><name><surname>Kurata</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Oxidized LDL increases and interferon-gamma decreases expression of CD36 in human monocyte-derived macrophages</article-title><source>Arterioscler Thromb Vasc Biol</source><year>1998</year><volume>18</volume><fpage>1350</fpage><lpage>1357</lpage><pub-id pub-id-type="doi">10.1161/01.atv.18.8.1350</pub-id><pub-id pub-id-type="pmid">9714144</pub-id>
</element-citation><mixed-citation id="mc-CR68" publication-type="journal">Nakagawa T, Nozaki S, Nishida M, Yakub JM, Tomiyama Y, Nakata A, Matsumoto K, Funahashi T, Kameda-Takemura K, Kurata Y, et al. Oxidized LDL increases and interferon-gamma decreases expression of CD36 in human monocyte-derived macrophages. Arterioscler Thromb Vasc Biol. 1998;18:1350&#x02013;7. 10.1161/01.atv.18.8.1350.<pub-id pub-id-type="pmid">9714144</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR69"><label>69.</label><citation-alternatives><element-citation id="ec-CR69" publication-type="journal"><person-group person-group-type="author"><name><surname>Nickel</surname><given-names>T</given-names></name><name><surname>Schmauss</surname><given-names>D</given-names></name><name><surname>Hanssen</surname><given-names>H</given-names></name><name><surname>Sicic</surname><given-names>Z</given-names></name><name><surname>Krebs</surname><given-names>B</given-names></name><name><surname>Jankl</surname><given-names>S</given-names></name><name><surname>Summo</surname><given-names>C</given-names></name><name><surname>Fraunberger</surname><given-names>P</given-names></name><name><surname>Walli</surname><given-names>AK</given-names></name><name><surname>Pfeiler</surname><given-names>S</given-names></name><etal/></person-group><article-title>oxLDL uptake by dendritic cells induces upregulation of scavenger-receptors, maturation and differentiation</article-title><source>Atherosclerosis</source><year>2009</year><volume>205</volume><fpage>442</fpage><lpage>450</lpage><pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2009.01.002</pub-id><pub-id pub-id-type="pmid">19203752</pub-id>
</element-citation><mixed-citation id="mc-CR69" publication-type="journal">Nickel T, Schmauss D, Hanssen H, Sicic Z, Krebs B, Jankl S, Summo C, Fraunberger P, Walli AK, Pfeiler S, et al. oxLDL uptake by dendritic cells induces upregulation of scavenger-receptors, maturation and differentiation. Atherosclerosis. 2009;205:442&#x02013;50. 10.1016/j.atherosclerosis.2009.01.002.<pub-id pub-id-type="pmid">19203752</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR70"><label>70.</label><citation-alternatives><element-citation id="ec-CR70" publication-type="journal"><person-group person-group-type="author"><name><surname>Bekkering</surname><given-names>S</given-names></name><name><surname>Quintin</surname><given-names>J</given-names></name><name><surname>Joosten</surname><given-names>LA</given-names></name><name><surname>van der Meer</surname><given-names>JW</given-names></name><name><surname>Netea</surname><given-names>MG</given-names></name><name><surname>Riksen</surname><given-names>NP</given-names></name></person-group><article-title>Oxidized low-density lipoprotein induces long-term proinflammatory cytokine production and foam cell formation via epigenetic reprogramming of monocytes</article-title><source>Arterioscler Thromb Vasc Biol</source><year>2014</year><volume>34</volume><fpage>1731</fpage><lpage>1738</lpage><pub-id pub-id-type="doi">10.1161/atvbaha.114.303887</pub-id><pub-id pub-id-type="pmid">24903093</pub-id>
</element-citation><mixed-citation id="mc-CR70" publication-type="journal">Bekkering S, Quintin J, Joosten LA, van der Meer JW, Netea MG, Riksen NP. Oxidized low-density lipoprotein induces long-term proinflammatory cytokine production and foam cell formation via epigenetic reprogramming of monocytes. Arterioscler Thromb Vasc Biol. 2014;34:1731&#x02013;8. 10.1161/atvbaha.114.303887.<pub-id pub-id-type="pmid">24903093</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR71"><label>71.</label><citation-alternatives><element-citation id="ec-CR71" publication-type="journal"><person-group person-group-type="author"><name><surname>Broeders</surname><given-names>W</given-names></name><name><surname>Bekkering</surname><given-names>S</given-names></name><name><surname>El Messaoudi</surname><given-names>S</given-names></name><name><surname>Joosten</surname><given-names>LAB</given-names></name><name><surname>van Royen</surname><given-names>N</given-names></name><name><surname>Riksen</surname><given-names>NP</given-names></name></person-group><article-title>Innate immune cells in the pathophysiology of calcific aortic valve disease: lessons to be learned from atherosclerotic cardiovascular disease?</article-title><source>Basic Res Cardiol</source><year>2022</year><volume>117</volume><fpage>28</fpage><pub-id pub-id-type="doi">10.1007/s00395-022-00935-6</pub-id><pub-id pub-id-type="pmid">35581364</pub-id>
</element-citation><mixed-citation id="mc-CR71" publication-type="journal">Broeders W, Bekkering S, El Messaoudi S, Joosten LAB, van Royen N, Riksen NP. Innate immune cells in the pathophysiology of calcific aortic valve disease: lessons to be learned from atherosclerotic cardiovascular disease? Basic Res Cardiol. 2022;117:28. 10.1007/s00395-022-00935-6.<pub-id pub-id-type="pmid">35581364</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR72"><label>72.</label><citation-alternatives><element-citation id="ec-CR72" publication-type="journal"><person-group person-group-type="author"><name><surname>Yamada</surname><given-names>T</given-names></name><name><surname>Satoh</surname><given-names>S</given-names></name><name><surname>Sueyoshi</surname><given-names>S</given-names></name><name><surname>Mitsumata</surname><given-names>M</given-names></name><name><surname>Matsumoto</surname><given-names>T</given-names></name><name><surname>Ueno</surname><given-names>T</given-names></name><name><surname>Uehara</surname><given-names>K</given-names></name><name><surname>Mizutani</surname><given-names>T</given-names></name></person-group><article-title>Ubiquitin-positive foam cells are identified in the aortic and mitral valves with atherosclerotic involvement</article-title><source>J Atheroscler Thromb</source><year>2009</year><volume>16</volume><fpage>472</fpage><lpage>479</lpage><pub-id pub-id-type="doi">10.5551/jat.No1248</pub-id><pub-id pub-id-type="pmid">19729866</pub-id>
</element-citation><mixed-citation id="mc-CR72" publication-type="journal">Yamada T, Satoh S, Sueyoshi S, Mitsumata M, Matsumoto T, Ueno T, Uehara K, Mizutani T. Ubiquitin-positive foam cells are identified in the aortic and mitral valves with atherosclerotic involvement. J Atheroscler Thromb. 2009;16:472&#x02013;9. 10.5551/jat.No1248.<pub-id pub-id-type="pmid">19729866</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR73"><label>73.</label><citation-alternatives><element-citation id="ec-CR73" publication-type="journal"><person-group person-group-type="author"><name><surname>Falkencrone</surname><given-names>S</given-names></name><name><surname>Poulsen</surname><given-names>LK</given-names></name><name><surname>Bindslev-Jensen</surname><given-names>C</given-names></name><name><surname>Woetmann</surname><given-names>A</given-names></name><name><surname>Odum</surname><given-names>N</given-names></name><name><surname>Poulsen</surname><given-names>BC</given-names></name><name><surname>Blom</surname><given-names>L</given-names></name><name><surname>Jensen</surname><given-names>BM</given-names></name><name><surname>Gibbs</surname><given-names>BF</given-names></name><name><surname>Yasinska</surname><given-names>IM</given-names></name><etal/></person-group><article-title>IgE-mediated basophil tumour necrosis factor alpha induces matrix metalloproteinase-9 from monocytes</article-title><source>Allergy</source><year>2013</year><volume>68</volume><fpage>614</fpage><lpage>620</lpage><pub-id pub-id-type="doi">10.1111/all.12143</pub-id><pub-id pub-id-type="pmid">23573943</pub-id>
</element-citation><mixed-citation id="mc-CR73" publication-type="journal">Falkencrone S, Poulsen LK, Bindslev-Jensen C, Woetmann A, Odum N, Poulsen BC, Blom L, Jensen BM, Gibbs BF, Yasinska IM, et al. IgE-mediated basophil tumour necrosis factor alpha induces matrix metalloproteinase-9 from monocytes. Allergy. 2013;68:614&#x02013;20. 10.1111/all.12143.<pub-id pub-id-type="pmid">23573943</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR74"><label>74.</label><citation-alternatives><element-citation id="ec-CR74" publication-type="journal"><person-group person-group-type="author"><name><surname>Potaczek</surname><given-names>DP</given-names></name><name><surname>Przytulska-Szczerbik</surname><given-names>A</given-names></name><name><surname>Bazan-Socha</surname><given-names>S</given-names></name><name><surname>Jurczyszyn</surname><given-names>A</given-names></name><name><surname>Okumura</surname><given-names>K</given-names></name><name><surname>Nishiyama</surname><given-names>C</given-names></name><name><surname>Undas</surname><given-names>A</given-names></name><name><surname>Wypasek</surname><given-names>E</given-names></name></person-group><article-title>Elements of immunoglobulin E network associate with aortic valve area in patients with acquired aortic stenosis</article-title><source>Biomedicines</source><year>2020</year><volume>9</volume><fpage>23</fpage><pub-id pub-id-type="doi">10.3390/biomedicines9010023</pub-id><pub-id pub-id-type="pmid">33396395</pub-id>
</element-citation><mixed-citation id="mc-CR74" publication-type="journal">Potaczek DP, Przytulska-Szczerbik A, Bazan-Socha S, Jurczyszyn A, Okumura K, Nishiyama C, Undas A, Wypasek E. Elements of immunoglobulin E network associate with aortic valve area in patients with acquired aortic stenosis. Biomedicines. 2020;9:23. 10.3390/biomedicines9010023.<pub-id pub-id-type="pmid">33396395</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR75"><label>75.</label><citation-alternatives><element-citation id="ec-CR75" publication-type="journal"><person-group person-group-type="author"><name><surname>Akahori</surname><given-names>H</given-names></name><name><surname>Tsujino</surname><given-names>T</given-names></name><name><surname>Masuyama</surname><given-names>T</given-names></name><name><surname>Ishihara</surname><given-names>M</given-names></name></person-group><article-title>Mechanisms of aortic stenosis</article-title><source>J Cardiol</source><year>2018</year><volume>71</volume><fpage>215</fpage><lpage>220</lpage><pub-id pub-id-type="doi">10.1016/j.jjcc.2017.11.007</pub-id><pub-id pub-id-type="pmid">29258711</pub-id>
</element-citation><mixed-citation id="mc-CR75" publication-type="journal">Akahori H, Tsujino T, Masuyama T, Ishihara M. Mechanisms of aortic stenosis. J Cardiol. 2018;71:215&#x02013;20. 10.1016/j.jjcc.2017.11.007.<pub-id pub-id-type="pmid">29258711</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR76"><label>76.</label><citation-alternatives><element-citation id="ec-CR76" publication-type="journal"><person-group person-group-type="author"><name><surname>Hourai</surname><given-names>R</given-names></name><name><surname>Kasashima</surname><given-names>S</given-names></name><name><surname>Fujita</surname><given-names>SI</given-names></name><name><surname>Sohmiya</surname><given-names>K</given-names></name><name><surname>Daimon</surname><given-names>M</given-names></name><name><surname>Hirose</surname><given-names>Y</given-names></name><name><surname>Katsumata</surname><given-names>T</given-names></name><name><surname>Kanki</surname><given-names>S</given-names></name><name><surname>Ozeki</surname><given-names>M</given-names></name><name><surname>Ishizaka</surname><given-names>N</given-names></name></person-group><article-title>A case of aortic stenosis with serum IgG4 elevation, and IgG4-positive plasmacytic infiltration in the aortic valve, epicardium, and aortic adventitia</article-title><source>Int Heart J</source><year>2018</year><volume>59</volume><fpage>1149</fpage><lpage>1154</lpage><pub-id pub-id-type="doi">10.1536/ihj.17-567</pub-id><pub-id pub-id-type="pmid">30101853</pub-id>
</element-citation><mixed-citation id="mc-CR76" publication-type="journal">Hourai R, Kasashima S, Fujita SI, Sohmiya K, Daimon M, Hirose Y, Katsumata T, Kanki S, Ozeki M, Ishizaka N. A case of aortic stenosis with serum IgG4 elevation, and IgG4-positive plasmacytic infiltration in the aortic valve, epicardium, and aortic adventitia. Int Heart J. 2018;59:1149&#x02013;54. 10.1536/ihj.17-567.<pub-id pub-id-type="pmid">30101853</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR77"><label>77.</label><citation-alternatives><element-citation id="ec-CR77" publication-type="journal"><person-group person-group-type="author"><name><surname>Leopold</surname><given-names>JA</given-names></name></person-group><article-title>Cellular mechanisms of aortic valve calcification</article-title><source>Circ Cardiovasc Interv</source><year>2012</year><volume>5</volume><fpage>605</fpage><lpage>614</lpage><pub-id pub-id-type="doi">10.1161/circinterventions.112.971028</pub-id><pub-id pub-id-type="pmid">22896576</pub-id>
</element-citation><mixed-citation id="mc-CR77" publication-type="journal">Leopold JA. Cellular mechanisms of aortic valve calcification. Circ Cardiovasc Interv. 2012;5:605&#x02013;14. 10.1161/circinterventions.112.971028.<pub-id pub-id-type="pmid">22896576</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR78"><label>78.</label><citation-alternatives><element-citation id="ec-CR78" publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>JD</given-names></name><name><surname>Weiss</surname><given-names>RM</given-names></name><name><surname>Heistad</surname><given-names>DD</given-names></name><name><surname>Towler</surname><given-names>DA</given-names></name></person-group><article-title>Calcific aortic valve stenosis: methods, models, and mechanisms</article-title><source>Circ Res</source><year>2011</year><volume>108</volume><fpage>1392</fpage><lpage>1412</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.110.234138</pub-id><pub-id pub-id-type="pmid">21617136</pub-id>
</element-citation><mixed-citation id="mc-CR78" publication-type="journal">Miller JD, Weiss RM, Heistad DD, Towler DA. Calcific aortic valve stenosis: methods, models, and mechanisms. Circ Res. 2011;108:1392&#x02013;412. 10.1161/CIRCRESAHA.110.234138.<pub-id pub-id-type="pmid">21617136</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR79"><label>79.</label><citation-alternatives><element-citation id="ec-CR79" publication-type="journal"><person-group person-group-type="author"><name><surname>Liuzzo</surname><given-names>G</given-names></name><name><surname>Goronzy</surname><given-names>JJ</given-names></name><name><surname>Yang</surname><given-names>H</given-names></name><name><surname>Kopecky</surname><given-names>SL</given-names></name><name><surname>Holmes</surname><given-names>DR</given-names></name><name><surname>Frye</surname><given-names>RL</given-names></name><name><surname>Weyand</surname><given-names>CM</given-names></name></person-group><article-title>Monoclonal T-cell proliferation and plaque instability in acute coronary syndromes</article-title><source>Circulation</source><year>2000</year><volume>101</volume><fpage>2883</fpage><lpage>2888</lpage><pub-id pub-id-type="doi">10.1161/01.cir.101.25.2883</pub-id><pub-id pub-id-type="pmid">10869258</pub-id>
</element-citation><mixed-citation id="mc-CR79" publication-type="journal">Liuzzo G, Goronzy JJ, Yang H, Kopecky SL, Holmes DR, Frye RL, Weyand CM. Monoclonal T-cell proliferation and plaque instability in acute coronary syndromes. Circulation. 2000;101:2883&#x02013;8. 10.1161/01.cir.101.25.2883.<pub-id pub-id-type="pmid">10869258</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR80"><label>80.</label><citation-alternatives><element-citation id="ec-CR80" publication-type="journal"><person-group person-group-type="author"><name><surname>Stemme</surname><given-names>S</given-names></name><name><surname>Faber</surname><given-names>B</given-names></name><name><surname>Holm</surname><given-names>J</given-names></name><name><surname>Wiklund</surname><given-names>O</given-names></name><name><surname>Witztum</surname><given-names>JL</given-names></name><name><surname>Hansson</surname><given-names>GK</given-names></name></person-group><article-title>T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein</article-title><source>Proc Natl Acad Sci USA</source><year>1995</year><volume>92</volume><fpage>3893</fpage><lpage>3897</lpage><pub-id pub-id-type="doi">10.1073/pnas.92.9.3893</pub-id><pub-id pub-id-type="pmid">7732003</pub-id>
</element-citation><mixed-citation id="mc-CR80" publication-type="journal">Stemme S, Faber B, Holm J, Wiklund O, Witztum JL, Hansson GK. T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein. Proc Natl Acad Sci USA. 1995;92:3893&#x02013;7. 10.1073/pnas.92.9.3893.<pub-id pub-id-type="pmid">7732003</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR81"><label>81.</label><citation-alternatives><element-citation id="ec-CR81" publication-type="journal"><person-group person-group-type="author"><name><surname>Andreae</surname><given-names>J</given-names></name><name><surname>Galle</surname><given-names>C</given-names></name><name><surname>Magdorf</surname><given-names>K</given-names></name><name><surname>Staab</surname><given-names>D</given-names></name><name><surname>Meyer</surname><given-names>L</given-names></name><name><surname>Goldman</surname><given-names>M</given-names></name><name><surname>Querfeld</surname><given-names>U</given-names></name></person-group><article-title>Severe atherosclerosis of the aorta and development of peripheral T-cell lymphoma in an adolescent with angiolymphoid hyperplasia with eosinophilia</article-title><source>Br J Dermatol</source><year>2005</year><volume>152</volume><fpage>1033</fpage><lpage>1038</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2133.2005.06421.x</pub-id><pub-id pub-id-type="pmid">15888166</pub-id>
</element-citation><mixed-citation id="mc-CR81" publication-type="journal">Andreae J, Galle C, Magdorf K, Staab D, Meyer L, Goldman M, Querfeld U. Severe atherosclerosis of the aorta and development of peripheral T-cell lymphoma in an adolescent with angiolymphoid hyperplasia with eosinophilia. Br J Dermatol. 2005;152:1033&#x02013;8. 10.1111/j.1365-2133.2005.06421.x.<pub-id pub-id-type="pmid">15888166</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR82"><label>82.</label><citation-alternatives><element-citation id="ec-CR82" publication-type="journal"><person-group person-group-type="author"><name><surname>Bondarenko</surname><given-names>S</given-names></name><name><surname>Catapano</surname><given-names>AL</given-names></name><name><surname>Norata</surname><given-names>GD</given-names></name></person-group><article-title>The CD1d-natural killer T cell axis in atherosclerosis</article-title><source>J Innate Immun</source><year>2014</year><volume>6</volume><fpage>3</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1159/000351034</pub-id><pub-id pub-id-type="pmid">23774666</pub-id>
</element-citation><mixed-citation id="mc-CR82" publication-type="journal">Bondarenko S, Catapano AL, Norata GD. The CD1d-natural killer T cell axis in atherosclerosis. J Innate Immun. 2014;6:3&#x02013;12. 10.1159/000351034.<pub-id pub-id-type="pmid">23774666</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR83"><label>83.</label><citation-alternatives><element-citation id="ec-CR83" publication-type="journal"><person-group person-group-type="author"><name><surname>Depuydt</surname><given-names>MAC</given-names></name><name><surname>Schaftenaar</surname><given-names>FH</given-names></name><name><surname>Prange</surname><given-names>KHM</given-names></name><name><surname>Boltjes</surname><given-names>A</given-names></name><name><surname>Hemme</surname><given-names>E</given-names></name><name><surname>Delfos</surname><given-names>L</given-names></name><name><surname>de Mol</surname><given-names>J</given-names></name><name><surname>de Jong</surname><given-names>MJM</given-names></name><name><surname>Bernab&#x000e9; Kleijn</surname><given-names>MNA</given-names></name><name><surname>Peeters</surname><given-names>JAHM</given-names></name><etal/></person-group><article-title>Single-cell T cell receptor sequencing of paired human atherosclerotic plaques and blood reveals autoimmune-like features of expanded effector T cells</article-title><source>Nat Cardiovasc Res</source><year>2023</year><volume>2</volume><fpage>112</fpage><lpage>125</lpage><pub-id pub-id-type="doi">10.1038/s44161-022-00208-4</pub-id><pub-id pub-id-type="pmid">38665903</pub-id>
</element-citation><mixed-citation id="mc-CR83" publication-type="journal">Depuydt MAC, Schaftenaar FH, Prange KHM, Boltjes A, Hemme E, Delfos L, de Mol J, de Jong MJM, Bernab&#x000e9; Kleijn MNA, Peeters JAHM, et al. Single-cell T cell receptor sequencing of paired human atherosclerotic plaques and blood reveals autoimmune-like features of expanded effector T cells. Nat Cardiovasc Res. 2023;2:112&#x02013;25. 10.1038/s44161-022-00208-4.<pub-id pub-id-type="pmid">38665903</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR84"><label>84.</label><citation-alternatives><element-citation id="ec-CR84" publication-type="journal"><person-group person-group-type="author"><name><surname>Blaser</surname><given-names>MC</given-names></name><name><surname>Kraler</surname><given-names>S</given-names></name><name><surname>L&#x000fc;scher</surname><given-names>TF</given-names></name><name><surname>Aikawa</surname><given-names>E</given-names></name></person-group><article-title>Network-guided multiomic mapping of aortic valve calcification</article-title><source>Arterioscler Thromb Vasc Biol</source><year>2023</year><volume>43</volume><fpage>417</fpage><lpage>426</lpage><pub-id pub-id-type="doi">10.1161/atvbaha.122.318334</pub-id><pub-id pub-id-type="pmid">36727519</pub-id>
</element-citation><mixed-citation id="mc-CR84" publication-type="journal">Blaser MC, Kraler S, L&#x000fc;scher TF, Aikawa E. Network-guided multiomic mapping of aortic valve calcification. Arterioscler Thromb Vasc Biol. 2023;43:417&#x02013;26. 10.1161/atvbaha.122.318334.<pub-id pub-id-type="pmid">36727519</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR85"><label>85.</label><citation-alternatives><element-citation id="ec-CR85" publication-type="journal"><person-group person-group-type="author"><name><surname>Staal</surname><given-names>AHJ</given-names></name><name><surname>Cortenbach</surname><given-names>KRG</given-names></name><name><surname>Gorris</surname><given-names>MAJ</given-names></name><name><surname>van der Woude</surname><given-names>LL</given-names></name><name><surname>Srinivas</surname><given-names>M</given-names></name><name><surname>Heijmen</surname><given-names>RH</given-names></name><name><surname>Geuzebroek</surname><given-names>GSC</given-names></name><name><surname>Grewal</surname><given-names>N</given-names></name><name><surname>Hebeda</surname><given-names>KM</given-names></name><name><surname>de Vries</surname><given-names>IJM</given-names></name><etal/></person-group><article-title>Adventitial adaptive immune cells are associated with ascending aortic dilatation in patients with a bicuspid aortic valve</article-title><source>Front Cardiovasc Med</source><year>2023</year><volume>10</volume><fpage>1127685</fpage><pub-id pub-id-type="doi">10.3389/fcvm.2023.1127685</pub-id><pub-id pub-id-type="pmid">37057097</pub-id>
</element-citation><mixed-citation id="mc-CR85" publication-type="journal">Staal AHJ, Cortenbach KRG, Gorris MAJ, van der Woude LL, Srinivas M, Heijmen RH, Geuzebroek GSC, Grewal N, Hebeda KM, de Vries IJM, et al. Adventitial adaptive immune cells are associated with ascending aortic dilatation in patients with a bicuspid aortic valve. Front Cardiovasc Med. 2023;10:1127685. 10.3389/fcvm.2023.1127685.<pub-id pub-id-type="pmid">37057097</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR86"><label>86.</label><citation-alternatives><element-citation id="ec-CR86" publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>K</given-names></name><name><surname>Xie</surname><given-names>S</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Zhou</surname><given-names>T</given-names></name><name><surname>Liu</surname><given-names>M</given-names></name><name><surname>Zhu</surname><given-names>P</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Shi</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>F</given-names></name><name><surname>Sellke</surname><given-names>FW</given-names></name><etal/></person-group><article-title>Cell-type transcriptome atlas of human aortic valves reveal cell heterogeneity and endothelial to mesenchymal transition involved in calcific aortic valve disease</article-title><source>Arterioscler Thromb Vasc Biol</source><year>2020</year><volume>40</volume><fpage>2910</fpage><lpage>2921</lpage><pub-id pub-id-type="doi">10.1161/atvbaha.120.314789</pub-id><pub-id pub-id-type="pmid">33086873</pub-id>
</element-citation><mixed-citation id="mc-CR86" publication-type="journal">Xu K, Xie S, Huang Y, Zhou T, Liu M, Zhu P, Wang C, Shi J, Li F, Sellke FW, et al. Cell-type transcriptome atlas of human aortic valves reveal cell heterogeneity and endothelial to mesenchymal transition involved in calcific aortic valve disease. Arterioscler Thromb Vasc Biol. 2020;40:2910&#x02013;21. 10.1161/atvbaha.120.314789.<pub-id pub-id-type="pmid">33086873</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR87"><label>87.</label><citation-alternatives><element-citation id="ec-CR87" publication-type="journal"><person-group person-group-type="author"><name><surname>van Duijn</surname><given-names>J</given-names></name><name><surname>Kritikou</surname><given-names>E</given-names></name><name><surname>Benne</surname><given-names>N</given-names></name><name><surname>van der Heijden</surname><given-names>T</given-names></name><name><surname>van Puijvelde</surname><given-names>GH</given-names></name><name><surname>Kr&#x000f6;ner</surname><given-names>MJ</given-names></name><name><surname>Schaftenaar</surname><given-names>FH</given-names></name><name><surname>Foks</surname><given-names>AC</given-names></name><name><surname>Wezel</surname><given-names>A</given-names></name><name><surname>Smeets</surname><given-names>H</given-names></name><etal/></person-group><article-title>CD8+ T-cells contribute to lesion stabilization in advanced atherosclerosis by limiting macrophage content and CD4+ T-cell responses</article-title><source>Cardiovasc Res</source><year>2019</year><volume>115</volume><fpage>729</fpage><lpage>738</lpage><pub-id pub-id-type="doi">10.1093/cvr/cvy261</pub-id><pub-id pub-id-type="pmid">30335148</pub-id>
</element-citation><mixed-citation id="mc-CR87" publication-type="journal">van Duijn J, Kritikou E, Benne N, van der Heijden T, van Puijvelde GH, Kr&#x000f6;ner MJ, Schaftenaar FH, Foks AC, Wezel A, Smeets H, et al. CD8+ T-cells contribute to lesion stabilization in advanced atherosclerosis by limiting macrophage content and CD4+ T-cell responses. Cardiovasc Res. 2019;115:729&#x02013;38. 10.1093/cvr/cvy261.<pub-id pub-id-type="pmid">30335148</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR88"><label>88.</label><citation-alternatives><element-citation id="ec-CR88" publication-type="journal"><person-group person-group-type="author"><name><surname>Mazzone</surname><given-names>A</given-names></name><name><surname>Epistolato</surname><given-names>MC</given-names></name><name><surname>De Caterina</surname><given-names>R</given-names></name><name><surname>Storti</surname><given-names>S</given-names></name><name><surname>Vittorini</surname><given-names>S</given-names></name><name><surname>Sbrana</surname><given-names>S</given-names></name><name><surname>Gianetti</surname><given-names>J</given-names></name><name><surname>Bevilacqua</surname><given-names>S</given-names></name><name><surname>Glauber</surname><given-names>M</given-names></name><name><surname>Biagini</surname><given-names>A</given-names></name><etal/></person-group><article-title>Neoangiogenesis, T-lymphocyte infiltration, and heat shock protein-60 are biological hallmarks of an immunomediated inflammatory process in end-stage calcified aortic valve stenosis</article-title><source>J Am Coll Cardiol</source><year>2004</year><volume>43</volume><fpage>1670</fpage><lpage>1676</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2003.12.041</pub-id><pub-id pub-id-type="pmid">15120829</pub-id>
</element-citation><mixed-citation id="mc-CR88" publication-type="journal">Mazzone A, Epistolato MC, De Caterina R, Storti S, Vittorini S, Sbrana S, Gianetti J, Bevilacqua S, Glauber M, Biagini A, et al. Neoangiogenesis, T-lymphocyte infiltration, and heat shock protein-60 are biological hallmarks of an immunomediated inflammatory process in end-stage calcified aortic valve stenosis. J Am Coll Cardiol. 2004;43:1670&#x02013;6. 10.1016/j.jacc.2003.12.041.<pub-id pub-id-type="pmid">15120829</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR89"><label>89.</label><citation-alternatives><element-citation id="ec-CR89" publication-type="journal"><person-group person-group-type="author"><name><surname>Shimoni</surname><given-names>S</given-names></name><name><surname>Bar</surname><given-names>I</given-names></name><name><surname>Meledin</surname><given-names>V</given-names></name><name><surname>Gandelman</surname><given-names>G</given-names></name><name><surname>George</surname><given-names>J</given-names></name></person-group><article-title>Circulating regulatory T cells in patients with aortic valve stenosis: association with disease progression and aortic valve intervention</article-title><source>Int J Cardiol</source><year>2016</year><volume>218</volume><fpage>181</fpage><lpage>187</lpage><pub-id pub-id-type="doi">10.1016/j.ijcard.2016.05.039</pub-id><pub-id pub-id-type="pmid">27236112</pub-id>
</element-citation><mixed-citation id="mc-CR89" publication-type="journal">Shimoni S, Bar I, Meledin V, Gandelman G, George J. Circulating regulatory T cells in patients with aortic valve stenosis: association with disease progression and aortic valve intervention. Int J Cardiol. 2016;218:181&#x02013;7. 10.1016/j.ijcard.2016.05.039.<pub-id pub-id-type="pmid">27236112</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR90"><label>90.</label><citation-alternatives><element-citation id="ec-CR90" publication-type="journal"><person-group person-group-type="author"><name><surname>Jian</surname><given-names>B</given-names></name><name><surname>Narula</surname><given-names>N</given-names></name><name><surname>Li</surname><given-names>QY</given-names></name><name><surname>Mohler</surname><given-names>ER</given-names><suffix>3rd</suffix></name><name><surname>Levy</surname><given-names>RJ</given-names></name></person-group><article-title>Progression of aortic valve stenosis: TGF-beta1 is present in calcified aortic valve cusps and promotes aortic valve interstitial cell calcification via apoptosis</article-title><source>Ann Thorac Surg</source><year>2003</year><volume>75</volume><fpage>457</fpage><lpage>465 </lpage><pub-id pub-id-type="doi">10.1016/s0003-4975(02)04312-6</pub-id><pub-id pub-id-type="pmid">12607654</pub-id>
</element-citation><mixed-citation id="mc-CR90" publication-type="journal">Jian B, Narula N, Li QY, Mohler ER 3rd, Levy RJ. Progression of aortic valve stenosis: TGF-beta1 is present in calcified aortic valve cusps and promotes aortic valve interstitial cell calcification via apoptosis. Ann Thorac Surg. 2003;75:457&#x02013;65. 10.1016/s0003-4975(02)04312-6. (discussion 465-456).<pub-id pub-id-type="pmid">12607654</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR91"><label>91.</label><citation-alternatives><element-citation id="ec-CR91" publication-type="journal"><person-group person-group-type="author"><name><surname>El Husseini</surname><given-names>D</given-names></name><name><surname>Boulanger</surname><given-names>MC</given-names></name><name><surname>Mahmut</surname><given-names>A</given-names></name><name><surname>Bouchareb</surname><given-names>R</given-names></name><name><surname>Laflamme</surname><given-names>MH</given-names></name><name><surname>Fournier</surname><given-names>D</given-names></name><name><surname>Pibarot</surname><given-names>P</given-names></name><name><surname>Boss&#x000e9;</surname><given-names>Y</given-names></name><name><surname>Mathieu</surname><given-names>P</given-names></name></person-group><article-title>P2Y2 receptor represses IL-6 expression by valve interstitial cells through Akt: implication for calcific aortic valve disease</article-title><source>J Mol Cell Cardiol</source><year>2014</year><volume>72</volume><fpage>146</fpage><lpage>156</lpage><pub-id pub-id-type="doi">10.1016/j.yjmcc.2014.02.014</pub-id><pub-id pub-id-type="pmid">24631773</pub-id>
</element-citation><mixed-citation id="mc-CR91" publication-type="journal">El Husseini D, Boulanger MC, Mahmut A, Bouchareb R, Laflamme MH, Fournier D, Pibarot P, Boss&#x000e9; Y, Mathieu P. P2Y2 receptor represses IL-6 expression by valve interstitial cells through Akt: implication for calcific aortic valve disease. J Mol Cell Cardiol. 2014;72:146&#x02013;56. 10.1016/j.yjmcc.2014.02.014.<pub-id pub-id-type="pmid">24631773</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR92"><label>92.</label><citation-alternatives><element-citation id="ec-CR92" publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Shi</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Xu</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>F</given-names></name><name><surname>Dong</surname><given-names>N</given-names></name></person-group><article-title>IL-21 promotes osteoblastic differentiation of human valvular interstitial cells through the JAK3/STAT3 pathway</article-title><source>Int J Med Sci</source><year>2020</year><volume>17</volume><fpage>3065</fpage><lpage>3072</lpage><pub-id pub-id-type="doi">10.7150/ijms.49533</pub-id><pub-id pub-id-type="pmid">33173427</pub-id>
</element-citation><mixed-citation id="mc-CR92" publication-type="journal">Liu Z, Wang Y, Shi J, Chen S, Xu L, Li F, Dong N. IL-21 promotes osteoblastic differentiation of human valvular interstitial cells through the JAK3/STAT3 pathway. Int J Med Sci. 2020;17:3065&#x02013;72. 10.7150/ijms.49533.<pub-id pub-id-type="pmid">33173427</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR93"><label>93.</label><citation-alternatives><element-citation id="ec-CR93" publication-type="journal"><person-group person-group-type="author"><name><surname>Cano-Gamez</surname><given-names>E</given-names></name><name><surname>Soskic</surname><given-names>B</given-names></name><name><surname>Roumeliotis</surname><given-names>TI</given-names></name><name><surname>So</surname><given-names>E</given-names></name><name><surname>Smyth</surname><given-names>DJ</given-names></name><name><surname>Baldrighi</surname><given-names>M</given-names></name><name><surname>Will&#x000e9;</surname><given-names>D</given-names></name><name><surname>Nakic</surname><given-names>N</given-names></name><name><surname>Esparza-Gordillo</surname><given-names>J</given-names></name><name><surname>Larminie</surname><given-names>CGC</given-names></name><etal/></person-group><article-title>Single-cell transcriptomics identifies an effectorness gradient shaping the response of CD4(+) T cells to cytokines</article-title><source>Nat Commun</source><year>2020</year><volume>11</volume><fpage>1801</fpage><pub-id pub-id-type="doi">10.1038/s41467-020-15543-y</pub-id><pub-id pub-id-type="pmid">32286271</pub-id>
</element-citation><mixed-citation id="mc-CR93" publication-type="journal">Cano-Gamez E, Soskic B, Roumeliotis TI, So E, Smyth DJ, Baldrighi M, Will&#x000e9; D, Nakic N, Esparza-Gordillo J, Larminie CGC, et al. Single-cell transcriptomics identifies an effectorness gradient shaping the response of CD4(+) T cells to cytokines. Nat Commun. 2020;11:1801. 10.1038/s41467-020-15543-y.<pub-id pub-id-type="pmid">32286271</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR94"><label>94.</label><citation-alternatives><element-citation id="ec-CR94" publication-type="journal"><person-group person-group-type="author"><name><surname>Ou</surname><given-names>HX</given-names></name><name><surname>Guo</surname><given-names>BB</given-names></name><name><surname>Liu</surname><given-names>Q</given-names></name><name><surname>Li</surname><given-names>YK</given-names></name><name><surname>Yang</surname><given-names>Z</given-names></name><name><surname>Feng</surname><given-names>WJ</given-names></name><name><surname>Mo</surname><given-names>ZC</given-names></name></person-group><article-title>Regulatory T cells as a new therapeutic target for atherosclerosis</article-title><source>Acta Pharmacol Sin</source><year>2018</year><volume>39</volume><fpage>1249</fpage><lpage>1258</lpage><pub-id pub-id-type="doi">10.1038/aps.2017.140</pub-id><pub-id pub-id-type="pmid">29323337</pub-id>
</element-citation><mixed-citation id="mc-CR94" publication-type="journal">Ou HX, Guo BB, Liu Q, Li YK, Yang Z, Feng WJ, Mo ZC. Regulatory T cells as a new therapeutic target for atherosclerosis. Acta Pharmacol Sin. 2018;39:1249&#x02013;58. 10.1038/aps.2017.140.<pub-id pub-id-type="pmid">29323337</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR95"><label>95.</label><citation-alternatives><element-citation id="ec-CR95" publication-type="journal"><person-group person-group-type="author"><name><surname>Kudryavtsev</surname><given-names>I</given-names></name><name><surname>Serebriakova</surname><given-names>M</given-names></name><name><surname>Zhiduleva</surname><given-names>E</given-names></name><name><surname>Murtazalieva</surname><given-names>P</given-names></name><name><surname>Titov</surname><given-names>V</given-names></name><name><surname>Malashicheva</surname><given-names>A</given-names></name><name><surname>Shishkova</surname><given-names>A</given-names></name><name><surname>Semenova</surname><given-names>D</given-names></name><name><surname>Irtyuga</surname><given-names>O</given-names></name><name><surname>Isakov</surname><given-names>D</given-names></name><etal/></person-group><article-title>CD73 rather than CD39 is mainly involved in controlling purinergic signaling in calcified aortic valve disease</article-title><source>Front Genet</source><year>2019</year><volume>10</volume><fpage>604</fpage><pub-id pub-id-type="doi">10.3389/fgene.2019.00604</pub-id><pub-id pub-id-type="pmid">31402927</pub-id>
</element-citation><mixed-citation id="mc-CR95" publication-type="journal">Kudryavtsev I, Serebriakova M, Zhiduleva E, Murtazalieva P, Titov V, Malashicheva A, Shishkova A, Semenova D, Irtyuga O, Isakov D, et al. CD73 rather than CD39 is mainly involved in controlling purinergic signaling in calcified aortic valve disease. Front Genet. 2019;10:604. 10.3389/fgene.2019.00604.<pub-id pub-id-type="pmid">31402927</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR96"><label>96.</label><citation-alternatives><element-citation id="ec-CR96" publication-type="journal"><person-group person-group-type="author"><name><surname>Nagy</surname><given-names>E</given-names></name><name><surname>Lei</surname><given-names>Y</given-names></name><name><surname>Mart&#x000ed;nez-Mart&#x000ed;nez</surname><given-names>E</given-names></name><name><surname>Body</surname><given-names>SC</given-names></name><name><surname>Schlotter</surname><given-names>F</given-names></name><name><surname>Creager</surname><given-names>M</given-names></name><name><surname>Assmann</surname><given-names>A</given-names></name><name><surname>Khabbaz</surname><given-names>K</given-names></name><name><surname>Libby</surname><given-names>P</given-names></name><name><surname>Hansson</surname><given-names>GK</given-names></name><etal/></person-group><article-title>Interferon-&#x003b3; released by activated CD8(+) T lymphocytes impairs the calcium resorption potential of osteoclasts in calcified human aortic valves</article-title><source>Am J Pathol</source><year>2017</year><volume>187</volume><fpage>1413</fpage><lpage>1425</lpage><pub-id pub-id-type="doi">10.1016/j.ajpath.2017.02.012</pub-id><pub-id pub-id-type="pmid">28431214</pub-id>
</element-citation><mixed-citation id="mc-CR96" publication-type="journal">Nagy E, Lei Y, Mart&#x000ed;nez-Mart&#x000ed;nez E, Body SC, Schlotter F, Creager M, Assmann A, Khabbaz K, Libby P, Hansson GK, et al. Interferon-&#x003b3; released by activated CD8(+) T lymphocytes impairs the calcium resorption potential of osteoclasts in calcified human aortic valves. Am J Pathol. 2017;187:1413&#x02013;25. 10.1016/j.ajpath.2017.02.012.<pub-id pub-id-type="pmid">28431214</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR97"><label>97.</label><citation-alternatives><element-citation id="ec-CR97" publication-type="journal"><person-group person-group-type="author"><name><surname>Shuvy</surname><given-names>M</given-names></name><name><surname>Ben Ya'acov</surname><given-names>A</given-names></name><name><surname>Zolotarov</surname><given-names>L</given-names></name><name><surname>Lotan</surname><given-names>C</given-names></name><name><surname>Ilan</surname><given-names>Y</given-names></name></person-group><article-title>Beta glycosphingolipids suppress rank expression and inhibit natural killer T cell and CD8+ accumulation in alleviating aortic valve calcification</article-title><source>Int J Immunopathol Pharmacol</source><year>2009</year><volume>22</volume><fpage>911</fpage><lpage>918</lpage><pub-id pub-id-type="doi">10.1177/039463200902200406</pub-id><pub-id pub-id-type="pmid">20074454</pub-id>
</element-citation><mixed-citation id="mc-CR97" publication-type="journal">Shuvy M, Ben Ya&#x02019;acov A, Zolotarov L, Lotan C, Ilan Y. Beta glycosphingolipids suppress rank expression and inhibit natural killer T cell and CD8+ accumulation in alleviating aortic valve calcification. Int J Immunopathol Pharmacol. 2009;22:911&#x02013;8. 10.1177/039463200902200406.<pub-id pub-id-type="pmid">20074454</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR98"><label>98.</label><citation-alternatives><element-citation id="ec-CR98" publication-type="journal"><person-group person-group-type="author"><name><surname>Lindman</surname><given-names>BR</given-names></name><name><surname>Fonarow</surname><given-names>GC</given-names></name><name><surname>Myers</surname><given-names>G</given-names></name><name><surname>Alger</surname><given-names>HM</given-names></name><name><surname>Rutan</surname><given-names>C</given-names></name><name><surname>Troll</surname><given-names>K</given-names></name><name><surname>Aringo</surname><given-names>A</given-names></name><name><surname>Shahriary</surname><given-names>M</given-names></name><name><surname>Jessup</surname><given-names>M</given-names></name><name><surname>Arnold</surname><given-names>SV</given-names></name><etal/></person-group><article-title>Target aortic stenosis: a national initiative to improve quality of care and outcomes for patients with aortic stenosis</article-title><source>Circ Cardiovasc Qual Outcomes</source><year>2023</year><volume>16</volume><fpage>e009712</fpage><pub-id pub-id-type="doi">10.1161/circoutcomes.122.009712</pub-id><pub-id pub-id-type="pmid">37339188</pub-id>
</element-citation><mixed-citation id="mc-CR98" publication-type="journal">Lindman BR, Fonarow GC, Myers G, Alger HM, Rutan C, Troll K, Aringo A, Shahriary M, Jessup M, Arnold SV, et al. Target aortic stenosis: a national initiative to improve quality of care and outcomes for patients with aortic stenosis. Circ Cardiovasc Qual Outcomes. 2023;16:e009712. 10.1161/circoutcomes.122.009712.<pub-id pub-id-type="pmid">37339188</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR99"><label>99.</label><citation-alternatives><element-citation id="ec-CR99" publication-type="journal"><person-group person-group-type="author"><name><surname>Tucker</surname><given-names>B</given-names></name><name><surname>Sawant</surname><given-names>S</given-names></name><name><surname>McDonald</surname><given-names>H</given-names></name><name><surname>Rye</surname><given-names>KA</given-names></name><name><surname>Patel</surname><given-names>S</given-names></name><name><surname>Ong</surname><given-names>KL</given-names></name><name><surname>Cochran</surname><given-names>BJ</given-names></name></person-group><article-title>The association of serum lipid and lipoprotein levels with total and differential leukocyte counts: results of a cross-sectional and longitudinal analysis of the UK Biobank</article-title><source>Atherosclerosis</source><year>2021</year><volume>319</volume><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2020.12.016</pub-id><pub-id pub-id-type="pmid">33453490</pub-id>
</element-citation><mixed-citation id="mc-CR99" publication-type="journal">Tucker B, Sawant S, McDonald H, Rye KA, Patel S, Ong KL, Cochran BJ. The association of serum lipid and lipoprotein levels with total and differential leukocyte counts: results of a cross-sectional and longitudinal analysis of the UK Biobank. Atherosclerosis. 2021;319:1&#x02013;9. 10.1016/j.atherosclerosis.2020.12.016.<pub-id pub-id-type="pmid">33453490</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR100"><label>100.</label><citation-alternatives><element-citation id="ec-CR100" publication-type="journal"><person-group person-group-type="author"><name><surname>Pearson</surname><given-names>GJ</given-names></name><name><surname>Thanassoulis</surname><given-names>G</given-names></name><name><surname>Anderson</surname><given-names>TJ</given-names></name><name><surname>Barry</surname><given-names>AR</given-names></name><name><surname>Couture</surname><given-names>P</given-names></name><name><surname>Dayan</surname><given-names>N</given-names></name><name><surname>Francis</surname><given-names>GA</given-names></name><name><surname>Genest</surname><given-names>J</given-names></name><name><surname>Gr&#x000e9;goire</surname><given-names>J</given-names></name><name><surname>Grover</surname><given-names>SA</given-names></name><etal/></person-group><article-title>2021 Canadian Cardiovascular Society Guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in adults</article-title><source>Can J Cardiol</source><year>2021</year><volume>37</volume><fpage>1129</fpage><lpage>1150</lpage><pub-id pub-id-type="doi">10.1016/j.cjca.2021.03.016</pub-id><pub-id pub-id-type="pmid">33781847</pub-id>
</element-citation><mixed-citation id="mc-CR100" publication-type="journal">Pearson GJ, Thanassoulis G, Anderson TJ, Barry AR, Couture P, Dayan N, Francis GA, Genest J, Gr&#x000e9;goire J, Grover SA, et al. 2021 Canadian Cardiovascular Society Guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in adults. Can J Cardiol. 2021;37:1129&#x02013;50. 10.1016/j.cjca.2021.03.016.<pub-id pub-id-type="pmid">33781847</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR101"><label>101.</label><citation-alternatives><element-citation id="ec-CR101" publication-type="journal"><person-group person-group-type="author"><name><surname>Kostyunin</surname><given-names>A</given-names></name><name><surname>Mukhamadiyarov</surname><given-names>R</given-names></name><name><surname>Glushkova</surname><given-names>T</given-names></name><name><surname>Bogdanov</surname><given-names>L</given-names></name><name><surname>Shishkova</surname><given-names>D</given-names></name><name><surname>Osyaev</surname><given-names>N</given-names></name><name><surname>Ovcharenko</surname><given-names>E</given-names></name><name><surname>Kutikhin</surname><given-names>A</given-names></name></person-group><article-title>Ultrastructural pathology of atherosclerosis, calcific aortic valve disease, and bioprosthetic heart valve degeneration: commonalities and differences</article-title><source>Int J Mol Sci</source><year>2020</year><volume>21</volume><fpage>7434</fpage><pub-id pub-id-type="doi">10.3390/ijms21207434</pub-id><pub-id pub-id-type="pmid">33050133</pub-id>
</element-citation><mixed-citation id="mc-CR101" publication-type="journal">Kostyunin A, Mukhamadiyarov R, Glushkova T, Bogdanov L, Shishkova D, Osyaev N, Ovcharenko E, Kutikhin A. Ultrastructural pathology of atherosclerosis, calcific aortic valve disease, and bioprosthetic heart valve degeneration: commonalities and differences. Int J Mol Sci. 2020;21:7434. 10.3390/ijms21207434.<pub-id pub-id-type="pmid">33050133</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR102"><label>102.</label><citation-alternatives><element-citation id="ec-CR102" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhong</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Shen</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Xu</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Tao</surname><given-names>Y</given-names></name><name><surname>Yin</surname><given-names>H</given-names></name></person-group><article-title>An update on lipid oxidation and inflammation in cardiovascular diseases</article-title><source>Free Radic Biol Med</source><year>2019</year><volume>144</volume><fpage>266</fpage><lpage>278</lpage><pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2019.03.036</pub-id><pub-id pub-id-type="pmid">30946962</pub-id>
</element-citation><mixed-citation id="mc-CR102" publication-type="journal">Zhong S, Li L, Shen X, Li Q, Xu W, Wang X, Tao Y, Yin H. An update on lipid oxidation and inflammation in cardiovascular diseases. Free Radic Biol Med. 2019;144:266&#x02013;78. 10.1016/j.freeradbiomed.2019.03.036.<pub-id pub-id-type="pmid">30946962</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR103"><label>103.</label><citation-alternatives><element-citation id="ec-CR103" publication-type="journal"><person-group person-group-type="author"><name><surname>Kutryb-Zajac</surname><given-names>B</given-names></name><name><surname>Jablonska</surname><given-names>P</given-names></name><name><surname>Serocki</surname><given-names>M</given-names></name><name><surname>Bulinska</surname><given-names>A</given-names></name><name><surname>Mierzejewska</surname><given-names>P</given-names></name><name><surname>Friebe</surname><given-names>D</given-names></name><name><surname>Alter</surname><given-names>C</given-names></name><name><surname>Jasztal</surname><given-names>A</given-names></name><name><surname>Lango</surname><given-names>R</given-names></name><name><surname>Rogowski</surname><given-names>J</given-names></name><etal/></person-group><article-title>Nucleotide ecto-enzyme metabolic pattern and spatial distribution in calcific aortic valve disease; its relation to pathological changes and clinical presentation</article-title><source>Clin Res Cardiol</source><year>2020</year><volume>109</volume><fpage>137</fpage><lpage>160</lpage><pub-id pub-id-type="doi">10.1007/s00392-019-01495-x</pub-id><pub-id pub-id-type="pmid">31144065</pub-id>
</element-citation><mixed-citation id="mc-CR103" publication-type="journal">Kutryb-Zajac B, Jablonska P, Serocki M, Bulinska A, Mierzejewska P, Friebe D, Alter C, Jasztal A, Lango R, Rogowski J, et al. Nucleotide ecto-enzyme metabolic pattern and spatial distribution in calcific aortic valve disease; its relation to pathological changes and clinical presentation. Clin Res Cardiol. 2020;109:137&#x02013;60. 10.1007/s00392-019-01495-x.<pub-id pub-id-type="pmid">31144065</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR104"><label>104.</label><mixed-citation publication-type="other">Schlotter F, de Freitas RCC, Rogers MA, Blaser MC, Wu PJ, Higashi H, Halu A, Iqbal F, Andraski AB, Rodia CN, Kuraoka S, Wen JR, Creager M, Pham T, Hutcheson JD, Body SC, Kohan AB, Sacks FM, Aikawa M, Singh SA, Aikawa E. ApoC-III is a novel inducer of calcification in human aortic valves. J Biol Chem. 2021;296:100193. 10.1074/jbc.RA120.015700.</mixed-citation></ref><ref id="CR105"><label>105.</label><citation-alternatives><element-citation id="ec-CR105" publication-type="journal"><person-group person-group-type="author"><name><surname>Capoulade</surname><given-names>R</given-names></name><name><surname>Torzewski</surname><given-names>M</given-names></name><name><surname>Mayr</surname><given-names>M</given-names></name><name><surname>Chan</surname><given-names>KL</given-names></name><name><surname>Mathieu</surname><given-names>P</given-names></name><name><surname>Boss&#x000e9;</surname><given-names>Y</given-names></name><name><surname>Dumesnil</surname><given-names>JG</given-names></name><name><surname>Tam</surname><given-names>J</given-names></name><name><surname>Teo</surname><given-names>KK</given-names></name><name><surname>Burnap</surname><given-names>SA</given-names></name><etal/></person-group><article-title>ApoCIII-Lp(a) complexes in conjunction with Lp(a)-OxPL predict rapid progression of aortic stenosis</article-title><source>Heart</source><year>2020</year><volume>106</volume><fpage>738</fpage><lpage>745</lpage><pub-id pub-id-type="doi">10.1136/heartjnl-2019-315840</pub-id><pub-id pub-id-type="pmid">32054669</pub-id>
</element-citation><mixed-citation id="mc-CR105" publication-type="journal">Capoulade R, Torzewski M, Mayr M, Chan KL, Mathieu P, Boss&#x000e9; Y, Dumesnil JG, Tam J, Teo KK, Burnap SA, et al. ApoCIII-Lp(a) complexes in conjunction with Lp(a)-OxPL predict rapid progression of aortic stenosis. Heart. 2020;106:738&#x02013;45. 10.1136/heartjnl-2019-315840.<pub-id pub-id-type="pmid">32054669</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR106"><label>106.</label><citation-alternatives><element-citation id="ec-CR106" publication-type="journal"><person-group person-group-type="author"><name><surname>Guddeti</surname><given-names>RR</given-names></name><name><surname>Patil</surname><given-names>S</given-names></name><name><surname>Ahmed</surname><given-names>A</given-names></name><name><surname>Sharma</surname><given-names>A</given-names></name><name><surname>Aboeata</surname><given-names>A</given-names></name><name><surname>Lavie</surname><given-names>CJ</given-names></name><name><surname>Alla</surname><given-names>VM</given-names></name></person-group><article-title>Lipoprotein(a) and calcific aortic valve stenosis: a systematic review</article-title><source>Prog Cardiovasc Dis</source><year>2020</year><volume>63</volume><fpage>496</fpage><lpage>502</lpage><pub-id pub-id-type="doi">10.1016/j.pcad.2020.06.002</pub-id><pub-id pub-id-type="pmid">32526213</pub-id>
</element-citation><mixed-citation id="mc-CR106" publication-type="journal">Guddeti RR, Patil S, Ahmed A, Sharma A, Aboeata A, Lavie CJ, Alla VM. Lipoprotein(a) and calcific aortic valve stenosis: a systematic review. Prog Cardiovasc Dis. 2020;63:496&#x02013;502. 10.1016/j.pcad.2020.06.002.<pub-id pub-id-type="pmid">32526213</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR107"><label>107.</label><citation-alternatives><element-citation id="ec-CR107" publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>KH</given-names></name><name><surname>Tsimikas</surname><given-names>S</given-names></name><name><surname>Pawade</surname><given-names>T</given-names></name><name><surname>Kroon</surname><given-names>J</given-names></name><name><surname>Jenkins</surname><given-names>WSA</given-names></name><name><surname>Doris</surname><given-names>MK</given-names></name><name><surname>White</surname><given-names>AC</given-names></name><name><surname>Timmers</surname><given-names>N</given-names></name><name><surname>Hjortnaes</surname><given-names>J</given-names></name><name><surname>Rogers</surname><given-names>MA</given-names></name><etal/></person-group><article-title>Lipoprotein(a) and oxidized phospholipids promote valve calcification in patients with aortic stenosis</article-title><source>J Am Coll Cardiol</source><year>2019</year><volume>73</volume><fpage>2150</fpage><lpage>2162</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2019.01.070</pub-id><pub-id pub-id-type="pmid">31047003</pub-id>
</element-citation><mixed-citation id="mc-CR107" publication-type="journal">Zheng KH, Tsimikas S, Pawade T, Kroon J, Jenkins WSA, Doris MK, White AC, Timmers N, Hjortnaes J, Rogers MA, et al. Lipoprotein(a) and oxidized phospholipids promote valve calcification in patients with aortic stenosis. J Am Coll Cardiol. 2019;73:2150&#x02013;62. 10.1016/j.jacc.2019.01.070.<pub-id pub-id-type="pmid">31047003</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR108"><label>108.</label><citation-alternatives><element-citation id="ec-CR108" publication-type="journal"><person-group person-group-type="author"><name><surname>Small</surname><given-names>A</given-names></name><name><surname>Kiss</surname><given-names>D</given-names></name><name><surname>Giri</surname><given-names>J</given-names></name><name><surname>Anwaruddin</surname><given-names>S</given-names></name><name><surname>Siddiqi</surname><given-names>H</given-names></name><name><surname>Guerraty</surname><given-names>M</given-names></name><name><surname>Chirinos</surname><given-names>JA</given-names></name><name><surname>Ferrari</surname><given-names>G</given-names></name><name><surname>Rader</surname><given-names>DJ</given-names></name></person-group><article-title>Biomarkers of calcific aortic valve disease</article-title><source>Arterioscler Thromb Vasc Biol</source><year>2017</year><volume>37</volume><fpage>623</fpage><lpage>632</lpage><pub-id pub-id-type="doi">10.1161/ATVBAHA.116.308615</pub-id><pub-id pub-id-type="pmid">28153876</pub-id>
</element-citation><mixed-citation id="mc-CR108" publication-type="journal">Small A, Kiss D, Giri J, Anwaruddin S, Siddiqi H, Guerraty M, Chirinos JA, Ferrari G, Rader DJ. Biomarkers of calcific aortic valve disease. Arterioscler Thromb Vasc Biol. 2017;37:623&#x02013;32. 10.1161/ATVBAHA.116.308615.<pub-id pub-id-type="pmid">28153876</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR109"><label>109.</label><citation-alternatives><element-citation id="ec-CR109" publication-type="journal"><person-group person-group-type="author"><name><surname>Cowell</surname><given-names>SJ</given-names></name><name><surname>Newby</surname><given-names>DE</given-names></name><name><surname>Prescott</surname><given-names>RJ</given-names></name><name><surname>Bloomfield</surname><given-names>P</given-names></name><name><surname>Reid</surname><given-names>J</given-names></name><name><surname>Northridge</surname><given-names>DB</given-names></name><name><surname>Boon</surname><given-names>NA</given-names></name></person-group><article-title>A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis</article-title><source>N Engl J Med</source><year>2005</year><volume>352</volume><fpage>2389</fpage><lpage>2397</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa043876</pub-id><pub-id pub-id-type="pmid">15944423</pub-id>
</element-citation><mixed-citation id="mc-CR109" publication-type="journal">Cowell SJ, Newby DE, Prescott RJ, Bloomfield P, Reid J, Northridge DB, Boon NA. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N Engl J Med. 2005;352:2389&#x02013;97. 10.1056/NEJMoa043876.<pub-id pub-id-type="pmid">15944423</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR110"><label>110.</label><citation-alternatives><element-citation id="ec-CR110" publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>KL</given-names></name><name><surname>Teo</surname><given-names>K</given-names></name><name><surname>Dumesnil</surname><given-names>JG</given-names></name><name><surname>Ni</surname><given-names>A</given-names></name><name><surname>Tam</surname><given-names>J</given-names></name></person-group><article-title>Effect of Lipid lowering with rosuvastatin on progression of aortic stenosis: results of the aortic stenosis progression observation: measuring effects of rosuvastatin (ASTRONOMER) trial</article-title><source>Circulation</source><year>2010</year><volume>121</volume><fpage>306</fpage><lpage>314</lpage><pub-id pub-id-type="doi">10.1161/circulationaha.109.900027</pub-id><pub-id pub-id-type="pmid">20048204</pub-id>
</element-citation><mixed-citation id="mc-CR110" publication-type="journal">Chan KL, Teo K, Dumesnil JG, Ni A, Tam J. Effect of Lipid lowering with rosuvastatin on progression of aortic stenosis: results of the aortic stenosis progression observation: measuring effects of rosuvastatin (ASTRONOMER) trial. Circulation. 2010;121:306&#x02013;14. 10.1161/circulationaha.109.900027.<pub-id pub-id-type="pmid">20048204</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR111"><label>111.</label><citation-alternatives><element-citation id="ec-CR111" publication-type="journal"><person-group person-group-type="author"><name><surname>Lehrer-Graiwer</surname><given-names>J</given-names></name><name><surname>Singh</surname><given-names>P</given-names></name><name><surname>Abdelbaky</surname><given-names>A</given-names></name><name><surname>Vucic</surname><given-names>E</given-names></name><name><surname>Korsgren</surname><given-names>M</given-names></name><name><surname>Baruch</surname><given-names>A</given-names></name><name><surname>Fredrickson</surname><given-names>J</given-names></name><name><surname>van Bruggen</surname><given-names>N</given-names></name><name><surname>Tang</surname><given-names>MT</given-names></name><name><surname>Frendeus</surname><given-names>B</given-names></name><etal/></person-group><article-title>FDG-PET imaging for oxidized LDL in stable atherosclerotic disease: a phase II study of safety, tolerability, and anti-inflammatory activity</article-title><source>JACC Cardiovasc Imaging</source><year>2015</year><volume>8</volume><fpage>493</fpage><lpage>494</lpage><pub-id pub-id-type="doi">10.1016/j.jcmg.2014.06.021</pub-id><pub-id pub-id-type="pmid">25457756</pub-id>
</element-citation><mixed-citation id="mc-CR111" publication-type="journal">Lehrer-Graiwer J, Singh P, Abdelbaky A, Vucic E, Korsgren M, Baruch A, Fredrickson J, van Bruggen N, Tang MT, Frendeus B, et al. FDG-PET imaging for oxidized LDL in stable atherosclerotic disease: a phase II study of safety, tolerability, and anti-inflammatory activity. JACC Cardiovasc Imaging. 2015;8:493&#x02013;4. 10.1016/j.jcmg.2014.06.021.<pub-id pub-id-type="pmid">25457756</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR112"><label>112.</label><citation-alternatives><element-citation id="ec-CR112" publication-type="journal"><person-group person-group-type="author"><name><surname>Elkhawad</surname><given-names>M</given-names></name><name><surname>Rudd</surname><given-names>JH</given-names></name><name><surname>Sarov-Blat</surname><given-names>L</given-names></name><name><surname>Cai</surname><given-names>G</given-names></name><name><surname>Wells</surname><given-names>R</given-names></name><name><surname>Davies</surname><given-names>LC</given-names></name><name><surname>Collier</surname><given-names>DJ</given-names></name><name><surname>Marber</surname><given-names>MS</given-names></name><name><surname>Choudhury</surname><given-names>RP</given-names></name><name><surname>Fayad</surname><given-names>ZA</given-names></name><etal/></person-group><article-title>Effects of p38 mitogen-activated protein kinase inhibition on vascular and systemic inflammation in patients with atherosclerosis</article-title><source>JACC Cardiovasc Imaging</source><year>2012</year><volume>5</volume><fpage>911</fpage><lpage>922</lpage><pub-id pub-id-type="doi">10.1016/j.jcmg.2012.02.016</pub-id><pub-id pub-id-type="pmid">22974804</pub-id>
</element-citation><mixed-citation id="mc-CR112" publication-type="journal">Elkhawad M, Rudd JH, Sarov-Blat L, Cai G, Wells R, Davies LC, Collier DJ, Marber MS, Choudhury RP, Fayad ZA, et al. Effects of p38 mitogen-activated protein kinase inhibition on vascular and systemic inflammation in patients with atherosclerosis. JACC Cardiovasc Imaging. 2012;5:911&#x02013;22. 10.1016/j.jcmg.2012.02.016.<pub-id pub-id-type="pmid">22974804</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR113"><label>113.</label><citation-alternatives><element-citation id="ec-CR113" publication-type="journal"><person-group person-group-type="author"><name><surname>Suzuki</surname><given-names>K</given-names></name><name><surname>Takahashi</surname><given-names>S</given-names></name><name><surname>Watanabe</surname><given-names>K</given-names></name><name><surname>Fujioka</surname><given-names>D</given-names></name><name><surname>Nakamura</surname><given-names>T</given-names></name><name><surname>Obata</surname><given-names>JE</given-names></name><name><surname>Kawabata</surname><given-names>K</given-names></name><name><surname>Katoh</surname><given-names>R</given-names></name><name><surname>Matsumoto</surname><given-names>M</given-names></name><name><surname>Kugiyama</surname><given-names>K</given-names></name></person-group><article-title>The expression of groups IIE and V phospholipase A2 is associated with an increased expression of osteogenic molecules in human calcified aortic valves</article-title><source>J Atheroscler Thromb</source><year>2014</year><volume>21</volume><fpage>1308</fpage><lpage>1325</lpage><pub-id pub-id-type="doi">10.5551/jat.24273</pub-id><pub-id pub-id-type="pmid">25132377</pub-id>
</element-citation><mixed-citation id="mc-CR113" publication-type="journal">Suzuki K, Takahashi S, Watanabe K, Fujioka D, Nakamura T, Obata JE, Kawabata K, Katoh R, Matsumoto M, Kugiyama K. The expression of groups IIE and V phospholipase A2 is associated with an increased expression of osteogenic molecules in human calcified aortic valves. J Atheroscler Thromb. 2014;21:1308&#x02013;25. 10.5551/jat.24273.<pub-id pub-id-type="pmid">25132377</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR114"><label>114.</label><citation-alternatives><element-citation id="ec-CR114" publication-type="journal"><person-group person-group-type="author"><name><surname>Rosenson</surname><given-names>RS</given-names></name><name><surname>Hislop</surname><given-names>C</given-names></name><name><surname>Elliott</surname><given-names>M</given-names></name><name><surname>Stasiv</surname><given-names>Y</given-names></name><name><surname>Goulder</surname><given-names>M</given-names></name><name><surname>Waters</surname><given-names>D</given-names></name></person-group><article-title>Effects of varespladib methyl on biomarkers and major cardiovascular events in acute coronary syndrome patients</article-title><source>J Am Coll Cardiol</source><year>2010</year><volume>56</volume><fpage>1079</fpage><lpage>1088</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2010.06.015</pub-id><pub-id pub-id-type="pmid">20863951</pub-id>
</element-citation><mixed-citation id="mc-CR114" publication-type="journal">Rosenson RS, Hislop C, Elliott M, Stasiv Y, Goulder M, Waters D. Effects of varespladib methyl on biomarkers and major cardiovascular events in acute coronary syndrome patients. J Am Coll Cardiol. 2010;56:1079&#x02013;88. 10.1016/j.jacc.2010.06.015.<pub-id pub-id-type="pmid">20863951</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR115"><label>115.</label><citation-alternatives><element-citation id="ec-CR115" publication-type="journal"><person-group person-group-type="author"><name><surname>Gaztanaga</surname><given-names>J</given-names></name><name><surname>Farkouh</surname><given-names>M</given-names></name><name><surname>Rudd</surname><given-names>JH</given-names></name><name><surname>Brotz</surname><given-names>TM</given-names></name><name><surname>Rosenbaum</surname><given-names>D</given-names></name><name><surname>Mani</surname><given-names>V</given-names></name><name><surname>Kerwin</surname><given-names>TC</given-names></name><name><surname>Taub</surname><given-names>R</given-names></name><name><surname>Tardif</surname><given-names>JC</given-names></name><name><surname>Tawakol</surname><given-names>A</given-names></name><etal/></person-group><article-title>A phase 2 randomized, double-blind, placebo-controlled study of the effect of VIA-2291, a 5-lipoxygenase inhibitor, on vascular inflammation in patients after an acute coronary syndrome</article-title><source>Atherosclerosis</source><year>2015</year><volume>240</volume><fpage>53</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2015.02.027</pub-id><pub-id pub-id-type="pmid">25752438</pub-id>
</element-citation><mixed-citation id="mc-CR115" publication-type="journal">Gaztanaga J, Farkouh M, Rudd JH, Brotz TM, Rosenbaum D, Mani V, Kerwin TC, Taub R, Tardif JC, Tawakol A, et al. A phase 2 randomized, double-blind, placebo-controlled study of the effect of VIA-2291, a 5-lipoxygenase inhibitor, on vascular inflammation in patients after an acute coronary syndrome. Atherosclerosis. 2015;240:53&#x02013;60. 10.1016/j.atherosclerosis.2015.02.027.<pub-id pub-id-type="pmid">25752438</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR116"><label>116.</label><citation-alternatives><element-citation id="ec-CR116" publication-type="journal"><person-group person-group-type="author"><name><surname>Hakonarson</surname><given-names>H</given-names></name><name><surname>Thorvaldsson</surname><given-names>S</given-names></name><name><surname>Helgadottir</surname><given-names>A</given-names></name><name><surname>Gudbjartsson</surname><given-names>D</given-names></name><name><surname>Zink</surname><given-names>F</given-names></name><name><surname>Andresdottir</surname><given-names>M</given-names></name><name><surname>Manolescu</surname><given-names>A</given-names></name><name><surname>Arnar</surname><given-names>DO</given-names></name><name><surname>Andersen</surname><given-names>K</given-names></name><name><surname>Sigurdsson</surname><given-names>A</given-names></name><etal/></person-group><article-title>Effects of a 5-lipoxygenase-activating protein inhibitor on biomarkers associated with risk of myocardial infarction: a randomized trial</article-title><source>JAMA</source><year>2005</year><volume>293</volume><fpage>2245</fpage><lpage>2256</lpage><pub-id pub-id-type="doi">10.1001/jama.293.18.2245</pub-id><pub-id pub-id-type="pmid">15886380</pub-id>
</element-citation><mixed-citation id="mc-CR116" publication-type="journal">Hakonarson H, Thorvaldsson S, Helgadottir A, Gudbjartsson D, Zink F, Andresdottir M, Manolescu A, Arnar DO, Andersen K, Sigurdsson A, et al. Effects of a 5-lipoxygenase-activating protein inhibitor on biomarkers associated with risk of myocardial infarction: a randomized trial. JAMA. 2005;293:2245&#x02013;56. 10.1001/jama.293.18.2245.<pub-id pub-id-type="pmid">15886380</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR117"><label>117.</label><citation-alternatives><element-citation id="ec-CR117" publication-type="journal"><person-group person-group-type="author"><name><surname>Ridker</surname><given-names>PM</given-names></name><name><surname>Everett</surname><given-names>BM</given-names></name><name><surname>Thuren</surname><given-names>T</given-names></name><name><surname>MacFadyen</surname><given-names>JG</given-names></name><name><surname>Chang</surname><given-names>WH</given-names></name><name><surname>Ballantyne</surname><given-names>C</given-names></name><name><surname>Fonseca</surname><given-names>F</given-names></name><name><surname>Nicolau</surname><given-names>J</given-names></name><name><surname>Koenig</surname><given-names>W</given-names></name><name><surname>Anker</surname><given-names>SD</given-names></name><etal/></person-group><article-title>Antiinflammatory therapy with canakinumab for atherosclerotic disease</article-title><source>N Engl J Med</source><year>2017</year><volume>377</volume><fpage>1119</fpage><lpage>1131</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1707914</pub-id><pub-id pub-id-type="pmid">28845751</pub-id>
</element-citation><mixed-citation id="mc-CR117" publication-type="journal">Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, Fonseca F, Nicolau J, Koenig W, Anker SD, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377:1119&#x02013;31. 10.1056/NEJMoa1707914.<pub-id pub-id-type="pmid">28845751</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR118"><label>118.</label><citation-alternatives><element-citation id="ec-CR118" publication-type="journal"><person-group person-group-type="author"><name><surname>Bartoli-Leonard</surname><given-names>F</given-names></name><name><surname>Aikawa</surname><given-names>E</given-names></name></person-group><article-title>Old drugs for an old pathology? Drug repurposing for calcific aortic valve disease</article-title><source>Circ Res</source><year>2021</year><volume>128</volume><fpage>1317</fpage><lpage>1319</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.121.319149</pub-id><pub-id pub-id-type="pmid">33914606</pub-id>
</element-citation><mixed-citation id="mc-CR118" publication-type="journal">Bartoli-Leonard F, Aikawa E. Old drugs for an old pathology? Drug repurposing for calcific aortic valve disease. Circ Res. 2021;128:1317&#x02013;9. 10.1161/CIRCRESAHA.121.319149.<pub-id pub-id-type="pmid">33914606</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR119"><label>119.</label><citation-alternatives><element-citation id="ec-CR119" publication-type="journal"><person-group person-group-type="author"><name><surname>Dutta</surname><given-names>P</given-names></name><name><surname>Kodigepalli</surname><given-names>KM</given-names></name><name><surname>LaHaye</surname><given-names>S</given-names></name><name><surname>Thompson</surname><given-names>JW</given-names></name><name><surname>Rains</surname><given-names>S</given-names></name><name><surname>Nagel</surname><given-names>C</given-names></name><name><surname>Thatcher</surname><given-names>K</given-names></name><name><surname>Hinton</surname><given-names>RB</given-names></name><name><surname>Lincoln</surname><given-names>J</given-names></name></person-group><article-title>KPT-330 prevents aortic valve calcification via a novel C/EBP&#x003b2; signaling pathway</article-title><source>Circ Res</source><year>2021</year><volume>128</volume><fpage>1300</fpage><lpage>1316</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.120.318503</pub-id><pub-id pub-id-type="pmid">33601919</pub-id>
</element-citation><mixed-citation id="mc-CR119" publication-type="journal">Dutta P, Kodigepalli KM, LaHaye S, Thompson JW, Rains S, Nagel C, Thatcher K, Hinton RB, Lincoln J. KPT-330 prevents aortic valve calcification via a novel C/EBP&#x003b2; signaling pathway. Circ Res. 2021;128:1300&#x02013;16. 10.1161/CIRCRESAHA.120.318503.<pub-id pub-id-type="pmid">33601919</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR120"><label>120.</label><citation-alternatives><element-citation id="ec-CR120" publication-type="journal"><person-group person-group-type="author"><name><surname>Hutcheson</surname><given-names>JD</given-names></name><name><surname>Aikawa</surname><given-names>E</given-names></name><name><surname>Merryman</surname><given-names>WD</given-names></name></person-group><article-title>Potential drug targets for calcific aortic valve disease</article-title><source>Nat Rev Cardiol</source><year>2014</year><volume>11</volume><fpage>218</fpage><lpage>231</lpage><pub-id pub-id-type="doi">10.1038/nrcardio.2014.1</pub-id><pub-id pub-id-type="pmid">24445487</pub-id>
</element-citation><mixed-citation id="mc-CR120" publication-type="journal">Hutcheson JD, Aikawa E, Merryman WD. Potential drug targets for calcific aortic valve disease. Nat Rev Cardiol. 2014;11:218&#x02013;31. 10.1038/nrcardio.2014.1.<pub-id pub-id-type="pmid">24445487</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR121"><label>121.</label><citation-alternatives><element-citation id="ec-CR121" publication-type="journal"><person-group person-group-type="author"><name><surname>Lawler</surname><given-names>PR</given-names></name><name><surname>Bhatt</surname><given-names>DL</given-names></name><name><surname>Godoy</surname><given-names>LC</given-names></name><name><surname>L&#x000fc;scher</surname><given-names>TF</given-names></name><name><surname>Bonow</surname><given-names>RO</given-names></name><name><surname>Verma</surname><given-names>S</given-names></name><name><surname>Ridker</surname><given-names>PM</given-names></name></person-group><article-title>Targeting cardiovascular inflammation: next steps in clinical translation</article-title><source>Eur Heart J</source><year>2021</year><volume>42</volume><fpage>113</fpage><lpage>131</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehaa099</pub-id><pub-id pub-id-type="pmid">32176778</pub-id>
</element-citation><mixed-citation id="mc-CR121" publication-type="journal">Lawler PR, Bhatt DL, Godoy LC, L&#x000fc;scher TF, Bonow RO, Verma S, Ridker PM. Targeting cardiovascular inflammation: next steps in clinical translation. Eur Heart J. 2021;42:113&#x02013;31. 10.1093/eurheartj/ehaa099.<pub-id pub-id-type="pmid">32176778</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR122"><label>122.</label><citation-alternatives><element-citation id="ec-CR122" publication-type="journal"><person-group person-group-type="author"><name><surname>Jaiswal</surname><given-names>S</given-names></name><name><surname>Natarajan</surname><given-names>P</given-names></name><name><surname>Silver</surname><given-names>AJ</given-names></name><name><surname>Gibson</surname><given-names>CJ</given-names></name><name><surname>Bick</surname><given-names>AG</given-names></name><name><surname>Shvartz</surname><given-names>E</given-names></name><name><surname>McConkey</surname><given-names>M</given-names></name><name><surname>Gupta</surname><given-names>N</given-names></name><name><surname>Gabriel</surname><given-names>S</given-names></name><name><surname>Ardissino</surname><given-names>D</given-names></name><etal/></person-group><article-title>Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease</article-title><source>N Engl J Med</source><year>2017</year><volume>377</volume><fpage>111</fpage><lpage>121</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1701719</pub-id><pub-id pub-id-type="pmid">28636844</pub-id>
</element-citation><mixed-citation id="mc-CR122" publication-type="journal">Jaiswal S, Natarajan P, Silver AJ, Gibson CJ, Bick AG, Shvartz E, McConkey M, Gupta N, Gabriel S, Ardissino D, et al. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. N Engl J Med. 2017;377:111&#x02013;21. 10.1056/NEJMoa1701719.<pub-id pub-id-type="pmid">28636844</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR123"><label>123.</label><citation-alternatives><element-citation id="ec-CR123" publication-type="journal"><person-group person-group-type="author"><name><surname>Rurik</surname><given-names>JG</given-names></name><name><surname>Tomb&#x000e1;cz</surname><given-names>I</given-names></name><name><surname>Yadegari</surname><given-names>A</given-names></name><name><surname>M&#x000e9;ndez Fern&#x000e1;ndez</surname><given-names>PO</given-names></name><name><surname>Shewale</surname><given-names>SV</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Kimura</surname><given-names>T</given-names></name><name><surname>Soliman</surname><given-names>OY</given-names></name><name><surname>Papp</surname><given-names>TE</given-names></name><name><surname>Tam</surname><given-names>YK</given-names></name><etal/></person-group><article-title>CAR T cells produced in vivo to treat cardiac injury</article-title><source>Science</source><year>2022</year><volume>375</volume><fpage>91</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.1126/science.abm0594</pub-id><pub-id pub-id-type="pmid">34990237</pub-id>
</element-citation><mixed-citation id="mc-CR123" publication-type="journal">Rurik JG, Tomb&#x000e1;cz I, Yadegari A, M&#x000e9;ndez Fern&#x000e1;ndez PO, Shewale SV, Li L, Kimura T, Soliman OY, Papp TE, Tam YK, et al. CAR T cells produced in vivo to treat cardiac injury. Science. 2022;375:91&#x02013;6. 10.1126/science.abm0594.<pub-id pub-id-type="pmid">34990237</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR124"><label>124.</label><citation-alternatives><element-citation id="ec-CR124" publication-type="journal"><person-group person-group-type="author"><name><surname>Rizvi</surname><given-names>F</given-names></name><name><surname>Everton</surname><given-names>E</given-names></name><name><surname>Smith</surname><given-names>AR</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Osota</surname><given-names>E</given-names></name><name><surname>Beattie</surname><given-names>M</given-names></name><name><surname>Tam</surname><given-names>Y</given-names></name><name><surname>Pardi</surname><given-names>N</given-names></name><name><surname>Weissman</surname><given-names>D</given-names></name><name><surname>Gouon-Evans</surname><given-names>V</given-names></name></person-group><article-title>Murine liver repair via transient activation of regenerative pathways in hepatocytes using lipid nanoparticle-complexed nucleoside-modified mRNA</article-title><source>Nat Commun</source><year>2021</year><volume>12</volume><fpage>613</fpage><pub-id pub-id-type="doi">10.1038/s41467-021-20903-3</pub-id><pub-id pub-id-type="pmid">33504774</pub-id>
</element-citation><mixed-citation id="mc-CR124" publication-type="journal">Rizvi F, Everton E, Smith AR, Liu H, Osota E, Beattie M, Tam Y, Pardi N, Weissman D, Gouon-Evans V. Murine liver repair via transient activation of regenerative pathways in hepatocytes using lipid nanoparticle-complexed nucleoside-modified mRNA. Nat Commun. 2021;12:613. 10.1038/s41467-021-20903-3.<pub-id pub-id-type="pmid">33504774</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR125"><label>125.</label><citation-alternatives><element-citation id="ec-CR125" publication-type="journal"><person-group person-group-type="author"><name><surname>Aghajanian</surname><given-names>H</given-names></name><name><surname>Rurik</surname><given-names>JG</given-names></name><name><surname>Epstein</surname><given-names>JA</given-names></name></person-group><article-title>CAR-based therapies: opportunities for immuno-medicine beyond cancer</article-title><source>Nat Metab</source><year>2022</year><volume>4</volume><fpage>163</fpage><lpage>169</lpage><pub-id pub-id-type="doi">10.1038/s42255-022-00537-5</pub-id><pub-id pub-id-type="pmid">35228742</pub-id>
</element-citation><mixed-citation id="mc-CR125" publication-type="journal">Aghajanian H, Rurik JG, Epstein JA. CAR-based therapies: opportunities for immuno-medicine beyond cancer. Nat Metab. 2022;4:163&#x02013;9. 10.1038/s42255-022-00537-5.<pub-id pub-id-type="pmid">35228742</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR126"><label>126.</label><citation-alternatives><element-citation id="ec-CR126" publication-type="journal"><person-group person-group-type="author"><name><surname>Goldrath</surname><given-names>AW</given-names></name><name><surname>Bevan</surname><given-names>MJ</given-names></name></person-group><article-title>Selecting and maintaining a diverse T-cell repertoire</article-title><source>Nature</source><year>1999</year><volume>402</volume><fpage>6</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1038/35005508</pub-id><pub-id pub-id-type="pmid">10573406</pub-id>
</element-citation><mixed-citation id="mc-CR126" publication-type="journal">Goldrath AW, Bevan MJ. Selecting and maintaining a diverse T-cell repertoire. Nature. 1999;402:6&#x02013;13. 10.1038/35005508.<pub-id pub-id-type="pmid">10573406</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR127"><label>127.</label><citation-alternatives><element-citation id="ec-CR127" publication-type="journal"><person-group person-group-type="author"><name><surname>Rizzuto</surname><given-names>GA</given-names></name><name><surname>Merghoub</surname><given-names>T</given-names></name><name><surname>Hirschhorn-Cymerman</surname><given-names>D</given-names></name><name><surname>Liu</surname><given-names>C</given-names></name><name><surname>Lesokhin</surname><given-names>AM</given-names></name><name><surname>Sahawneh</surname><given-names>D</given-names></name><name><surname>Zhong</surname><given-names>H</given-names></name><name><surname>Panageas</surname><given-names>KS</given-names></name><name><surname>Perales</surname><given-names>MA</given-names></name><name><surname>Altan-Bonnet</surname><given-names>G</given-names></name><etal/></person-group><article-title>Self-antigen-specific CD8+ T cell precursor frequency determines the quality of the antitumor immune response</article-title><source>J Exp Med</source><year>2009</year><volume>206</volume><fpage>849</fpage><lpage>866</lpage><pub-id pub-id-type="doi">10.1084/jem.20081382</pub-id><pub-id pub-id-type="pmid">19332877</pub-id>
</element-citation><mixed-citation id="mc-CR127" publication-type="journal">Rizzuto GA, Merghoub T, Hirschhorn-Cymerman D, Liu C, Lesokhin AM, Sahawneh D, Zhong H, Panageas KS, Perales MA, Altan-Bonnet G, et al. Self-antigen-specific CD8+ T cell precursor frequency determines the quality of the antitumor immune response. J Exp Med. 2009;206:849&#x02013;66. 10.1084/jem.20081382.<pub-id pub-id-type="pmid">19332877</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR128"><label>128.</label><mixed-citation publication-type="other">Pettmann J, Huhn A, Shah EA, Kutuzov MA, Wilson DB, Dustin ML, Davis, van der Merwe PA, Dushek&#x000a0;O. The discriminatory power of the T cell receptor. eLife. 2021;10:e67092. 10.7554/eLife.67092</mixed-citation></ref><ref id="CR129"><label>129.</label><citation-alternatives><element-citation id="ec-CR129" publication-type="journal"><person-group person-group-type="author"><name><surname>June</surname><given-names>CH</given-names></name><name><surname>Sadelain</surname><given-names>M</given-names></name></person-group><article-title>Chimeric antigen receptor therapy</article-title><source>N Engl J Med</source><year>2018</year><volume>379</volume><fpage>64</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1056/NEJMra1706169</pub-id><pub-id pub-id-type="pmid">29972754</pub-id>
</element-citation><mixed-citation id="mc-CR129" publication-type="journal">June CH, Sadelain M. Chimeric antigen receptor therapy. N Engl J Med. 2018;379:64&#x02013;73. 10.1056/NEJMra1706169.<pub-id pub-id-type="pmid">29972754</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR130"><label>130.</label><citation-alternatives><element-citation id="ec-CR130" publication-type="journal"><person-group person-group-type="author"><name><surname>Feins</surname><given-names>S</given-names></name><name><surname>Kong</surname><given-names>W</given-names></name><name><surname>Williams</surname><given-names>EF</given-names></name><name><surname>Milone</surname><given-names>MC</given-names></name><name><surname>Fraietta</surname><given-names>JA</given-names></name></person-group><article-title>An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer</article-title><source>Am J Hematol</source><year>2019</year><volume>94</volume><fpage>S3</fpage><lpage>S9</lpage><pub-id pub-id-type="doi">10.1002/ajh.25418</pub-id><pub-id pub-id-type="pmid">30680780</pub-id>
</element-citation><mixed-citation id="mc-CR130" publication-type="journal">Feins S, Kong W, Williams EF, Milone MC, Fraietta JA. An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer. Am J Hematol. 2019;94:S3&#x02013;9. 10.1002/ajh.25418.<pub-id pub-id-type="pmid">30680780</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR131"><label>131.</label><citation-alternatives><element-citation id="ec-CR131" publication-type="journal"><person-group person-group-type="author"><name><surname>Srivastava</surname><given-names>S</given-names></name><name><surname>Riddell</surname><given-names>SR</given-names></name></person-group><article-title>Engineering CAR-T cells: design concepts</article-title><source>Trends Immunol</source><year>2015</year><volume>36</volume><fpage>494</fpage><lpage>502</lpage><pub-id pub-id-type="doi">10.1016/j.it.2015.06.004</pub-id><pub-id pub-id-type="pmid">26169254</pub-id>
</element-citation><mixed-citation id="mc-CR131" publication-type="journal">Srivastava S, Riddell SR. Engineering CAR-T cells: design concepts. Trends Immunol. 2015;36:494&#x02013;502. 10.1016/j.it.2015.06.004.<pub-id pub-id-type="pmid">26169254</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR132"><label>132.</label><citation-alternatives><element-citation id="ec-CR132" publication-type="journal"><person-group person-group-type="author"><name><surname>Sterner</surname><given-names>RC</given-names></name><name><surname>Sterner</surname><given-names>RM</given-names></name></person-group><article-title>CAR-T cell therapy: current limitations and potential strategies</article-title><source>Blood Cancer J</source><year>2021</year><volume>11</volume><fpage>69</fpage><pub-id pub-id-type="doi">10.1038/s41408-021-00459-7</pub-id><pub-id pub-id-type="pmid">33824268</pub-id>
</element-citation><mixed-citation id="mc-CR132" publication-type="journal">Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 2021;11:69. 10.1038/s41408-021-00459-7.<pub-id pub-id-type="pmid">33824268</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR133"><label>133.</label><citation-alternatives><element-citation id="ec-CR133" publication-type="journal"><person-group person-group-type="author"><name><surname>Rurik</surname><given-names>JG</given-names></name><name><surname>Aghajanian</surname><given-names>H</given-names></name><name><surname>Epstein</surname><given-names>JA</given-names></name></person-group><article-title>Immune cells and immunotherapy for cardiac injury and repair</article-title><source>Circ Res</source><year>2021</year><volume>128</volume><fpage>1766</fpage><lpage>1779</lpage><pub-id pub-id-type="doi">10.1161/circresaha.121.318005</pub-id><pub-id pub-id-type="pmid">34043424</pub-id>
</element-citation><mixed-citation id="mc-CR133" publication-type="journal">Rurik JG, Aghajanian H, Epstein JA. Immune cells and immunotherapy for cardiac injury and repair. Circ Res. 2021;128:1766&#x02013;79. 10.1161/circresaha.121.318005.<pub-id pub-id-type="pmid">34043424</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR134"><label>134.</label><citation-alternatives><element-citation id="ec-CR134" publication-type="journal"><person-group person-group-type="author"><name><surname>Amor</surname><given-names>C</given-names></name><name><surname>Feucht</surname><given-names>J</given-names></name><name><surname>Leibold</surname><given-names>J</given-names></name><name><surname>Ho</surname><given-names>YJ</given-names></name><name><surname>Zhu</surname><given-names>C</given-names></name><name><surname>Alonso-Curbelo</surname><given-names>D</given-names></name><name><surname>Mansilla-Soto</surname><given-names>J</given-names></name><name><surname>Boyer</surname><given-names>JA</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Giavridis</surname><given-names>T</given-names></name><etal/></person-group><article-title>Senolytic CAR T cells reverse senescence-associated pathologies</article-title><source>Nature</source><year>2020</year><volume>583</volume><fpage>127</fpage><lpage>132</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2403-9</pub-id><pub-id pub-id-type="pmid">32555459</pub-id>
</element-citation><mixed-citation id="mc-CR134" publication-type="journal">Amor C, Feucht J, Leibold J, Ho YJ, Zhu C, Alonso-Curbelo D, Mansilla-Soto J, Boyer JA, Li X, Giavridis T, et al. Senolytic CAR T cells reverse senescence-associated pathologies. Nature. 2020;583:127&#x02013;32. 10.1038/s41586-020-2403-9.<pub-id pub-id-type="pmid">32555459</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR135"><label>135.</label><citation-alternatives><element-citation id="ec-CR135" publication-type="journal"><person-group person-group-type="author"><name><surname>Guedan</surname><given-names>S</given-names></name><name><surname>Calderon</surname><given-names>H</given-names></name><name><surname>Posey</surname><given-names>AD</given-names><suffix>Jr</suffix></name><name><surname>Maus</surname><given-names>MV</given-names></name></person-group><article-title>Engineering and design of chimeric antigen receptors</article-title><source>Mol Ther Methods Clin Dev</source><year>2019</year><volume>12</volume><fpage>145</fpage><lpage>156</lpage><pub-id pub-id-type="doi">10.1016/j.omtm.2018.12.009</pub-id><pub-id pub-id-type="pmid">30666307</pub-id>
</element-citation><mixed-citation id="mc-CR135" publication-type="journal">Guedan S, Calderon H, Posey AD Jr, Maus MV. Engineering and design of chimeric antigen receptors. Mol Ther Methods Clin Dev. 2019;12:145&#x02013;56. 10.1016/j.omtm.2018.12.009.<pub-id pub-id-type="pmid">30666307</pub-id>
</mixed-citation></citation-alternatives></ref></ref-list></back></article>